WO2022142977A1 - HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用 - Google Patents

HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用 Download PDF

Info

Publication number
WO2022142977A1
WO2022142977A1 PCT/CN2021/134715 CN2021134715W WO2022142977A1 WO 2022142977 A1 WO2022142977 A1 WO 2022142977A1 CN 2021134715 W CN2021134715 W CN 2021134715W WO 2022142977 A1 WO2022142977 A1 WO 2022142977A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
ligand protein
epitope
hrpz
amino acid
Prior art date
Application number
PCT/CN2021/134715
Other languages
English (en)
French (fr)
Inventor
吴伯骥
吴保珍
Original Assignee
吴伯骥
昆明锐斯得科技有限公司
吴保珍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202011631000.3A external-priority patent/CN114762723A/zh
Priority claimed from CN202011644674.7A external-priority patent/CN114681591A/zh
Application filed by 吴伯骥, 昆明锐斯得科技有限公司, 吴保珍 filed Critical 吴伯骥
Priority to AU2021411563A priority Critical patent/AU2021411563A1/en
Publication of WO2022142977A1 publication Critical patent/WO2022142977A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Definitions

  • the invention relates to the field of biomedicine, in particular to the application of HrpZ-type protein in the pharmacy of identifying and activating multiple types of receptors and/or membrane proteins and their signal pathways and causing cascade biological effects.
  • Molecular biology is a science that studies life phenomena at the molecular level. It clarifies the nature of various life phenomena by studying the structure, function and metabolism of biological macromolecules, and its research content covers the whole process of life.
  • DNA, RNA and protein are three important biological macromolecules, which are the molecular basis of life phenomena.
  • the genome determines what life has, the proteome determines what life can do, and the metabolome determines what actually happens to life.
  • Modern life sciences, biotechnology and medical biotechnology, especially proteomics and metabolomics have developed by leaps and bounds, updating the concepts of disease understanding, diagnosis, prevention and control, treatment and rehabilitation, creating new and efficient The new understanding and new approach of safe drugs have brought the development of modern medicine into a new stage and opened up broad application prospects.
  • Ligand is a kind of signal substance. Except for recognizing, binding and activating the receptor, it has no other direct functions. It cannot participate in metabolism to produce useful products, nor does it directly induce any cell activity, and it has no enzyme characteristics. Its only function is to transmit special signals or information that exist in the internal and external environment to cells through the recognition, binding and activation of receptors.
  • Signaling pathway refers to the communication mechanism that sends and receives information with high precision and efficiency between cells or within cells of multicellular organisms, and causes rapid cellular physiological and biochemical reactions through amplification, or initiates gene activity, and then a series of events occur.
  • the physiological and biochemical activities of cells coordinate the activities of various organizations, and promote the unified whole of life to make a comprehensive response to the changing internal and external environment.
  • Receptors refer to a class of functional proteins that mediate cell signal transduction. They can recognize certain trace substances in the surrounding environment (internal and external environment of cells), recognize, bind to, and be activated to trigger subsequent physiological processes through the signal amplification system. biochemical reaction. Receptors are biological macromolecules composed of cell membranes and intracellular proteins, nucleic acids, lipids, and polysaccharides. Receptor is a very broad concept in cell biology, which refers to any biological macromolecules that can bind to hormones, neurotransmitters, drugs or signal molecules inside and outside cells and can cause changes in cell function. called ligands. There are hundreds of different signaling molecules in multicellular organisms that transmit information between and within cells.
  • These signaling molecules include proteins, amino acid derivatives, nucleotides, cholesterol, fatty acid derivatives, and soluble gas molecules.
  • the receptors present on the cytoplasmic membrane are called membrane receptors, and most of the chemical essences are sugar mosaic proteins; the receptors located in the cytosol and nucleus are called intracellular receptors, and they are all DNA-binding proteins.
  • Ligand is a kind of signal substance. Except for recognizing, binding and activating the receptor, it has no other direct functions. It cannot participate in metabolism to produce useful products, nor does it directly induce any cell activity, and it has no enzyme characteristics. Its only function is to transmit special signals or information that exist in the internal and external environment to cells through the recognition, binding and activation of receptors.
  • the binding of ligands and receptors is an intermolecular recognition and activation process, which relies on ionic coordination bonds, hydrogen bonds, ⁇ - ⁇ stacking, electrostatic interaction, hydrophobic interaction, van der Waals force, etc., with the complementarity of the two molecular spatial structures.
  • the degree of interaction increases, the distance between the interacting groups will be shortened, and the interaction force will be greatly increased. Therefore, the interaction and complementarity of the spatial structure of the ligand and receptor molecules are the main factors for specific binding, that is, the The concept of "structural group" or "epitope" employed in the invention.
  • the same ligand may correspond to two or more different receptors, and the binding of the same ligand to different types of receptors will produce different cellular responses.
  • the ligand After the ligand binds to the receptor, it will trigger a series of physiological activities, no matter whether the ligand is endogenous or exogenous, after binding to the receptor, the two form a ligand-receptor binding surface or complex, thereby Transmission of information, through conduction and transduction, and through amplification to cause rapid cellular physiological and biochemical reactions, or to initiate gene activity, and then a series of cascade reactions occur to coordinate the activities of various tissues, organs, and cells, and contribute to the unity of life. Make a comprehensive response to the changing internal and external environment.
  • leader et al. first proposed the idea of classification according to the pharmacological effects of proteins, and divided protein drugs into the following four categories: (1) protein drugs using the enzymatic activity and regulating activity of proteins for treatment; (2) proteins with special targeting activities Drugs; 3 recombinant protein vaccines; 4 recombinant protein drugs for diagnosis.
  • the first and second categories are mainly used for basic protein therapy, and the third and fourth categories emphasize the application of proteins in vaccines and diagnostic drugs.
  • protein drugs After more than a century of exploration and tortuous development, protein drugs have matured step by step and play an important role in the pharmaceutical industry and clinical applications.
  • the phenylalanine (Phe 82), isoleucine (Ile83), and pyrimidine (Val 85) of the binding epitope are the key amino acid residues for recognizing binding to bovine IgG2 receptor, for another example, positions 142-149 of boFc ⁇ RI Threonine (Thr 142), asparagine (Asn 143), leucine (Leu 144), glycine (Gly 148) and isoleucine (Ile 149) of the linear ligand-binding epitope of the polypeptide TNLSHNGI are recognized binding
  • Harpin is a class of proteins with similar properties and functions encoded by genes in the "hyper sensitive response and pathogenicity (hrp)" gene cluster of Gram-negative bacteria, rich in glycine and not containing cystine , Sensitive to protein enzymes, thermostable, and can cause allergic reactions in non-host plants.
  • Hypersensitive reaction (HR) is characterized by rapid and local atrophy and necrosis of infected tissues of non-host plants, which limits the spread of pathogenic bacteria and induces systemic resistance, which is a common manifestation of plant resistance to pathogenic infection. and effective ways. After nearly 30 years of research, these encoded proteins have been recognized by biologists, phytopathologists and applied researchers in the field. Harpin hypersensitivity proteins belong to the class of anti-inducing proteins that induce plant systemic resistance. In the field of protection, biopesticides can safely induce plants to produce disease resistance, insect repellency, stress resistance, and promote plant growth and development and increase yield.
  • the conserved domain of HrpZpss protein consists of 343 amino acids, and the entire sequence is the conserved domain 1-343; -265, 290-309, 317-336.
  • HrpZpst protein (GenBank accession number: AY999001) is the expression product of hrpZpst gene (Pseudomonas syringae pv tomato Strain CSCS008), which consists of 370 amino acid residues, a non-enzymatic protein with one, two and three tertiary structures but no quaternary structure, Does not contain cystine and cysteine, rich in glycine and serine, the molecule is 36.52kDa, the HrpZpst protein conserved domain consists of 370 amino acids, the full sequence is the conserved structural region, 1-370, ⁇ -helical structure 33-49 , 58-70, 78-92, 136-155, 172-183, 192-197, 204-223, 265-277, 279-284, 314-333, 341-359, 364-366 proteins.
  • Structural domains are regions of biological macromolecules with specific structures and independent functions, especially the independent stable structural regions in proteins composed of different secondary structures and super-secondary structures. Domains are also protein functional units. In domain proteins, different domains are often associated with different functions; the secondary and super-secondary structures of proteins are mainly maintained by hydrogen bonds, including ⁇ -helix, ⁇ -sheet, ⁇ -turn, random coil, and IDPs-structure ( Intrinsically disordered proteins, intrinsically disordered proteins, referred to as IDPs), etc., ⁇ helix is a repetitive structure, and the ⁇ and ⁇ of each ⁇ -carbon in the helix are around -57° and -47°, respectively.
  • IDPs Intrinsically disordered proteins, intrinsically disordered proteins, referred to as IDPs
  • Each turn of the helix occupies 3.6 amino acid residues, rising 0.54 nm along the helix axis, each residue rotates 100° around the axis, rising 0.15 nm along the axis, and hydrogen bonds are formed between adjacent turns, and the orientation of the hydrogen bonds is almost the same as
  • the helical axes are parallel;
  • IDPs-structure is the structural region of intrinsically disordered proteins (IDPs), which has a wide range of allosteric effects. It is widely involved in and regulates transcription, translation, cell division, protein aggregation and cell signal transduction with high repeatability, chargeability, easy binding, spatial superiority and high coordination, and is particularly involved in the process of self-assembly regulation .
  • IDPs intrinsically disordered proteins
  • HrpZ-type proteins are a class of proteins encoded by genes in the "hyper sensitive response and pathogenicity (hrp)" gene cluster with similar properties and functions, including high homology and close evolutionary relationship.
  • hrp hyper sensitive response and pathogenicity
  • the application prospects of various types of receptors, membrane proteins, and signaling pathways and metabolic pathways in animal (including human) cells can cause multifunctional cascade biological effects. However, there are no reports and applications of this kind of protein cross-border recognition, especially in animals and humans.
  • HrpZ-type protein in the pharmacy of identifying and activating multiple types of receptors and/or membrane proteins and their signaling pathways and causing cascade biological effects.
  • HrpZ-type proteins as a class of ligand protein molecules with special structures rich in multiple linear and conformational epitopes, can recognize, activate, and bind membrane receptors, membrane proteins, information pathways and metabolic pathways across various types of animals.
  • HrpZ-type proteins are a class of ligand proteins with special multiple epitope structures, new functions, new mechanisms of action and new application prospects. They induce multi-directional, multi-level and multi-faceted biological effects and functions.
  • HrpZ-type protein According to the structural characteristics of HrpZ-type protein and its ability to recognize and bind membrane receptors and membrane proteins of various types of animals across borders, thereby activating multiple information pathways and metabolic pathways, we call it HrpZ-type polyprotein. Epitope-like ligand proteins (multi epitopic-like ligand proteins).
  • HrpZ-type multi-epitope ligand proteins in food, cosmetics, health care products or pharmaceuticals that recognize and activate various types of receptors and/or membrane proteins and their signaling pathways and cause cascade biological effects.
  • HrpZ-type multi-epitope ligand protein in recognizing food, disinfectant, cosmetic, health care product or medicine that activates various types of receptors and/or membrane proteins and their signaling pathways and causes cascade biological effects.
  • HrpZ-type multi-epitopic ligand proteins contain structural groups or epitopes of one or more hydrophobic non-polar amino acid residues, structural groups or epitopes containing one or more polar uncharged amino acid residues, contain one or more A structural group or epitope of an amide polar uncharged amino acid residue, a structural group or epitope containing one or more acidic positively charged, basic negatively charged amino acid residues; hydrophobic nonpolar amino acid residues: Valine, leucine, isoleucine, alanine, phenylalanine, methionine, polar uncharged amino acid residues: serine, amide polar uncharged amino acid residues: asparagine, glutamine Amides, acidic positively charged, basic negatively charged amino acid residues: asparagine, glutamic acid, lysine, histidine, arginine; hydrophobic non-polar amino acid residues, polar uncharged amino acid residues The polar uncharged amino acid residues,
  • HrpZ-type multi-epitope ligand proteins include HrpZPsa, HrpZPsm, HrpZPss, HrpZPst, HrpZPsap, HrpZPsr, HrpZPsth, HrpZPave, HrpZPam, HrpZPcar, HrpZPcor, HrpZPcst, HrpZPcat, HrpZPcory, HrpZPcp, HrpZPsav, HrpZPvirp, HrpZPvir HrpZPade, HrpZPsac, HrpZPsg, HrpZPsc.
  • these molecules are highly homologous, ranging from 60% to 99%;
  • HrpZ polymimetic epitope ligand protein homology comparison is as follows:
  • HrpZ-type multi-epitope ligand protein is rich in multiple linear and conformational structural groups or epitopes. It refers to a functional group composed of amino acid residues that can recognize and bind to cell membrane receptors, membrane proteins, etc.
  • This functional group It is composed of the following amino acid residues, including rich proton-donating or proton-accepting amino acid residues that can recognize, bind, and activate with receptors; further, contains one or more hydrophobic non-polar amino acid residues, contains one or more Acidic positively charged, basic negatively charged amino acid residues, containing one or more amide-group polar uncharged amino acid residues, containing one or more polar uncharged amino acid residues; further, rich in proton-donating type (methionine residues) or proton-accepting (including methionine residues) amino acid residues: glutamic acid, aspartic acid, lysine, histidine, methionine, serine, threonine, tyrosine, arginine , they can recognize and activate connection with the corresponding amino acid residues of multiple types of receptor proteins by hydrogen bonding to form binding surfaces or complexes; further, hydrophobic non-polar amino acid residues: valine, leucine, isoleucine , Alan
  • HrpZpss polypeptide has 343 amino acid residues, 235 key amino acid residues, 105 hydrophobic non-polar amino acid residues, 33 polar uncharged amino acid residues, 40 amide amino acid residues, and acidic amino acid residues.
  • HrpZpst multi-epitope ligand protein has 370 amino acid residues, the full sequence is a conserved structural region, there are 370 amino acid residues, accounting for 100% of the full sequence, 261 key amino acid residues, hydrophobic non-hydrophobic There are 114 polar amino acid residues, 43 polar uncharged amino acid residues, 54 amide amino acid residues, 50 acidic positively charged and basic negatively charged amino acid residues, and key amino acid residues account for the total amino acid residues 70.5%, molecular weight 36.52kd, isoelectric point PI 4.01; 12 ⁇ -helices, 2 ⁇ -sheets and 7 do-structure regions; ⁇ -helix region, 164 amino acid residues, key amino acid residues 136, 66 hydrophobic non-polar amino acid residues, 12 polar uncharged amino acid residues, 29 amide amino acid residues, 29 acidic positively charged, basic negatively charged amino acid residues, key amino acid residues accounted for 82
  • the complementarity , interaction, and specific recognition, activation, and binding of inter-structure and electrical properties can form tight binding surfaces or complexes with multiple types of receptors, which can cause changes in the conformation, energy, electrical properties and information of receptor molecules.
  • signal transduction and transduction a series of biological effects are amplified and expressed.
  • Multifunctional cascade biological effects refer to the significant differences in the expression of related functional gene groups at three levels of cellular components, molecular functions and biological processes in different organs and tissues, including cellular components (including cells, cell nodes, and cell parts). , extracellular matrix, extracellular matrix components, extracellular region, extracellular region part, macromolecular complex, membrane, membrane part, membrane-enclosed cavity, organelle, organelle part, supramolecular fiber, synapse, synaptic part, Antioxidant activity, etc.), molecular functions (including binding, catalytic activity, chemoattractant activity, chemorepellent activity, electron carrier activity, metal chaperone protein activity, molecular function regulators, active molecular sensors, nucleic acid binding transcription factors) activity, signal sensor activity, structural molecular activity, transcription factor activity protein binding, transport activity, etc.), biological processes (including behavior, bioadhesion, bioregulation, cell aggregation, cell death, cellular component organization or biogenesis, cellular processes, Detoxification, processes of
  • the amino acid sequence of the HrpZpst multi-mimetic epitope ligand protein is shown in SEQ ID NO: 1; the amino acid sequence of the HrpZpst multi-mimetic epitope ligand protein is shown in SEQ ID NO: 2.
  • the HrpZ-type multi-epitope ligand protein is HrpZpss multi-epitope ligand protein
  • the multi-type receptors that recognize and bind include HLA-C major histocompatibility complex, I, C type receptors, free fatty acids
  • HLA-C major histocompatibility complex I, C type receptors, free fatty acids
  • receptor 4 tyrosine protein kinase transmembrane receptor 1
  • ASGPR1 asialoglycoprotein receptor 1 adipocyte plasma membrane-associated protein receptor
  • insulin-like growth factor 2 receptor insulin-like growth factor 2 receptor
  • the HrpZ type multi-epitope ligand protein is HrpZpst multi-epitope ligand protein
  • the multi-type receptors that recognize and bind include HLA-C major histocompatibility complex, I, C type receptors, ASGPR1 One or more of sialoglycoprotein receptor 1, adipocyte plasma membrane associated protein receptor, insulin-like growth factor 2 receptor, LDL receptor associated protein 1.
  • the HrpZ type multi-epitope ligand protein is HrpZpss multi-mimetic epitope ligand protein
  • the membrane proteins that recognize and bind include solute carrier family 5, member 6, solute carrier family 26, member 4, solute carrier family 38, member 2.
  • DNM2 dynein 2 CAP1 adenylyl cyclase-related protein 1, ICAM1 intercellular adhesion molecule 1, LanC-like protein 1, MLEC stress protein-androgen-like receptor kinase, TJP2 tight junction protein 2, ZYX plaques one or more of catenin.
  • the HrpZ-type multi-epitope ligand protein is HrpZpst multi-epitope ligand protein
  • the membrane proteins that recognize and bind include solute carrier family 38, member 2, DNM2 dynein 2, SPTAN1 non-erythrocyte 1 ⁇ spectrin, ⁇ - Mutual protein 1, CAP1 adenylate cyclase-related protein 1, ICAM1 intercellular adhesion molecule 1, LanC-like protein 1, MLEC stress protein-androgen-like receptor kinase, TJP2 claudin 2, ZYX plaques one or more of catenin.
  • the HrpZ-type multi-epitope ligand protein is HrpZpss multi-epitope ligand protein
  • the receptors that recognize the binding and the signaling pathways involved in membrane proteins include hsa04933 The role of age-anger signaling pathway in diabetic complications, hsa04064 One or more of NF-kappa B signaling pathway and hsa04072 phospholipase D signaling pathway.
  • the HrpZ-type multi-epitope ligand protein is HrpZpst multi-epitope ligand protein
  • the receptors that recognize the binding and the signaling pathways involved in membrane proteins include hsa04933 The role of age-anger signaling pathway in diabetic complications, hsa04064 One or more of NF-kappa B signaling pathway, hsa04072 phospholipase D signaling pathway, and hsa04668TNF signaling pathway.
  • the signaling pathways involved in the recognition of activated receptors and membrane proteins include metabolic signaling pathways, and the metabolic signaling pathways include antiviral, antibacterial, anti-foreign body, and anti-inflammatory metabolic pathways; including nucleic acid, protein, amino acid, sugar, and fat metabolism Pathways; including cell junctions, neural junctions, blood vessels, endocrine, reproductive system metabolic pathways.
  • the HrpZ-type multi-epitope ligand protein is HrpZpss multi-epitope ligand protein, and the anti-viral, anti-bacterial, anti-foreign body, and anti-inflammatory metabolic pathways involved in the recognition of activated membrane proteins: hsa04144 endocytosis , hsa04145 phagosome, hsa04142 lysosome, hsa04666Fc gamma r-mediated phagocytosis, hsa04210 apoptosis, hsa04218 cellular senescence, hsa05130: pathogenic E.
  • coli infection hsa04612 antigen processing and presentation, hsa05100 bacterial invasion of epithelial cells, hsa05168 herpes simplex virus 1 infection, hsa05203 viral carcinogenesis, hsa05164 influenza A, hsa05150 staphylococcus aureus infection, hsa05167 Kaposi sarcoma with herpes virus infection, hsa04916: bactericidal effect, hsa04650 natural killer cell-mediated cytotoxicity, hsa05169 Epstein-Barr virus infection, hsa05416 viral myocarditis, hsa05110 Vibrio cholerae infection, hsa05144 malaria, hsa05163 human cytomegalovirus infection, hsa05170 human immunodeficiency virus type 1 infection, hsa05323 rheumatoid arthritis, hsa04670 leukocyte transcellular migration;
  • the HrpZ-type multi-epitope ligand protein is the HrpZpst protein, which recognizes the antiviral, antibacterial, anti-foreign and anti-inflammatory metabolic pathways involved in the activated membrane protein: hsa04144 endocytosis, hsa04145 phagosome, hsa04142 lysosome , hsa04666Fc gamma r-mediated phagocytosis, hsa04210 apoptosis, hsa04218 cellular senescence, hsa04612 antigen processing and presentation, hsa05100 bacterial invasion of epithelial cells, hsa05168 herpes simplex virus 1 infection, hsa05203 viral carcinogenesis, hsa05164 influenza A, hsa05150 Staphylococcus aureus infection, hsa05143 African trypanosomiasis, hsa04650 Natural killer cell-mediated cyto
  • the HrpZ-type multi-epitope ligand protein is HrpZpss multi-epitope ligand protein, and the cascade biological effects include Cellular Processes, Environmental Information Processing, Genetic Information Processing ), Metabolism and Organismal Systems and other functional pathways; further, 1 Cellular Processes: Multiple differentially expressed genes induced by HrpZpss protein are involved in transport and catabolism, cell population, cell activity , cell processes such as cell growth and death; 2Environmental Information Processing: Multiple differentially expressed genes induced by HrpZpss multi-epitope ligand protein are involved in signaling molecules and interactions, signal transduction, membrane transport and other environments Information processing process; 3 Genetic Information Processing: Multiple differentially expressed genes induced by HrpZpss multi-epitope ligand protein are involved in biological processes such as translation, replication and repair, folding, classification and degradation; 4 Metabolism (Metabolism ): HrpZpss polyepitopic ligand protein-induced multiple
  • HrpZ-type multi-epitope ligand protein is HrpZpst multi-epitope ligand protein, and the cascade biological effects include Cellular Processes, Environmental Information Processing, Genetic Information Processing ), Metabolism and Organismal Systems and other functional pathways; further, 1 Cellular Processes: Multiple differentially expressed genes induced by HrpZpst multi-epitope ligand protein are involved in transport and catabolism , cell population, cell activity, cell growth and death and other cellular processes; 2Environmental Information Processing: Multiple differentially expressed genes induced by HrpZpst multi-epitope ligand protein are involved in signaling molecules and interactions, signal transduction 3 Genetic Information Processing: Multiple differentially expressed genes induced by HrpZpst multi-epitope ligand protein are involved in translation, replication and repair, folding, classification and degradation of biological Process; 4Metabolism: Multiple differentially expressed genes induced by HrpZpst multi-epitope ligand protein are involved
  • the HrpZ-type multi-epitope ligand protein is HrpZpss multi-epitope ligand protein
  • the cascade biological effect also includes the results of the significant differential expression of gene functional groups induced by the HrpZpss multi-epitope ligand protein, including: 1Differentially expressed genes related to biological processes: including reproduction, cell death, immune system processes, behavior, metabolic processes, cellular processes, reproductive processes, bioadhesion, signaling, multicellular biological processes, developmental processes, growth, movement, single Organizing processes, biological phases, rhythmic processes, positive regulation of biological processes, negative regulation of biological processes, regulation of biological processes, stimulus response, localization, biological regulation, cellular component organization or biogenesis, cellular aggregation, detoxification, and presynaptic
  • the process involves synaptic transmission; 2 Differentially expressed genes related to cellular components: covering cells and extracellular regions, nucleoids, membranes, virions, cell junctions, extracellular matrix, cell membrane enclosed cavity, complex
  • the HrpZ-type multi-epitope ligand protein is HrpZpst multi-epitope ligand protein
  • the cascade biological effect also includes the results of the significant differential expression of gene functional groups induced by the HrpZpst multi-epitope ligand protein, including: 1Differentially expressed genes related to biological processes: including reproduction, cell death, immune system processes, behavior, metabolic processes, cellular processes, reproductive processes, bioadhesion, signaling, multicellular biological processes, developmental processes, growth, movement, single Organizing processes, biological phases, rhythmic processes, positive regulation of biological processes, negative regulation of biological processes, regulation of biological processes, stimulus response, localization, biological regulation, cellular component organization or biogenesis, cellular aggregation, detoxification, and presynaptic
  • the process involves synaptic transmission; 2 Differentially expressed genes related to cellular components: covering cells and extracellular regions, nucleoids, membranes, virions, cell junctions, extracellular matrix, cell membrane closed cavity, complex
  • the dosage form of the product or drug used in the pharmacy is liquid, powder, tablet or capsule.
  • the pharmaceutical application further includes active compounds (HrpZpss polyepitope ligand protein preparations and/or drugs) and derivatives thereof for HrpZpss polyepitope ligand protein according to pharmaceutical treatment, usually in unit dosage form or Multiple dosage forms are formulated and administered, each unit dosage containing a predetermined quantity of the therapeutically active compound in association with the required pharmaceutical carrier, vehicle or excipient sufficient to produce the desired therapeutic effect.
  • active compounds HrpZpss polyepitope ligand protein preparations and/or drugs
  • derivatives thereof for HrpZpss polyepitope ligand protein according to pharmaceutical treatment usually in unit dosage form or Multiple dosage forms are formulated and administered, each unit dosage containing a predetermined quantity of the therapeutically active compound in association with the required pharmaceutical carrier, vehicle or excipient sufficient to produce the desired therapeutic effect.
  • unit dosage forms include ampoules and syringes and individually packaged tablets or capsules.
  • the unit dosage form can be administered in fractions or multiples thereof.
  • Examples of multiple dosage forms include vials, bottles of tablets or capsules, or gallon bottles.
  • a multiple-dose form is a number of unit doses that are not separated in packaging.
  • Dosage forms or compositions can be prepared containing from 0.001% to 100% of the active ingredient, the remainder consisting of a non-toxic carrier, for oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules, which are prepared by conventional methods of pharmacy Acceptable excipients such as binders (including, but not limited to, pregelatinized cornstarch, polyvinylpyrrolidone, or propylmethylcellulose); fillers (including, but not limited to, lactose, microcrystalline cellulose lubricants (including, but not limited to, magnesium stearate, talc, or silicon dioxide); disintegrants (including, but not limited to, potato starch or sodium starch glycolate); or wetting agents (including, But not limited to, sodium lauryl sulfate) preparation.
  • binders including, but
  • compositions can also be in liquid form, including, but not limited to, solutions, syrups or suspensions, or can be presented as a pharmaceutical product for reconstitution with water or other suitable vehicle before use.
  • Such liquid formulations can be prepared by conventional methods with pharmaceutically acceptable additives such as suspending agents (including, but not limited to, sorbitol syrup, cellulose derivatives, or edible fats); emulsifiers (including, but not limited to, edible fats); without limitation, lecithin or acacia); non-aqueous vehicles (including, but not limited to, almond oil, oily esters, or fractionated vegetable oils); and preservatives (including, but not limited to, methylparaben) or propyl ester or sorbic acid).
  • suspending agents including, but not limited to, sorbitol syrup, cellulose derivatives, or edible fats
  • emulsifiers including, but not limited to, edible fats
  • non-aqueous vehicles including, but not limited to, almond oil, oily esters, or fraction
  • Formulations suitable for rectal administration may be presented as unit dose suppositories. These can be prepared by mixing the HrpZpss polymimetic ligand protein active compound with one or more solid carriers, such as cocoa butter, and shaping the resulting mixture.
  • Formulations suitable for topical application to the skin or eye include, but are not limited to, cartilage agents, creams, lotions, pastes, gels, sprays, aerosols and oils.
  • Exemplary carriers include, but are not limited to, petrolatum, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the topical formulation may also contain from 0.001% to 15%, 20%, 25% by weight of a thickening agent selected from the group consisting of, but not limited to, hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, Polyvinyl alcohol, polyethylene glycol, poly/hydroxyalkyl(meth)acrylates or poly(meth)acrylamides.
  • Topical formulations are typically applied by instillation or as a cartilaginous agent into the conjunctival capsule. It can also be used to flush or lubricate the eyes, facial sinuses and external auditory canal. It can also be injected into the anterior chamber and elsewhere.
  • Topical formulations in liquid form can also be presented in the form of tapes or contact lenses in a hydrophilic three-dimensional polymer matrix from which the active ingredient is released.
  • Formulations suitable for buccal (sublingual) administration include, but are not limited to, lozenges containing the active compound in a flavored base (usually sucrose and acacia or tragacanth); and lozenges in an inert base include, but are not limited to , pastilles containing the compound in gelatin and glycerin or sucrose and acacia.
  • Pharmaceutical compositions of ligand isoforms can be formulated for parenteral administration by injection, including, but not limited to, by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, eg, in ampoules or in multi-dose containers, with added additives.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may include, but are not limited to, formulatory agents such as suspending agents, stabilizing agents, alternatively, the active ingredient may be in powder form for use.
  • a suitable carrier such as sterile pyrogen-free water or other solvent.
  • Formulations suitable for transdermal administration may be presented as discrete patches suitable for maintaining intimate contact with the epidermis of the recipient for extended periods of time. Such patches suitably contain the active compound as an optionally buffered aqueous solution of the active compound.
  • Formulations suitable for transdermal administration may be delivered by iontophoresis and take the form of an optionally buffered aqueous solution of the active compound.
  • the pharmaceutical application further includes active compounds (HrpZpst poly-epitope ligand protein preparations and/or drugs) and derivatives thereof for HrpZpst poly-epitope ligand protein according to pharmaceutical treatment, usually in unit dosage form or Multiple dosage forms are formulated and administered, each unit dosage containing a predetermined quantity of the therapeutically active compound in association with the required pharmaceutical carrier, vehicle or excipient sufficient to produce the desired therapeutic effect.
  • unit dosage forms include ampoules and syringes and individually packaged tablets or capsules.
  • the unit dosage form can be administered in fractions or multiples thereof.
  • a multiple dosage form is a plurality of identical unit dosage forms packaged in a single container, which are to be administered in separate unit dosage forms.
  • Examples of multiple dosage forms include vials, bottles of tablets or capsules, or gallon bottles.
  • a multiple-dose form is a number of unit doses that are not separated in packaging.
  • Dosage forms or compositions can be prepared containing from 0.001% to 100% of the active ingredient, the remainder consisting of a non-toxic carrier, for oral administration, the pharmaceutical compositions can take the form of, for example, tablets or capsules, which are prepared by conventional methods of pharmacy Acceptable excipients such as binders (including, but not limited to, pregelatinized cornstarch, polyvinylpyrrolidone, or propylmethylcellulose); fillers (including, but not limited to, lactose, microcrystalline cellulose lubricants (including, but not limited to, magnesium stearate, talc, or silicon dioxide); disintegrants (including, but not limited to, potato starch or sodium starch glycolate); or wetting agents (including, But not limited to, sodium lauryl sulfate) preparation.
  • binders including, but
  • compositions can also be in liquid form, including, but not limited to, solutions, syrups or suspensions, or can be presented as a pharmaceutical product for reconstitution with water or other suitable vehicle before use.
  • Such liquid formulations can be prepared by conventional methods with pharmaceutically acceptable additives such as suspending agents (including, but not limited to, sorbitol syrup, cellulose derivatives, or edible fats); emulsifiers (including, but not limited to, edible fats); without limitation, lecithin or acacia); non-aqueous vehicles (including, but not limited to, almond oil, oily esters, or fractionated vegetable oils); and preservatives (including, but not limited to, methylparaben) or propyl ester or sorbic acid).
  • suspending agents including, but not limited to, sorbitol syrup, cellulose derivatives, or edible fats
  • emulsifiers including, but not limited to, edible fats
  • non-aqueous vehicles including, but not limited to, almond oil, oily esters, or fraction
  • Formulations suitable for rectal administration may be presented as unit dose suppositories. These can be prepared by mixing the HrpZpst polymimetic ligand protein active compound with one or more solid carriers, such as cocoa butter, and shaping the resulting mixture.
  • Formulations suitable for topical application to the skin or eye include, but are not limited to, cartilage agents, creams, lotions, pastes, gels, sprays, aerosols and oils.
  • Exemplary carriers include, but are not limited to, petrolatum, lanolin, polyethylene glycols, alcohols, and combinations of two or more thereof.
  • the topical formulation may also contain from 0.001% to 15%, 20%, 25% by weight of a thickening agent selected from the group consisting of, but not limited to, hydroxypropyl methylcellulose, methylcellulose, polyvinylpyrrolidone, Polyvinyl alcohol, polyethylene glycol, poly/hydroxyalkyl(meth)acrylates or poly(meth)acrylamides.
  • Topical formulations are typically applied by instillation or as a cartilaginous agent into the conjunctival capsule. It can also be used to flush or lubricate the eyes, facial sinuses and external auditory canal. It can also be injected into the anterior chamber and elsewhere.
  • Topical formulations in liquid form can also be presented in the form of tapes or contact lenses in a hydrophilic three-dimensional polymer matrix from which the active ingredient is released.
  • Formulations suitable for buccal (sublingual) administration include, but are not limited to, lozenges containing the active compound in a flavored base (usually sucrose and acacia or tragacanth); and lozenges in an inert base include, but are not limited to , pastilles containing the compound in gelatin and glycerin or sucrose and acacia.
  • Pharmaceutical compositions of ligand isoforms can be formulated for parenteral administration by injection, including, but not limited to, by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, eg, in ampoules or in multi-dose containers, with added additives.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may include, but are not limited to, formulatory agents such as suspending agents, stabilizing agents, alternatively, the active ingredient may be in powder form for use.
  • a suitable carrier such as sterile pyrogen-free water or other solvent.
  • Formulations suitable for transdermal administration may be presented as discrete patches suitable for maintaining intimate contact with the epidermis of the recipient for extended periods of time. Such patches suitably contain the active compound as an optionally buffered aqueous solution of the active compound.
  • Formulations suitable for transdermal administration may be delivered by iontophoresis and take the form of an optionally buffered aqueous solution of the active compound.
  • the HrpZ type polymimetic epitope ligand protein is HrpZpss polymimetic epitope ligand protein
  • the product or medicine is mainly prepared from purified HrpZEcb polymimetic epitope ligand protein, and the mass content is 0.001%-100%.
  • the HrpZ-type polymimetic epitope ligand protein is HrpZpst polymimetic epitope ligand protein
  • the product or medicine is mainly prepared from purified HrpZEch polymimetic epitope ligand protein, and the mass content is 0.001%-100%.
  • the HrpZ-type multi-epitope ligand protein is a purified HrpZ-type protein.
  • the method for purifying HrpZ-type protein includes the following steps:
  • Step 1 The high pressure crusher crushes the engineering bacteria, and the crushed bacteria liquid is passed into the butterfly continuous flow centrifuge to remove the cell wall, and the high pressure range is 800-1000Mpa;
  • Step 2 Purify the HrpZ polymimetic epitope ligand protein-His recombinant protein with a Ni-NTA agarose column to obtain a purified HrpZ-type polymimetic epitope ligand protein original drug.
  • the high-efficiency expression, purification and production of the HrpZpss polymimetic epitope ligand protein used in the present invention comprises the following steps:
  • HrpZpss multi-mimetic epitope ligand protein the genes (including, but not limited to, natural genes of biological samples, chemically synthesized genes, transgenic genetic recombinant genes) encoding HrpZpss multi-mimetic epitope ligand proteins are prepared.
  • the high-pressure crusher crushes engineering bacteria, and continuously uses 800-1000Mpa pressure to crush engineering bacteria.
  • centrifugal force range 1000-8000g, preferably centrifugal force 1000-2000g; preferably centrifugal force 2000-3500g; preferably centrifugal force 8000-6000g; preferably centrifugal force 6000-4500g; most preferably The centrifugal force is 3500-4500g.
  • the HrpZpss multi-epitope ligand protein was present in the supernatant.
  • the application route of the HrpZpss protein preparation that recognizes and activates multiple types of receptors, membrane proteins and their signaling pathways in animals and induces multifunctional cascade biological effects according to the present invention can be administered by any route known to those skilled in the art, Such routes include internal, topical, oral, injection, intramuscular, intravenous, intradermal, intraperitoneal, subcutaneous, nasal, oral, rectal, topical, buccal and transdermal administration or any route; by any convenient Routes of administration of HrpZpss polyepitopic ligand proteins, such as by perfusion or rapid perfusion, absorption through epithelia or mucocutaneous linings (eg, oral mucosa, nasal mucosa, gastric mucosa, rectal and intestinal mucosa, etc.), and can be combined with other
  • the biologically active agents are administered sequentially, intermittently, or in the same composition; depending on the site of treatment, administration can be topical, topical, or systemic.
  • Topical administration to the area in need of treatment can be, but is not limited to, local infusion, topical application, by immersion, by injection, by catheter, by suppository; administration can also include controlled release systems, including controlled release formulations and devices controlled release, such as by Pump; the most appropriate route in any given situation will depend on the nature and severity of the disease or condition being treated and the nature of the particular composition used.
  • Various delivery systems are known and can be used to administer the multi-epitope ligand protein, which can be encapsulated in liposomes, microparticles, microcapsules.
  • Pharmaceutical compositions of the polymimetic ligand protein can be prepared, typically, as approved by a regulatory agency or as a pharmaceutically acceptable composition for use in a patient.
  • the functions are widely involved in the diagnosis, or prevention, or treatment, or recovery of multi-system, tissue, organ, and cell-related diseases and conditions, as well as food, elimination, makeup, machinery, and health related diseases and conditions. Pharmacy applications of products or drugs.
  • HrpZpss multi-epitope ligand proteins that recognize and activate various types of receptors, membrane proteins and their signaling pathways in animals and induce multifunctional cascade biological effects and are used in the pharmacy of the present invention are used in diagnosis, or and application in the prevention, or treatment, or rehabilitation of diseases and conditions of the nervous system, digestive system, motor system, circulatory system, respiratory system, endocrine system, immune system, urinary system, reproductive system:
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in the diagnosis, or prevention, or treatment, or rehabilitation of neural connection diseases, dementia, Parkinson's disease, central nervous system disease, neuromuscular disease, epilepsy, Use in headache and neuralgia, peripheral neuropathy, attention deficit hyperactivity disorder and tic disorder, insomnia, depression, anxiety disorders, bipolar disorder, psychotic disorders, neurodermatitis-related neurological diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in the diagnosis, or prevention, or treatment, or recovery of gastric acid secretion disorder, gastrointestinal neurosis, gastrointestinal motility, gastrointestinal mucositis, liver Use in diseases and disorders of the digestive system associated with diseases and micro-ecological disorders;
  • the product or drug of the polyepitope ligand protein of the present invention is useful in the diagnosis, or prevention, or treatment, or rehabilitation of arthritis, muscle spasm, pain, muscular dystrophy, muscle and nerve injury, and dehydration-related motor systems Applications in diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of heart failure, arrhythmia, hypertension, myocardial injury, ischemia, angina pectoris, hyperlipidemia , calcium channel blockade, vasospasm, blood coagulation, abnormal blood picture, myocardial infarction-related circulatory system diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of asthma, chronic obstructive pulmonary disease, bronchiectasis, allergen immunity, allergy, pneumonia, acute Or chronic bronchitis, bronchial asthma, gastroesophageal reflux, rhinitis-related respiratory diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in the diagnosis, or prevention, or treatment, or rehabilitation of diabetes, thyroid disease, pituitary disease, hyperprolactinemia, diabetes insipidus, adrenal disease, Parathyroid disease, osteoporosis-related endocrine system diseases and conditions;
  • the application of the product or medicine of the multi-epitope ligand protein of the present invention in diagnosis, or prevention, or treatment, or rehabilitation of immune system diseases and conditions related to immunosuppression, rheumatoid arthritis, and lupus erythematosus;
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of nephrotic syndrome, interstitial nephritis, renal failure, urinary and reproductive system infections, pyelonephritis, Cystitis, prostatitis, urethritis, epididymitis or orchitis, benign prostatic hyperplasia, overactive bladder, sexual dysfunction-related, as well as various male and gynecological infectious inflammatory and functional diseases and other urogenital diseases and conditions Applications.
  • the products or medicines of the multi-epitope ligand protein of the present invention can be used in diagnosis, or prevention, or treatment, or rehabilitation of whole body skin cell nutrition, activation, regeneration, repair, clearing, delicate and smooth, ultraviolet melanin deposition, eczema , rough, cracked, dark lines, dry, crusty, erythema, allergies, neurodermatitis, lesions, pimples, acne, scars, dullness, mites, oily skin, inflammatory skin diseases, autoimmune skin diseases, pigmentation Skin diseases related to skin diseases, skin atrophy, thinning, dryness, hyperpigmentation, wrinkle hyperplasia, dyskeratosis, xeroderma, contact dermatitis, anti-aging, improving skin function, whitening and freckle, preventing and treating skin diseases Applications in Diseases and Conditions.
  • the preparation of the HrpNEcb polymimetic epitope ligand protein that recognizes and activates multiple types of receptors, membrane proteins and their signaling pathways in animals and induces multifunctional cascade biological effects includes the following methods:
  • HrpZpss polymimetic epitope ligand protein using the engineering bacteria containing the hrpZpss gene (GenBank: AAY36247.1) (cloned into the high-efficiency expression vector PET28a(+)), through fermentation, purification and preparation of HrpZpss polymimetic epitope Ligand protein:
  • the engineering bacteria fermentation preparation of HrpZpss protein the engineering bacteria (E. coli), the production line of the related protein is a specially modified derivative of the original K-12 bacteria JY-01 (DE3), in LB liquid medium (containing 50 micrograms of kanamycin per liter) at a certain temperature
  • LB liquid medium containing 50 micrograms of kanamycin per liter
  • IPTG isopropylthiogalactoside, Isopropyl ⁇ -D-Thiogalactosid
  • final concentration 1 mMol was added, and the cells were collected by centrifugation after continuing the culture.
  • the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system the pH range of the buffer system is 1-14; preferably pH 1-3; preferably pH 14-10; preferably pH 4-5; pH 9-7; most preferably pH 6.5-5.5;
  • the fermentation temperature range is 0-60°C.
  • the temperature is 0-20°C; preferably the temperature is 20-35°C; preferably the temperature is 60-50°C; preferably the temperature is 50-45°C; most preferably the temperature is 37-38°C;
  • Fermentation proliferation liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 0.00%-0.01%; preferably 1.00%-0.3%; most preferably 0.01%-0.05%; most preferably 0.1%-0.05%;
  • Fermentation induction liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 1.00%-0.3%; preferably 0.3%-0.1%; preferably 0.1%-0.05%; most preferably 0.05 %-0.00%;
  • Fermentation induction liquid medium lactose concentration range 10.00%-0.00%; preferably 10.00%-1.00%; preferably 0.00%-0.1%; preferably 1.00%-0.6%; preferably 0.1%-0.3%; most preferably 0.5 %-0.4%;
  • the time range of fermentation induction liquid culture is 0-24h; preferably time is 0-2h; preferably time is 24-15h; preferably time is 2-6h; preferably time is 15-10h; most preferably time is 7-9h.
  • HrpZpss polymimetic epitope ligand protein Purify HrpZpss polymimetic epitope ligand protein-His recombinant protein with NI-NTA agarose column. Purification and preparation of HrpZpss polymimetic epitope ligand protein.
  • the preparation of the HrpZpss polymimetic epitope ligand protein can also be prepared by the expression protein of an "artificially synthesized gene", and the HrpZpss polymimetic epitope ligand protein can be prepared by fermentation and purification. Somatic protein, including the following steps:
  • the artificial gene synthesis was entrusted to the GeneArt Gene Synthesis and Services Division of Thermo Fisher Scientific.
  • the advantages of artificially synthesized protein genes are: a) the synthesis cycle is short, and the sequence can be guaranteed to be 100% correct; b) the codons can be optimized to improve the expression efficiency of the gene; due to the different coding codons preferred by each species, When heterologous proteins are expressed in E. coli, some proteins are difficult to express at high levels. If the codon of the heterologous protein is changed to the codon preferred by Escherichia coli, the high-efficiency expression of the protein gene can be achieved, the expression level of the gene can be improved, and it is suitable for large-scale industrial production; c) The gene can be designated as needed. Mutations are used to modify genes and improve the efficiency of proteins; d) researchers can design genes that are difficult to obtain or even do not exist in nature according to their own wishes.
  • the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system the pH range of the buffer system is 1-14; preferably pH 1-3; preferably pH 14-10; preferably pH 4-5; pH 9-7; most preferably pH 6.5-5.5;
  • the fermentation temperature range is 0-60°C.
  • the temperature is 0-20°C; preferably the temperature is 20-35°C; preferably the temperature is 60-50°C; preferably the temperature is 50-45°C; most preferably the temperature is 37-38°C;
  • Fermentation proliferation liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 0.00%-0.01%; preferably 1.00%-0.3%; most preferably 0.01%-0.05%; most preferably 0.1%-0.05%;
  • Fermentation induction liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 1.00%-0.3%; preferably 0.3%-0.1%; preferably 0.1%-0.05%; most preferably 0.05 %-0.00%;
  • Fermentation induction liquid medium lactose concentration range 10.00%-0.00%; preferably 10.00%-1.00%; preferably 0.00%-0.1%; preferably 1.00%-0.6%; preferably 0.1%-0.3%; most preferably 0.5 %-0.4%;
  • the time range of fermentation induction liquid culture is 0-24h; preferably time is 0-2h; preferably time is 24-15h; preferably time is 2-6h; preferably time is 15-10h; most preferably time is 7-9h.
  • HrpZpss polymimetic epitope ligand protein Purify HrpZpss polymimetic epitope ligand protein-His recombinant protein with NI-NTA agarose column. Purification and preparation of HrpZpss polymimetic epitope ligand protein.
  • the high-efficiency expression of HrpZpst protein adopted in the present invention comprises the following steps:
  • HrpZpst protein The engineering bacteria fermentation preparation of HrpZpst protein: the genes (including, but not limited to, natural genes of biological samples, chemically synthesized genes, transgenic genetic recombinant genes, and similar genes and their genes) encoding HrpZpst polymimetic epitope ligand proteins are used.
  • Modified) plasmid engineering bacteria E.coli
  • IPTG isopropyl thiogalactoside, Isopropyl ⁇ -D-Thiogalactosid
  • the expression product HrpZpst protein was analyzed by 10% SDS-PAGE polyacrylamide gel electrophoresis.
  • the high-pressure crusher crushes engineering bacteria, and continuously uses 800-1000Mpa pressure to crush engineering bacteria.
  • centrifugal force range 1000-8000g, preferably centrifugal force 1000-2000g; preferably centrifugal force 2000-3500g; preferably centrifugal force 8000-6000g; preferably centrifugal force 6000-4500g; most preferably The centrifugal force is 3500-4500g.
  • the HrpZpst poly-epitope ligand protein was present in the supernatant.
  • the application route of the HrpZpst protein preparation that recognizes and activates multiple types of receptors, membrane proteins and their signaling pathways in animals and induces multifunctional cascade biological effects according to the present invention can be administered by any route known to those skilled in the art, Such routes include internal, topical, oral, injection, intramuscular, intravenous, intradermal, intraperitoneal, subcutaneous, nasal, oral, rectal, topical, buccal and transdermal administration or any route; by any convenient HrpZpst polyepitopic ligand proteins are administered by routes such as by perfusion or rapid perfusion, absorption through epithelia or mucocutaneous linings (eg, oral mucosa, nasal mucosa, gastric mucosa, rectal and intestinal mucosa, etc.), and can be combined with other
  • the bioactive agents are administered sequentially, intermittently, or in the same composition; the administration may be topical, topical, or systemic, depending on the site of treatment.
  • Topical application to the area in need of treatment can be, but is not limited to, local infusion, topical application, by immersion, by injection, by catheter, by suppository; administration can also include controlled release systems, including controlled release formulations and devices controlled release, such as by Pump; the most appropriate route in any given situation will depend on the nature and severity of the disease or condition being treated and the nature of the particular composition used.
  • Various delivery systems are known and can be used to administer polymimetic ligand proteins, which can be encapsulated in liposomes, microparticles, microcapsules.
  • Pharmaceutical compositions of the polymimetic ligand protein can be prepared, typically, as approved by a regulatory agency or as a pharmaceutically acceptable composition for use in a patient.
  • the preparations or medicines involving HrpZpst multi-epitope ligand proteins that recognize and activate various types of receptors, membrane proteins and their signaling pathways in animals and induce multi-functional cascade biological effects used in the pharmacy of the present invention are used in diagnosis, or and application in the prevention, or treatment, or rehabilitation of diseases and conditions of the nervous system, digestive system, motor system, circulatory system, respiratory system, endocrine system, immune system, urinary system, reproductive system:
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in the diagnosis, or prevention, or treatment, or rehabilitation of neural connection diseases, dementia, Parkinson's disease, central nervous system disease, neuromuscular disease, epilepsy, Use in headache and neuralgia, peripheral neuropathy, attention deficit hyperactivity disorder and tic disorder, insomnia, depression, anxiety disorders, bipolar disorder, psychotic disorders, neurodermatitis-related neurological diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in the diagnosis, or prevention, or treatment, or recovery of gastric acid secretion disorder, gastrointestinal neurosis, gastrointestinal motility, gastrointestinal mucositis, liver Use in diseases and disorders of the digestive system associated with diseases and micro-ecological disorders;
  • the product or drug of the polyepitope ligand protein of the present invention is useful in the diagnosis, or prevention, or treatment, or rehabilitation of arthritis, muscle spasm, pain, muscular dystrophy, muscle and nerve injury, and dehydration-related motor systems Applications in diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of heart failure, arrhythmia, hypertension, myocardial injury, ischemia, angina pectoris, hyperlipidemia , calcium channel blockade, vasospasm, blood coagulation, abnormal blood picture, myocardial infarction-related circulatory system diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of asthma, chronic obstructive pulmonary disease, bronchiectasis, allergen immunity, allergy, pneumonia, acute Or chronic bronchitis, bronchial asthma, gastroesophageal reflux, rhinitis-related respiratory diseases and conditions;
  • the products or medicines of the multi-epitope ligand protein of the present invention are used in the diagnosis, or prevention, or treatment, or rehabilitation of diabetes, thyroid disease, pituitary disease, hyperprolactinemia, diabetes insipidus, adrenal disease, Parathyroid disease, osteoporosis-related endocrine system diseases and conditions;
  • the application of the product or medicine of the multi-epitope ligand protein of the present invention in diagnosis, or prevention, or treatment, or rehabilitation of immune system diseases and conditions related to immunosuppression, rheumatoid arthritis, and lupus erythematosus;
  • the products or medicines of the multi-epitope ligand protein described in the present invention are used in diagnosis, or prevention, or treatment, or rehabilitation of nephrotic syndrome, interstitial nephritis, renal failure, urinary and reproductive system infections, pyelonephritis, Cystitis, prostatitis, urethritis, epididymitis or orchitis, benign prostatic hyperplasia, overactive bladder, sexual dysfunction-related, as well as various male and gynecological infectious inflammatory and functional diseases and other urogenital diseases and conditions Applications.
  • the products or medicines of the multi-epitope ligand protein of the present invention can be used in diagnosis, or prevention, or treatment, or rehabilitation of whole body skin cell nutrition, activation, regeneration, repair, clearing, delicate and smooth, ultraviolet melanin deposition, eczema , rough, cracked, dark lines, dry, crusty, erythema, allergies, neurodermatitis, lesions, pimples, acne, scars, dullness, mites, oily skin, inflammatory skin diseases, autoimmune skin diseases, pigmentation Skin diseases related to skin diseases, skin atrophy, thinning, dryness, hyperpigmentation, wrinkle hyperplasia, dyskeratosis, xeroderma, contact dermatitis, anti-aging, improving skin function, whitening and freckle, preventing and treating skin diseases Applications in Diseases and Conditions.
  • the preparation of the HrpZpst polymimetic epitope ligand protein that recognizes and activates multiple types of receptors, membrane proteins and their signaling pathways in animals and induces multifunctional cascade biological effects includes the following methods:
  • IPTG isopropyl thiogalactoside, Isopropyl ⁇ -D-Thiogalactosid
  • the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system the pH range of the buffer system is 1-14; preferably pH 1-3; preferably pH 14-10; preferably pH 4-5; pH 9-7; most preferably pH 6.5-5.5;
  • the fermentation temperature range is 0-60°C.
  • the temperature is 0-20°C; preferably the temperature is 20-35°C; preferably the temperature is 60-50°C; preferably the temperature is 50-45°C; most preferably the temperature is 37-38°C;
  • Fermentation proliferation liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 0.00%-0.01%; preferably 1.00%-0.3%; most preferably 0.01%-0.05%; most preferably 0.1%-0.05%; fermentation induction liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 1.00%-0.3%; preferably 0.3%-0.1%; preferably 0.1%-0.05 %; most preferably 0.05%-0.00%; fermentation induction broth lactose concentration range 10.00%-0.00%; preferably 10.00%-1.00%; preferably 0.00%-0.1%; preferably 1.00%-0.6%; preferably 0.1%-0.3%; most preferably 0.5%-0.4%;
  • the time range of fermentation induction liquid culture is 0-24h; preferably time is 0-2h; preferably time is 24-15h; preferably time is 2-6h; preferably time is 15-10h; most preferably time is 7-9h.
  • HrpZpst polymimetic epitope ligand protein Purify HrpZpst polymimetic epitope ligand protein-His recombinant protein with NI-NTA agarose column. Purification and preparation of HrpZpst polymimetic epitope ligand protein.
  • the preparation of the HrpZpst polymimetic epitope ligand protein can also be prepared by the expression protein of "artificially synthesized gene", and the HrpZpst polymimetic epitope ligand protein can be prepared by fermentation and purification, specifically including the following step:
  • the artificial gene synthesis was entrusted to the GeneArt Gene Synthesis and Services Division of Thermo Fisher Scientific.
  • the advantages of artificially synthesized protein genes are: a) the synthesis cycle is short, and the sequence can be guaranteed to be 100% correct; b) the codons can be optimized to improve the expression efficiency of the gene; due to the different coding codons preferred by each species, When heterologous proteins are expressed in E. coli, some proteins are difficult to express at high levels. If the codon of the heterologous protein is changed to the codon preferred by Escherichia coli, the high-efficiency expression of the protein gene can be achieved, the expression level of the gene can be improved, and it is suitable for large-scale industrial production; c) The gene can be designated as needed. Mutations are used to modify genes and improve the efficiency of proteins; d) researchers can design genes that are difficult to obtain or even do not exist in nature according to their own wishes.
  • the HrpZpst protein encodes a 36.52kda band on the sample lane of the electrophoresis gel plate, which is the HrpZps
  • the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system the pH range of the buffer system is 1-14; preferably pH 1-3; preferably pH 14-10; preferably pH 4-5; pH 9-7; most preferably pH 6.5-5.5;
  • the fermentation temperature range is 0-60°C.
  • the temperature is 0-20°C; preferably the temperature is 20-35°C; preferably the temperature is 60-50°C; preferably the temperature is 50-45°C; most preferably the temperature is 37-38°C;
  • Fermentation proliferation liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 0.00%-0.01%; preferably 1.00%-0.3%; most preferably 0.01%-0.05%; most preferably 0.1%-0.05%;
  • Fermentation induction liquid medium glucose concentration range 3.00%-0.00%; preferably 3.00%-1.00%; preferably 1.00%-0.3%; preferably 0.3%-0.1%; preferably 0.1%-0.05%; most preferably 0.05 %-0.00%;
  • Fermentation induction liquid medium lactose concentration range 10.00%-0.00%; preferably 10.00%-1.00%; preferably 0.00%-0.1%; preferably 1.00%-0.6%; preferably 0.1%-0.3%; most preferably 0.5 %-0.4%;
  • the time range of fermentation induction liquid culture is 0-24h; preferably time is 0-2h; preferably time is 24-15h; preferably time is 2-6h; preferably time is 15-10h; most preferably time is 7-9h.
  • HrpZpst polymimetic epitope ligand protein Purify HrpZpst polymimetic epitope ligand protein-His recombinant protein with NI-NTA agarose column. Purification and preparation of HrpZpst polymimetic epitope ligand protein.
  • HrpZ-type multi-epitope ligand proteins as a class of ligand proteins rich in multiple linear and conformational epitopes with special structures, can recognize, activate and bind membrane receptors, membrane proteins, Information pathways and metabolic pathways, HrpZ-type multi-epitope ligand proteins are a class of ligand proteins with special multiple epitope structures, new functions, new mechanisms of action and new application prospects. They induce multi-directional, multi-level and Multi-faceted biological effects and functions, widely involved in the diagnosis, or prevention, or treatment, or recovery of multi-system, multi-tissue, multi-organ, and multi-cell related diseases and conditions, and related diseases and conditions. , eliminate font size, makeup font size, mechanical font size and health font size products or drugs in the pharmaceutical application.
  • Figure 1 shows the electrophoresis detection of the HrpZpst polymimetic epitope ligand protein before and after purification: the left side is the molecular weight marker band, of which 1: the highly expressed HrpZpst polymimetic epitope ligand protein band (before purification); 2: the polymimetic epitope protein after purification The ligand protein HrpZpst band;
  • Fig. 2 is that HrpZpst multi-epitope ligand protein liquid injection induces allergic reaction diagram of tobacco leaves: the focal spot is formed through HrpZpst protein liquid processing about 24hr, both sides: H 2 O injection; 1, 2: HrpZpst Protein solution (300 ⁇ g/ml) injection, that is, the hypersensitivity reaction of HrpZpst protein on tobacco leaves, both sides are controls, 1 and 2 are treatments;
  • Figure 3 is a volcano plot of the HrpZpst multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to express differentially expressed genes in the liver, from left to right: oral administration for 6 hours, oral administration for 24 hours;
  • Figure 4 is a volcano diagram of the HrpZpst polyepitopic ligand protein of the present invention induced by oral administration and smearing of experimental mice to induce differential gene expression in the thalamus, from left to right: oral administration for 6h, oral administration for 24h; smear for 6h;
  • Figure 5 is a volcano plot of the HrpZpst multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to express differentially expressed genes in the heart, from left to right: oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 6 is a volcano diagram of the HrpZpst multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to express differentially expressed genes in the cerebral cortex, from left to right: oral administration for 6 hours, oral administration for 24 hours; application for 6 hours, application for 12 hours;
  • Figure 7 is a volcano diagram of the HrpZpst multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to induce differential gene expression in the hippocampus of the brain, from left to right: oral administration for 6h, oral administration for 24h;
  • Figure 8 is a cluster heat map of the differentially expressed genes in the liver induced by oral administration of HrpZpst multi-epitope ligand protein and smearing experimental mice, from left to right: oral administration for 6h, oral administration for 24h; application for 6h; (treatment group left 3 Lane, control group, lane 4 from the right);
  • Figure 9 is a clustering heat map of the differentially expressed gene sets in the thalamus induced by oral administration of HrpZpst multi-epitope ligand protein and smearing experimental mice, from left to right: oral administration for 6h, oral administration for 24h; application for 6h; (treatment group left 3 Lane, control group, lane 4 from the right);
  • Figure 10 is a cluster heat map of HrpZpst multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to induce differentially expressed gene sets in the hippocampus, from left to right: oral administration for 6h, oral administration for 24h; 3 lanes from the left of the group, 3 lanes from the right of the treatment group);
  • Figure 11 is a clustering heat map of the differentially expressed gene sets in the cerebral cortex induced by oral administration of HrpZpst multi-epitope ligand protein and smearing of experimental mice, from left to right: oral administration for 6h, oral administration for 24h; application for 6h, application for 12h; ( 3 lanes on the left in the control group, 3 lanes on the right in the treatment group);
  • Figure 12 shows the comparison of the KEGG Pathway (total gene) in the liver of the experimental mice treated with the HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right: oral administration for 6h, oral administration for 24h; smear for 6h;
  • Figure 13 shows the comparison of KEGG Pathway (up-regulated gene) in the liver of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention and the control.
  • Figure 14 shows the comparison of the KEGG Pathway (down-regulated gene) in the liver of the experimental mice treated with the HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h and oral administration for 24h;
  • Figure 15 shows the comparison of the KEGG Pathway (total gene) of the experimental mouse heart treated with the HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smearing for 6h, smearing for 12h;
  • Figure 16 shows the comparison of KEGG Pathway (up-regulated gene) in the heart of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 17 shows the comparison of the KEGG Pathway (down-regulated gene) in the hearts of experimental mice treated with the HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6 hours, oral administration for 24 hours;
  • Figure 18 is the comparison of KEGG Pathway (total gene) in the hippocampus of experimental mice treated with HrpZpst poly-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smearing for 6h, smearing for 12h;
  • Figure 19 shows the comparison of KEGG Pathway (up-regulated gene) in the hippocampus of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention (up-regulated genes), from left to right, oral administration for 6h, oral administration for 24h; smearing 6h, smearing 12h;
  • Figure 20 is a comparison of KEGG Pathway (down-regulated gene) in the hippocampus of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 21 shows the comparison of KEGG Pathway (total gene) in the cerebral cortex of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 22 shows the comparison of KEGG Pathway (up-regulated gene) in the cerebral cortex of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention (up-regulated genes), from left to right, oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 23 shows the comparison of KEGG Pathway (down-regulated gene) in the cerebral cortex of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smear for 6h, smear for 12h;
  • Figure 24 is a comparison of the KEGG Pathway (total gene) of the rat cerebral thalamus treated with the HrpZpst multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h; smear for 6h;
  • Figure 25 shows the comparison of KEGG Pathway (up-regulated gene) in the cerebral thalamus of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention (up-regulated gene), from left to right, oral administration for 6h, oral administration for 24h;
  • Figure 26 shows the comparison of KEGG Pathway (down-regulated gene) in the cerebral thalamus of experimental mice treated with HrpZpst multi-epitope ligand protein of the present invention (down-regulated gene), from left to right, oral administration for 6h, oral administration for 24h; smearing for 6h;
  • Figure 27 is a flow chart of the mRNA (RNA-Seq) sequencing experiment of the present invention.
  • Figure 28 is a flow chart of mRNA sequencing data analysis of the present invention.
  • Figure 29 shows the electrophoresis detection of HrpZpss protein before and after purification: the left side is the molecular weight marker band, 1: HrpZpss multi-mimetic epitope ligand protein band before purification; 2: HrpZpss multi-mimetic epitope ligand protein band after purification;
  • Figure 30 is a graph of the allergic reaction of tobacco leaves induced by HrpZpss multi-mimetic epitope ligand protein liquid injection: the focal spots seen are formed by HrpZpss multi-mimetic epitope ligand protein liquid treatment for about 24hr, both sides: H 2 O injection ; 3, 4: HrpZpss multi-epitope ligand protein solution (300 ⁇ g/ml) injection, namely the hypersensitivity reaction of HrpZpss multi-epitope ligand protein on tobacco leaves, both sides are controls, 3 and 4 are treatments;
  • Figure 31 is a volcano plot of the HrpHrpZpss multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to express differentially expressed genes in the kidneys, from left to right: oral administration for 6 hours, oral administration for 24 hours; application for 6 hours;
  • Figure 32 is a volcano diagram of the HrpHrpZpss multi-epitope ligand protein of the present invention induced by oral administration and smearing of experimental mice to express differentially expressed genes in testis, from left to right: oral administration for 6h, oral administration for 24h; smear for 6h;
  • Figure 33 is a cluster heat map of the differentially expressed gene sets in the kidneys induced by oral administration of the HrpHrpZpss multi-epitope ligand protein of the present invention and smearing in experimental mice, from left to right: oral administration for 6 hours, oral administration for 24 hours; application for 6 hours;
  • Figure 34 is a cluster heat map of the differentially expressed genes in testis induced by oral administration of HrpHrpZpss multi-epitope ligand protein and smearing in experimental mice, from left to right: oral administration for 6 hours, oral administration for 24 hours; application for 6 hours;
  • Figure 35 shows the comparison of the KEGG Pathway (total gene) of the experimental mouse kidney treated with the HrpZpss multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6 hours, oral administration for 24 hours;
  • Figure 36 shows the comparison of the KEGG Pathway (up-regulated gene) in the kidneys of experimental mice treated with HrpZpss multi-epitope ligand protein of the present invention (up-regulated genes), from left to right, oral administration for 6h, oral administration for 24h; smearing for 6h;
  • Figure 37 shows the comparison of the KEGG Pathway (down-regulated gene) in the kidneys of experimental mice treated with HrpZpss multi-epitope ligand protein of the present invention and the control, from left to right: oral administration for 6h, oral administration for 24h; smear for 6h;
  • Figure 38 shows the comparison of KEGG Pathway (total gene) in the testis of experimental mice treated with HrpZpss multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h;
  • Figure 39 shows the comparison of KEGG Pathway (up-regulated gene) in the testis of experimental mice treated with HrpZpss multi-epitope ligand protein of the present invention (up-regulated gene), from left to right, oral administration for 6h, oral administration for 24h; smearing for 6h;
  • Figure 40 shows the comparison of KEGG Pathway (down-regulated genes) in the testis of experimental mice treated with HrpZpss multi-epitope ligand protein of the present invention and the control, from left to right, oral administration for 6h, oral administration for 24h;
  • Figure 41 is a flow chart of the mRNA (RNA-Seq) sequencing experiment of the present invention.
  • Figure 42 is a flow chart of mRNA sequencing data analysis of the present invention.
  • test methods used in the following examples are conventional methods unless otherwise specified.
  • the HrpZpst multi-epitope ligand protein is fermented, purified, prepared and collected using the engineered bacteria with the registered (Pseudomonas syringae pv tomato Strain CSCS008) hrpZpst gene (GenBank: AY999001) (cloned into the high-efficiency expression vector PET28a(+)) plasmid
  • the HrpZpst polymimetic epitope ligand protein specifically includes the following steps:
  • E.coli engineering bacteria fermentation preparation of HrpZpst multi-epitope ligand protein
  • the pH of the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system is 6.5-5.5; the fermentation temperature is 37-38° C.; the glucose concentration of the fermentation and proliferation liquid medium is 0.01%-0.05%; 0.05%-0.00%; the lactose concentration of the fermentation induction liquid medium is 0.5%-0.4%; the fermentation induction liquid culture time is 7-9h.
  • the HrpZpst poly-epitope ligand protein was present in the supernatant.
  • the HrpNEcb protein is prepared by the expression protein of "artificially synthesized gene", which specifically includes the following steps:
  • the first step artificial synthesis of the hrpZpst gene encoding the HrpZpst protein
  • Step 2 2) According to the above DNA sequence, when artificially synthesizing protein gene, add BamHI and HindIII enzyme cleavage sites to the 5' and 3' of the gene respectively to facilitate protein gene cloning;
  • the third step artificial gene synthesis is entrusted to the GeneArt gene synthesis and service department of Thermo Fisher Scientific. 3)
  • the synthetic DNA fragments encoding the HrpZpst protein gene are cloned into the BamHI-HindIII site of the high-efficiency protein expression vector PET28a(+) (containing His-Tag label) one by one, and the accuracy of the clone is ensured through DNA sequencing;
  • the fourth step clone the gene encoding HrpZpst protein from 1) to 3) and transfer it into Escherichia coli engineering bacteria (E.coli), and the production line (E.coli) of the relevant protein is the original K-12 bacteria after special transformation.
  • the fermentation medium is Na 2 HPO 4 -KH 2 PO 4 buffer system
  • the pH of the buffer system is 6.5-5.5
  • the concentration of glucose in the fermentation and proliferation liquid medium is 0.01%-0.05%
  • the concentration of lactose in the fermentation induction liquid medium is 0.5%- 0.4%;
  • Step 5 Suspend the collected cells into Na 2 HPO 4 -KH 2 PO 4 buffer, complete the sterilization treatment at 80°C for 30 minutes, quickly cool down to 30°C, and place in a butterfly continuous flow centrifuge. Wash the engineering bacteria five to eight times, import it into a high-pressure crusher, and continuously use 800-1000Mpa pressure to crush the engineering bacteria, pass the crushed bacteria liquid into a butterfly continuous flow centrifuge, remove the cell wall, and collect HrpZpst polymimetic epitope ligands The protein molecule, HrpZpst multi-epitope ligand protein, was present in the supernatant;
  • the polymimetic epitope ligand protein-His recombinant protein was purified by NI-NTA agarose column.
  • the protein purification was carried out according to the method recommended by the manufacturer of the NI-NTA agarose column to complete the purification and preparation of the HrpZpst polymimetic epitope ligand protein. .
  • the highly expressed purified protein-His recombinant band was detected by 10% SDS polyacrylamide gel electrophoresis, see Figure 1 for details.
  • the left side is the molecular weight identification band
  • lane 1 is the electrophoresis band before purification, and there are more bands in the corresponding molecular weight region, including the 36.52kda band
  • lane 2 is the purified HrpZpst protein band
  • the molecular weight is 36.52kda, which is in the corresponding molecular weight region of the protein, indicating that the corresponding purified HrpZpst polymimetic epitope ligand protein has been obtained.
  • the allergy test detection of the purified polymimetic epitope ligand protein HrpZpst polymimetic epitope ligand protein preparation and the reaction results of tobacco leaves after 24hr of sterile water treatment are shown in Figure 2, wherein, A, C The point is the injection of 300 ⁇ g ⁇ mL -1 of HrpZpst polymimetic epitope ligand protein solution of 100 ⁇ L; the points B and D are the injection of 100 ⁇ L of sterile water as the control treatment. 300 ⁇ g ⁇ mL -1 of HrpEcb poly-epitope ligand protein solution treatment for about 12hrs caused tobacco leaves to shrink and collapse, and 24hrs to die; the water control treatment of tobacco leaves had no allergic reaction.
  • the purified multi-epitope ligand protein can generally induce hypersensitivity reactions in various plant leaves.
  • the tested plant species can be: tobacco, pepper, eggplant, tomato, potato, strawberry, cucumber, spinach, celosia, glass begonia, September chrysanthemum, pansy, nopal, petunia, grape, rose, locust tree, pea, peach tree, bunch of red, loofah, green beans, cauliflower, spinach, rape, yam, cowpea, broad bean, corn, 36 kinds of different plants such as rice, soybean, cyclamen, mulberry, pumpkin, loquat, toon tree, etc.
  • the research object of mRNA sequencing is all RNAs with a poly-A tail that can be transcribed by a specific cell in a certain functional state, mainly mRNA.
  • Cell-generated mRNA is converted into DNA (cDNA, complementation, and library construction of the obtained cDNA) by a process of reverse transcription.
  • the resulting DNA is then sequenced and from the observed abundance of specific DNA, the original amount of mRNA in the cell can be inferred from it to find genes or transcripts whose transcription levels change under the experimental conditions, i.e. differentially expressed.
  • mice 8-week-old balb/C mice were selected for the experiment and divided into HrpZpst multi-epitope ligand protein treatment groups, including oral administration for 6 hours, 24 hours, and application for 6 hours and 12 hours, a total of 4 treatments. There were 3 experimental mice for each treatment, a total of 12 mice; the blank control group had 4 experimental mice; the buffer without HrpZpst multi-epitope ligand protein controlled the sham-operated group, including oral administration for 6 hours, 24 hours and application for 6 hours, 12 hours.
  • mice in the experimental treatment group were fed and smeared with HrpZpst polymimetic ligand protein buffer at a concentration of 600 mg ⁇ L-1
  • the mice in the buffer control sham-operated group were fed and smeared with buffer, and the mice in the blank control group did not receive any treatment.
  • the mice were grouped into liver, thalamus, heart, cerebral cortex, cerebral hippocampus and other tissues for RNA-Seq sequencing and analysis.
  • RNA-Seq mRNA sequencing experimental flow chart
  • RNA extraction of the samples was performed using the miRNeasy Micro Kit (Cat#1071023 Qiagen) and according to the standard operating procedure provided by the manufacturer.
  • Total RNA was quality-checked by NanoDrop ND-2000 spectrophotometer and Agilent Bioanalyzer 4200 (Agilent technologies, Santa Clara, CA, US), and RNA that passed the quality check was used for subsequent sequencing experiments.
  • Oligo(dT) can be used to enrich mRNAs with polyA tails.
  • the enriched mRNA is then subjected to fragmentation, double-stranded cDNA synthesis, end repair, addition of A at the 3' end, ligation of adapters, and amplification.
  • the constructed library uses 2.0 Fluorometer detects concentration, Agilent2100 detects size.
  • Illumina sequencing is performed on the library, and the sequencer captures the fluorescent signal and converts the light signal into a sequencing peak through computer software to obtain the sequence information of the fragment to be detected.
  • the differential gene volcano plot was used to display the overall distribution of genes with significant differential expression induced by HrpZpst multi-epitope ligand protein.
  • Horizontal axis fold change of gene expression in different samples (log2 Fold-Change); vertical axis: significant level of gene expression difference (-log10 p-value); the expression of the right point is significantly up-regulated gene; the expression of the left point Significantly down-regulated genes; genes with no significant changes in expression at lower points.
  • Figures 3-7 show the differential gene volcano map of HrpZpst multi-epitope ligand protein induced by oral administration and smearing in the liver, thalamus, heart, cerebral cortex and cerebral hippocampus of mice, respectively. HrpZpst is abbreviated as Z1 in the figure.
  • FIGS. 8-11 are cluster heatmaps of differentially expressed gene sets in liver, thalamus, cerebral cortex, and hippocampus, respectively. HrpZpst is abbreviated as Z1 in the figure.
  • Gene Ontology is an ontology widely used in the field of bioinformatics.
  • Gene Ontology is a description of genes in different dimensions and levels, covering biological processes (biological_process), cellular components (cellular_component) and molecular functions (molecular_function).
  • biological processes are describing which biological processes the gene is involved in; cellular components explain where the gene is present, including whether the gene is in the cytoplasm or in the nucleus? If cytoplasm is present in which organelle? If it is in the mitochondria, is it on the mitochondrial membrane or in the matrix of the mitochondria, etc., this information belongs to the cell group; the molecular function explains what is the function of the gene at the molecular level?
  • Gene Ontology database is a structured standard biological model constructed by the GO organization (Gene Ontology Consortium) in 2000. It aims to establish a standard vocabulary system for knowledge of genes and their products, covering the biological process of genes. process), cellular component, molecular function.
  • Term is the basic description unit in GO. GO Terms are used to describe the function of gene products. By performing GO enrichment analysis on differential genes, genes can be classified according to different functions, so as to achieve the purpose of annotating and classifying genes.
  • HrpZpst multi-epitope ligand protein we carried out GO term enrichment analysis on the differentially expressed genes induced by HrpZpst multi-epitope ligand protein, and the results proved and confirmed that HrpZpst multi-epitope ligand protein, as a class of special structures with multiple epitopes, new functions , a ligand protein with a new mechanism of action and a new application prospect, induced the differential expression of multiple genes in multiple organs (liver, thalamus, heart, cerebral cortex and brain hippocampus, etc.) of the tested mice, and these differentially expressed genes covered biological processes. , cellular components and molecular functions. Differentially expressed genes were analyzed by GO using Fisher's exact test. Fisher's exact test was calculated to obtain the p-value, and multiple hypothesis test correction was performed to obtain the q-value. GO entries with p-value less than 0.05 were screened as significantly enriched GO entries.
  • the results of GO enrichment analysis of differential genes induced by HrpZpst protein are further expressed as follows: 1 biological process (biological_process) related differentially expressed genes include reproduction, cell death, immune system process, behavior, metabolic process, cellular process, reproductive process, biological adhesion attachment, signaling, multicellular biological processes, developmental processes, growth, movement, processes in a single tissue, biological phases, rhythmic processes, positive regulation of biological processes, negative regulation of biological processes, regulation of biological processes, stimulus response, localization, biology Regulation, organization or biogenesis of cellular components, cell aggregation, detoxification, and presynaptic processes involve synaptic transmission.
  • the results of GO enrichment analysis of biological processes are shown in Tables 1 to 6.
  • differentially expressed genes related to cellular components cover cells and extracellular regions, nucleoids, membranes, virus particles, cell junctions, extracellular matrix, cell membrane closed cavity, complex macromolecules, organelles, extracellular matrix components, cells Parts of the outer region, organelle parts, virion parts, membrane parts, synaptic parts, cell parts, synapses, and cellular supramolecular fibers, etc.
  • the results of GO enrichment analysis of cell components are shown in Table 1 to Table 6.
  • Molecular function-related differentially expressed genes cover transcription factor activity, protein binding, nucleic acid binding transcription factor activity, catalytic activity, signal sensor activity, structural molecular activity, transport activity, binding, electron carrier activity, and morphogen activity , antioxidant activity, metal chaperone protein activity, protein labeling, chemoattractant activity, translation regulation, chemorepellent activity, active molecular sensors, molecular function regulation, etc.
  • the molecular function GO enrichment analysis results are shown in Table 1 to Table 6.
  • HrpZpst in Tables 1-6 is abbreviated as HrpZ1.
  • HrpZ1 HrpZ1
  • blanks indicate that the corresponding data that does not meet the standard of p-value less than 0.05 have not been collected.
  • the blanks in the following and all tables have the same meaning.
  • Table 1 HrpZpst multi-epitope ligand protein induces the biological process, cellular components and molecular function-related functional groups of the liver and the heart to significantly up-regulate the expression of GO terms. 12 hours)
  • HrpZpst multi-epitope ligand protein induces the biological process, cellular components and molecular function-related functional groups of the thalamus and hippocampus to significantly up-regulate the expression of GO terms. 12 hours
  • HrpZpst multi-epitope ligand protein induces the biological process, cellular components and molecular function-related functional groups of the thalamus and hippocampus to significantly down-regulate the expression of GO terms. 12 hours
  • Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database for systematic analysis of gene function and genomic information. The process of gene and expression information is studied holistically as a network.
  • KEGG The main feature of KEGG is to link genes with various biochemical reactions, providing integrated metabolic pathways.
  • KEGG currently contains a total of 19 sub-databases, which are classified into three categories: systematic information, genomic information and chemical information. In organisms, different gene products coordinate with each other to perform biological functions.
  • Pathway annotation analysis of differentially expressed genes is helpful for further interpretation of gene functions.
  • the KEGG pathway enrichment analysis was performed on the differentially expressed genes induced by HrpZpst protein to obtain the roles (upstream and downstream relationship) and biological functions of these differentially expressed genes in the signaling pathway, and to deeply understand the relationship between genes and functions.
  • Pathway analysis of differentially expressed genes was performed using Fisher's exact test. Fisher's exact test was calculated to obtain the p-value, and multiple hypothesis test correction was performed to obtain the q-value. Pathways with p-value less than 0.05 were screened as significantly enriched Pathways.
  • HrpZpst multi-epitope ligand protein as a kind of ligand protein with multi-epitope special structure, new function, new mechanism of action and new application prospect, induces multiple organs (liver, thalamus) of mice. , heart, cerebral cortex and brain hippocampus, etc.) differential expression of multiple genes, these differentially expressed genes are involved in cellular processes (Cellular Processes), environmental information processing (Environmental Information Processing), genetic information processing (Genetic Information Processing), metabolism Functional pathways such as Metabolism and Organismal Systems.
  • Cellular Processes Cellular Processes
  • environmental information processing Environmental Information Processing
  • genetic information processing Genetic Information Processing
  • metabolism Functional pathways such as Metabolism and Organismal Systems.
  • HrpZpst multi-epitope ligand protein are involved in biological processes such as translation, replication and repair, folding, classification and degradation (see Figure 12 to Figure 26 for details) .
  • 4Metabolism Multiple differentially expressed genes induced by HrpZpst polyepitopic ligand protein are involved in biodegradation and metabolism, nucleotide metabolism, metabolism of other amino acids, metabolic cofactors and vitamins, lipid metabolism, sugar Global and overview maps of biosynthesis and metabolism, energy metabolism, carbohydrate metabolism and amino acid metabolism and other metabolic processes (see Figure 12 to Figure 26 for details).
  • the right side of the figure shows the cellular process, information process, genetic information process, metabolic process, and tissue phylogenetic process; abscissa: the number of genes in each functional gene group involved in expression differences; ordinate: cellular processes involved in expression differences, Functional gene groups for information processes, genetic information processes, metabolic processes, and tissue phylogeny.
  • the HrpZpst polymimetic epitope ligand protein-His recombinant protein was purified by NI-NTA agarose column. The protein purification was carried out according to the method recommended by the NI-NTA agarose column manufacturer. The prepared HrpZpst polymimetic epitope ligand protein was used for later use. (hereinafter referred to as capture protein or target protein).
  • bait protein Extraction of total protein from cultured hepatocytes (hereinafter referred to as bait protein) for experiments
  • Biotin blocking 1Add 250 ⁇ l biotin blocking solution to the Spin Column tube. Tighten the top cover and bottom stopper, and gently invert 4 times to mix; 2Incubate at room temperature for 5 min. Remove the top cover, put the Spin Column tube in the collection tube, and centrifuge at 1250 ⁇ g for 50s; 3 Repeat steps 1 and 2 once; 4 Add 250 ⁇ l of TBS to the Spin Column tube. Tighten the top cap and invert it upside down 4 times to mix it up; 5Remove the top cap, put it in a collection tube, and centrifuge at 1250 ⁇ g for 50s; 6Repeat steps 3 and 4 twice, and put the Spin Column tube back into the collection tube Tube.
  • HrpZpst multi-epitope ligand protein recognizes bound cell membrane receptors: recognizes and binds to 5 membrane receptors, including HLA-C major histocompatibility complex, class I, C receptors, ASGPR1 asialoglycoprotein Receptor 1, adipocyte plasma membrane-associated protein receptor (APMAP), insulin-like growth factor 2 receptor (IGF2R), LDL receptor-associated protein 1 (LRPAP1).
  • HLA-C major histocompatibility complex class I, C receptors, ASGPR1 asialoglycoprotein Receptor 1, adipocyte plasma membrane-associated protein receptor (APMAP), insulin-like growth factor 2 receptor (IGF2R), LDL receptor-associated protein 1 (LRPAP1).
  • HrpZpst multi-epitope ligand protein recognizes bound cell membrane proteins: recognizes and binds to 10 membrane proteins, including solute carrier family 38, member 2 (SLC38A2), DNM2 dynein 2, SPTAN1 non-erythrocyte 1 ⁇ spectrin, ⁇ - Mutual protein 1 (SNTB1), CAP1 adenylate cyclase-related protein 1, ICAM1 intercellular adhesion molecule 1, LanC-like protein 1 (lanthionine synthase C) (LANCL1), MLEC stress protein-androgen Hormone-like receptor kinase, TJP2 claudin 2, ZYX patchin.
  • HrpZpst multi-epitope ligand protein recognition and binding of membrane proteins involved in signaling pathways recognition and binding of 4, including hsa04933 age-anger signaling pathway in diabetes complications, hsa04064 NF-kappa B signaling pathway, hsa04072 phospholipid Enzyme D signaling pathway, hsa04668TNF signaling pathway.
  • HrpZpst multi-epitope ligand protein recognizes and binds membrane proteins and participates in antiviral, antibacterial, anti-foreign body, and anti-inflammatory related metabolic pathways: recognizes and binds 27, hsa04144 endocytosis, hsa04145 phagosome, hsa04142 lysis Enzyme, hsa04666Fc gamma r-mediated phagocytosis, hsa04210 apoptosis, hsa04218 cellular senescence, hsa04612 antigen processing and presentation, hsa05100 bacterial invasion of epithelial cells, hsa05168 herpes simplex virus 1 infection, hsa05203 virus carcinogenesis, hsa05164 influenza A , hsa05150 Staphylococcus aureus infection, hsa05143 African trypanosomiasis, hsa04650 Natural killer cell-mediated mediated
  • HrpZpst multi-epitope ligand protein recognizes and binds membrane proteins involved in important neurological disease metabolic pathways: not detected.
  • HrpZpst multi-epitope ligand protein recognizes and binds membrane proteins involved in nucleic acid, protein, amino acid, sugar, fat metabolism-related pathways: recognizes and binds one, including hsa04974 protein digestion and absorption.
  • HrpZpst multi-epitope ligand protein recognizes and binds membrane proteins involved in cell junction, neural junction, blood vessel, endocrine, reproductive system and other metabolic pathways: recognizes and binds 12, hsa04510 focal adhesions, hsa04724 glutamatergic synapses , hsa04530 tight junctions, hsa04940 type I diabetes, hsa04721 synaptic vesicle cycle, hsa04961 endocrine and other factors regulate calcium reabsorption, hsa04979 cholesterol metabolism, hsa04918 thyroid hormone synthesis, hsa04514 cell adhesion molecules (CAMs), hsa04727 neuronal synapses, hsa05320 Autoimmune thyroid disease, hsa05418 Fluid shear stress and atherosclerosis.
  • CAMs cell adhesion molecules
  • HrpZpst multi-epitope ligand protein as a class of ligand protein molecules rich in special multiple linear and conformational epitope structures, can recognize and bind various types of membrane receptors, membrane proteins, information pathways and metabolism across borders Pathways, and further analyze the location, structure, properties, mechanism of action and function of these membrane receptors, membrane proteins, information pathways and metabolic pathways, which are widely involved in and affect the growth, development, metabolism, defense and life of programmed cell death.
  • HrpZpst multi-epitope ligand protein is a kind of special multi-epitope ligand protein with new function, new mechanism of action and new application prospect.
  • the HrpZpss polymimetic epitope ligand protein is fermented, highly expressed, purified and prepared by engineering bacteria with registered genes, which specifically includes the following steps:
  • HrpZpss polymimetic epitope ligand protein The engineering bacteria fermentation preparation of HrpZpss polymimetic epitope ligand protein: the genes (including, but not limited to, natural genes of biological samples, chemically synthesized genes, transgenic genetic recombinant genes) encoding HrpZpss polymimetic epitope ligand proteins are prepared.
  • the pH of the fermentation medium Na 2 HPO 4 -KH 2 PO 4 buffer system is 6.5-5.5; the fermentation temperature is 37-38° C.; the glucose concentration of the fermentation and proliferation liquid medium is 0.01%-0.05%; 0.05%-0.00%; the lactose concentration of the fermentation induction liquid medium is 0.5%-0.4%; the fermentation induction liquid culture time is 7-9h.
  • HrpZpss polymimetic epitope ligand protein molecule use NI-NTA agarose column to purify HrpZpss polymimetic epitope ligand protein-His recombinant protein. The method is implemented to complete the preparation of purified HrpZpss polymimetic epitope ligand protein.
  • the HrpZpss polymimetic epitope ligand protein is prepared by expressing the "artificially synthesized gene", which specifically includes the following steps:
  • the first step artificial synthesis of the hrpZpss gene encoding the HrpZpss protein
  • Step 2 2) According to the above DNA sequence, when artificially synthesizing protein gene, add BamHI and HindIII enzyme cleavage sites to the 5' and 3' of the gene respectively to facilitate protein gene cloning;
  • the third step artificial gene synthesis is entrusted to the GeneArt gene synthesis and service department of Thermo Fisher Scientific. 3) The synthetic DNA fragment encoding HrpNEcb protein gene is cloned into the BamHI-HindIII site of the high-efficiency protein expression vector PET28a(+) (containing His-Tag label), and the accuracy of the clone is ensured through DNA sequencing;
  • the fermentation medium is Na 2 HPO 4 -KH 2 PO 4 buffer system
  • the pH of the buffer system is 6.5-5.5
  • the concentration of glucose in the fermentation and proliferation liquid medium is 0.01%-0.05%
  • the concentration of lactose in the fermentation induction liquid medium is 0.5%- 0.4%;
  • Step 5 Suspend the collected cells into Na 2 HPO 4 -KH 2 PO 4 buffer, complete the sterilization treatment at 80°C for 30 minutes, quickly cool down to 30°C, and place in a butterfly continuous flow centrifuge. Clean the engineering bacteria five to eight times, and then introduce it into a high-pressure crusher. Under the continuous pressure of 800-1000Mpa, crush the engineering bacteria, and pass the broken bacteria liquid into the butterfly continuous flow centrifuge to remove the cell wall;
  • Step 6 Purify the HrpZpss polymimetic epitope ligand protein-His recombinant protein with NI-NTA agarose column.
  • the protein purification is carried out according to the method recommended by the NI-NTA agarose column manufacturer to complete the purification of HrpZpss polymimetic epitopes. Preparation of ligand proteins.
  • the highly expressed purified protein-His recombinant band was detected by 10% SDS polyacrylamide gel electrophoresis, see Figure 29 for details.
  • the left side is the molecular weight identification band
  • lane 1 is the electrophoresis band before purification, and there are more bands in the corresponding molecular weight region, including the 34.73kd band
  • lane 2 is the purified HrpZpss polymimetic epitope ligand
  • the body protein band, with a molecular weight of 34.73kd, is in the corresponding molecular weight region of the protein, indicating that the corresponding HrpZpss purified protein has been obtained.
  • HrpZpss multi-epitope ligand protein preparation As shown in Figure 30, the allergy test of HrpZpss multi-epitope ligand protein: HrpZpss multi-epitope ligand protein preparation and the reaction results of tobacco leaves after 24hr of sterile water treatment are shown in Figure 31, among which, points A and C are shown in Figure 31. 100 ⁇ L of HrpZpss polymimetic epitope ligand protein solution of 300 ⁇ g ⁇ mL -1 was injected; B and D points were injected with 100 ⁇ L of sterile water as the control treatment. 300 ⁇ g ⁇ mL -1 of HrpZpss poly-epitope ligand protein solution treatment for about 12hrs caused tobacco leaves to shrink and collapse, and 24hrs to die; the water control treatment of tobacco leaves had no allergic reaction.
  • the purified HrpZpss multi-epitope ligand protein can generally induce hypersensitivity reactions in leaves of various plants.
  • the tested plant species can be: tobacco, pepper, eggplant, tomato, potato, strawberry, cucumber, water spinach, celosia, glass begonia , September chrysanthemum, pansy, nopal, petunia, grape, rose, locust tree, pea, peach tree, bunch of red, loofah, green beans, cauliflower, spinach, rapeseed, yam, cowpea, broad bean, corn , rice, soybean, cyclamen, mulberry, pumpkin, loquat, toon tree and other 36 kinds of different plants.
  • the research object of mRNA sequencing is all RNAs with a poly-A tail that can be transcribed by a specific cell in a certain functional state, mainly mRNA.
  • Cell-generated mRNA is converted into DNA (cDNA, complementation, and library construction of the obtained cDNA) by a process of reverse transcription.
  • the resulting DNA is then sequenced and from the observed abundance of specific DNA, the original amount of mRNA in the cell can be inferred from it to find genes or transcripts whose transcription levels change under the experimental conditions, i.e. differentially expressed.
  • Experimental sample treatment 8-week-old balb/C mice were selected for the experiment and divided into HrpZpss multi-epitope ligand protein treatment groups, including oral administration for 6 hours, 24 hours, and application for 6 hours and 12 hours, a total of 4 treatments.
  • mice for each treatment There were 3 experimental mice for each treatment, a total of 12 mice; 4 experimental mice in the blank control group; the buffer control sham-operated group without HrpZpss multi-epitope ligand protein, including oral administration for 6 hours, 24 hours and application for 6 hours, There were 4 kinds of treatments in 12 hours, 4 experimental mice in each treatment, a total of 16 experimental mice, repeated three times; the mice in the experimental treatment group were fed and smeared with a buffer containing 600 mg ⁇ L-1HrpZpss polymimetic ligand protein. The mice in the buffer control sham-operated group were fed and smeared with buffer, and the mice in the blank control group did not receive any treatment. Under the same feeding conditions, at different times, the mouse kidneys, testis and other tissues were grouped and collected for RNA-Seq sequencing and analysis.
  • RNA-Seq mRNA sequencing experimental flow chart
  • RNA extraction of the samples was performed using the miRNeasy Micro Kit (Cat#1071023 Qiagen) and according to the standard operating procedure provided by the manufacturer.
  • the total RNA was quality-checked by NanoDrop ND-2000 spectrophotometer and Agilent Bioanalyzer 4200 (Agilent technologies, Santa Clara, CA, US), and the qualified RNA was used for subsequent sequencing experiments.
  • Oligo(dT) can be used to enrich mRNAs with polyA tails.
  • the enriched mRNA is then subjected to fragmentation, double-stranded cDNA synthesis, end repair, addition of A at the 3' end, ligation of adapters, and amplification.
  • the constructed library uses 2.0 Fluorometer detects concentration, Agilent2100 detects size.
  • Illumina sequencing is performed on the library that has passed the quality inspection.
  • the sequencer captures the fluorescent signal and converts the optical signal into a sequencing peak through computer software to obtain the sequence information of the fragment to be tested.
  • the differential gene volcano plot was used to display the overall distribution of genes with significant differential expression induced by HrpNEcb protein.
  • Horizontal axis fold change of gene expression in different samples (log2Fold-Change); vertical axis: significant level of gene expression difference (-log10p-value); the expression of the right point is significantly up-regulated; the left point is significantly down-regulated Genes; genes with no significant changes in expression at lower points.
  • Figures 31-32 are the differential gene volcano plots of mouse kidney and testis HrpZpss protein induced by oral administration and smearing, respectively, in which HrpZpss is abbreviated as Z2.
  • FIGS. 33-34 are cluster heat maps of differentially expressed gene sets in kidney and testis, respectively, in which HrpZpss is abbreviated as Z2.
  • Gene Ontology is an ontology widely used in the field of bioinformatics.
  • Gene Ontology is a description of genes in different dimensions and levels, covering biological processes (biological_process), cellular components (cellular_component) and molecular functions (molecular_function).
  • biological processes are describing which biological processes the gene is involved in; cellular components explain where the gene is present, including whether the gene is in the cytoplasm or in the nucleus? If cytoplasm is present in which organelle? If it is in the mitochondria, is it on the mitochondrial membrane or in the matrix of the mitochondria, etc., this information belongs to the cell group; the molecular function explains what is the function of the gene at the molecular level?
  • Gene Ontology database is a structured standard biological model constructed by the GO organization (Gene Ontology Consortium) in 2000. It aims to establish a standard vocabulary system for knowledge of genes and their products, covering the biological process of genes. process), cellular component, molecular function.
  • Term is the basic description unit in GO. GO Terms are used to describe the function of gene products. By performing GO enrichment analysis on differential genes, genes can be classified according to different functions, so as to achieve the purpose of annotating and classifying genes.
  • HrpNEcb multi-epitope ligand protein we carried out GO term enrichment analysis on the differentially expressed genes induced by HrpNEcb multi-epitope ligand protein, and the results proved and confirmed that HrpNEcb multi-epitope ligand protein, as a class of special structures with multiple epitopes, new functions , a ligand protein with a new mechanism of action and a new application prospect, induced the differential expression of multiple genes in multiple organs (kidney, testis) of the tested mice, and these differentially expressed genes covered biological processes, cellular components and molecular functions. Differentially expressed genes were analyzed by GO using Fisher's exact test. Fisher's exact test was calculated to obtain the p-value, and multiple hypothesis test correction was performed to obtain the q-value.
  • the results of GO enrichment analysis of differentially expressed genes induced by HrpNEcb multi-epitope ligand proteins are further described as follows: 1
  • the biological process (biological_process) related differentially expressed genes include reproduction, cell death, immune system processes, behavior, metabolic processes, and cellular processes.
  • reproductive processes bioadhesion, signaling, multicellular biological processes, developmental processes, growth, motility, processes in individual tissues, biological phases, rhythmic processes, positive regulation of biological processes, negative regulation of biological processes, regulation of biological processes, Stimulatory responses, localization, bioregulation, cellular component organization or biogenesis, cellular aggregation, detoxification, and presynaptic processes involve synaptic transmission.
  • the GO enrichment analysis results of biological processes are shown in Tables 8 to 9.
  • differentially expressed genes related to cellular components cover cells and extracellular regions, nucleoids, membranes, virus particles, cell junctions, extracellular matrix, cell membrane closed cavity, complex macromolecules, organelles, extracellular matrix components, cells Parts of the outer region, organelle parts, virion parts, membrane parts, synaptic parts, cell parts, synapses, and cellular supramolecular fibers, etc.
  • the results of GO enrichment analysis of cell components are shown in Tables 8 to 9.
  • Molecular function-related differentially expressed genes cover transcription factor activity, protein binding, nucleic acid binding transcription factor activity, catalytic activity, signal sensor activity, structural molecular activity, transport activity, binding, electron carrier activity, and morphogen activity , Antioxidant activity, metal chaperone protein activity, protein labeling, chemoattractant activity, translation regulation, chemorepellent activity, active molecular sensor, molecular function regulation, etc.
  • the molecular function GO enrichment analysis results are shown in Tables 8 to 9.
  • HrpZpss in Tables 8-9 is abbreviated as HrpZ2.
  • HrpZ2 HrpZ2
  • blanks indicate that the corresponding data that does not meet the standard of p-value less than 0.05 have not been collected.
  • the blanks in the following and all tables have the same meaning.
  • HrpZpss multi-epitope ligand protein induces the biological processes, cellular components and molecular function-related functional groups of testis and kidneys to significantly up-regulate and express GO terms.
  • Statistical table of the number of classified genes (6, 24 hours after oral administration and 6 hours after application)
  • Table 9 The biological process, cellular components and molecular function-related functional groups of testis and kidney induced by HrpZpss multi-epitope ligand protein were significantly down-regulated.
  • Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database for systematic analysis of gene function and genomic information. The process of gene and expression information is studied holistically as a network.
  • KEGG The main feature of KEGG is to link genes with various biochemical reactions, providing integrated metabolic pathways.
  • KEGG currently contains a total of 19 sub-databases, which are classified into three categories: systematic information, genomic information and chemical information. In organisms, different gene products coordinate with each other to perform biological functions. Pathway annotation analysis of differentially expressed genes is helpful for further interpretation of gene functions.
  • KEGG pathway enrichment analysis was performed on the differentially expressed genes induced by HrpZpss multi-epitope ligand protein, and the roles (upstream and downstream relationship) and biological functions of these differentially expressed genes in the signaling pathway were obtained, and the relationship between genes and functions was deeply understood. .
  • HrpZpss multi-epitope ligand protein as a kind of ligand protein with multi-epitope special structure, new function, new mechanism of action and new application prospect, induces multiple organs (kidney, testis) of mice. etc.) differential expression of multiple genes involved in cellular processes, environmental information processing, genetic information processing, metabolism (Metabolism) and biological systems ( Organismal Systems) and other functional pathways.
  • HrpZpss multi-epitope ligand protein are involved in biological processes such as translation, replication and repair, folding, classification and degradation (see Figure 35 to Figure 40 for details) .
  • 4Metabolism Multiple differentially expressed genes induced by HrpZpss multi-epitope ligand protein are involved in biodegradation and metabolism, nucleotide metabolism, metabolism of other amino acids, metabolic cofactors and vitamins, lipid metabolism, sugar Global and overview maps of biosynthesis and metabolism, metabolic processes such as energy metabolism, carbohydrate metabolism and amino acid metabolism (see Figure 35 to Figure 40 for details).
  • the HrpZpss polymimetic epitope ligand protein-His recombinant protein was purified by NI-NTA agarose column. The protein purification was carried out according to the method recommended by the NI-NTA agarose column manufacturer. The HrpZpss polymimetic epitope ligand protein prepared was purified. Standby (hereinafter referred to as capture protein or target protein).
  • bait protein Extraction of total protein from cultured hepatocytes (hereinafter referred to as bait protein) for experiments
  • Biotin blocking 1Add 250 ⁇ l biotin blocking solution to the Spin Column tube. Tighten the top cover and bottom stopper, and gently invert 4 times to mix; 2Incubate at room temperature for 5 min. Remove the top cover, put the Spin Column tube in the collection tube, and centrifuge at 1250 ⁇ g for 50s; 3 Repeat steps 1 and 2 once; 4 Add 250 ⁇ l of TBS to the Spin Column tube. Tighten the top cap and invert it upside down 4 times to mix it up; 5Remove the top cap, put it in a collection tube, and centrifuge at 1250 ⁇ g for 50s; 6Repeat steps 3 and 4 twice, and put the Spin Column tube back into the collection tube Tube.
  • HrpZpss multi-epitope ligand protein recognizes and binds to cell membrane receptors: HLA-C major histocompatibility complex, I, C class receptors, free fatty acid receptor 4, tyrosine protein kinase transmembrane receptors 1.
  • APMAP adipocyte plasma membrane-associated protein receptor
  • IGF2R insulin-like growth factor 2 receptor
  • HrpZpss multi-epitope ligand proteins recognize and bind cell membrane proteins: solute carrier family 5 (sodium-dependent vitamin transporter), member 6, solute carrier family 26, member 4, solute carrier family 38, member 2 (SLC38A2), DNM2 dynein 2, CAP1 adenylate cyclase-related protein 1, ICAM1 intercellular adhesion molecule 1 LanC-like protein 1 (lanthionine synthase C) (LANCL1), MLEC stress protein-androgen-like receptor Kinase, TJP2 claudin 2, ZYX patchin.
  • HrpZpss multi-epitope ligand protein recognition and binding signaling pathways hsa04933 age-anger signaling pathway in diabetes complications, hsa04064 NF-kappa B signaling pathway, hsa04072 phospholipase D signaling pathway.
  • HrpZpss multi-epitope ligand protein recognizes and binds membrane proteins and participates in antiviral, antibacterial, anti-foreign body, and anti-inflammatory metabolic pathways: hsa04144 endocytosis, hsa04145 phagosome, hsa04142 lysosome, hsa04666Fc gamma r-mediated phagocytosis, hsa04210 cell apoptosis, hsa04218 cell senescence, hsa05130: pathogenic E.
  • coli infection hsa04612 antigen processing and presentation, hsa05100 bacterial invasion of epithelial cells, hsa05168 herpes simplex virus 1 infection, hsa05203 viral carcinogenesis, hsa05164 Influenza A, hsa05150 Staphylococcus aureus infection, hsa05167 Kaposi's sarcoma with herpes virus infection, hsa04916: bactericidal effect, hsa04650 Natural killer cell-mediated cytotoxicity, hsa05169 Epstein-Barr virus infection, hsa05416 viral myocarditis, hsa05110 Vibrio cholerae infection, hsa05144 malaria, hsa05163 human cytomegalovirus infection, hsa05170 human immunodeficiency virus type 1 infection, hsa05323 rheumatoid arthritis, hsa04670 leukocyte transcellular migration.
  • HrpZpss multi-epitope ligand protein recognizes important neurological disease metabolic pathways involved in binding membrane proteins: not detected.
  • HrpZpss multi-epitope ligand proteins recognize nucleic acid, protein, amino acid, sugar, and fat metabolism-related pathways involved in binding membrane proteins: hsa03050: proteasome, hsa04974 protein digestion and absorption, hsa04120: ubiquitin-mediated proteolysis.
  • HrpZpss multi-epitope ligand protein recognizes the metabolic pathways involved in cell junctions, neural junctions, blood vessels, endocrine, and reproductive systems that bind to membrane proteins: hsa04510 focal adhesions, hsa04724 glutamatergic synapses, hsa04530 tight junctions, hsa04261 : Adrenergic signaling of cardiomyocytes, hsa04940 type I diabetes, hsa04924: renin secretion, hsa04721 synaptic vesicle cycle, hsa04961 endocrine and other factors regulate calcium reabsorption, hsa04970: salivary secretion, hsa04979 cholesterol metabolism, hsa04918 thyroid hormone synthesis , hsa04514 cell adhesion molecules (CAMs), hsa04727 neuronal synapses, hsa05320 autoimmune thyroid disease, h
  • HrpZpss multi-epitopic ligand protein as a class of ligand protein molecules rich in special multiple linear and conformational epitope structures, can recognize and bind various types of membrane receptors, membrane proteins, information pathways and metabolism across borders Pathways, and further analyze the location, structure, properties, mechanism of action and function of these membrane receptors, membrane proteins, information pathways and metabolic pathways, which widely affect the growth, development, metabolism, defense and the basic properties of life of programmed cell death. , and is widely involved in the diagnosis, prevention, treatment, rehabilitation of diseases and conditions of the nervous system, digestive system, motor system, circulatory system, respiratory system, endocrine system, immune system, urinary system, reproductive system, and skin system.
  • HrpZpss multi-epitope ligand protein is a special multi-epitope ligand protein with new functions, new mechanism of action and new application prospects.
  • the application of the HrpZ type multi-epitope ligand protein of the present invention in food, cosmetics, health care products and medicines also involves identifying and activating multiple types of receptors, membrane proteins and their signaling pathways in animals, and inducing multifunctional cascade biology
  • the application of HrpZpst, HrpZpss and other multi-mimetic ligand protein products in food, cosmetics and health care products; further, the pull-down experiments of HrpZpst, HrpZpss and other multi-mimetic epitope ligand proteins that recognize and bind to specific proteins show that , they recognize multiple types of receptors, membrane proteins and their signaling pathway proteins in bound animals, from inside to outside the body, and are widely involved in the body's growth function, developmental function, defense, immunity, sterilization and anti-inflammatory functions, endocrine, multi-type
  • the expression and regulatory control of molecular metabolic functions and programmed cell death functions are widely involved in the regeneration, repair and clearance of different systems, organs
  • HrpZpst, HrpZpss and other multi-epitope ligands HrpZ-type multi-epitope ligand protein products can be widely used in food, cosmetics, and health care products.
  • the auxiliary conditioning functions of HrpZ-type multi-epitope ligand protein mainly include 1 , Enhance immune function; 2. Assist blood lipid lowering function; 3. Assist blood sugar lowering function; 4. Antioxidant function; 5. Assist in improving memory function; 6. Relieve visual fatigue function; Pharyngeal function; 9. Auxiliary blood pressure lowering function; 10. Improve sleep function; 11. Promote lactation function; 12. Relieve physical fatigue function; 13. Improve hypoxia tolerance function; 14. Have auxiliary protective function against radiation hazards; 15 , weight loss function; 16, improve growth and development function; 17, increase Bone density function; 18. Improve nutritional anemia function; 19. Auxiliary protection function against chemical liver damage; 20. Anti-acne function; 21. Remove melasma function; 22. Improve skin moisture function; 23. Improve skin oil 24. Regulate intestinal flora function; 25. Promote digestive function; 26. Laxative function; 27. Have auxiliary protective function for gastric mucosal damage. further:
  • the preparations of the HrpZ-type multi-epitope ligand protein of the present invention can be used in food supplements for regulating the expression and regulation of the body's growth, development, defense, metabolism, and programmed cell death functions, including various human Finished products and raw materials for eating or drinking;
  • the preparations of the HrpZ-type multi-epitope ligand protein of the present invention can be used in cosmetics that assist in regulating the expression and regulation of the body's growth, development, defense, metabolism, and programmed cell death functions, including rubbing, Spraying or other similar methods, spread on any part of the human body surface, including skin, hair, nails, lips, etc., to achieve cleaning, eliminating bad odor, skin care, beauty and modification purposes Biotechnology products, or including ordinary cosmetics and special purposes cosmetic;
  • the HrpZ-type polyepitope ligand protein product of the present invention can be used in health care products that assist in regulating the growth, development, defense, metabolism, and the expression and regulation of programmed cell death functions of the body, including health care functional foods , is a type of food, has the commonality of general food, can regulate the functions of the human body, and is suitable for consumption by specific groups of people, but not for the purpose of curing diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用， HrpZ型多拟表位配体蛋白包括HrpZPsa、HrpZPsm、HrpZPss、HrpZPst,HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat，HrpZ型多拟表位配体蛋白作为一类富含多个表位(线性和构象)的特殊结构的配体蛋白分子，能够跨界识别、激活、结合多种类型的动物的膜受体、膜蛋白、信息通路和代谢通路，是一类特殊多拟表位配体蛋白。

Description

HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用 技术领域
本发明涉及生物医药领域，具体的涉及HrpZ型蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的制药中的应用。
背景技术
分子生物学是在分子水平上研究生命现象的科学，通过研究生物大分子的结构、功能和代谢来阐明各种生命现象的本质，其研究内容涵盖了生命的全过程。DNA，RNA和蛋白质是三种重要的生物大分子，是生命现象的分子基础。基因组决定了生命有什么，蛋白质组决定了生命能做什么，代谢组决定了生命实际发生了什么。现代生命科学、生物技术和医药生物技术，特别是蛋白质组学和代谢组学，得到了突飞猛进的发展，更新了对疾病的认识、诊断、防控、治疗和康复的理念，开创了对新型高效安全药物的新认识和新途径，使现代医学的发展进入到了一个崭新阶段，开辟了广阔的应用前景。
现代生命科学的受体理论是药效学的基本理论之一，是从分子水平解释生命的可控的生理过程和病理过程、药物的药理作用机制、药物分子的结构效应关系的一个重要依据。配体是一类信号物质，除了与受体识别、结合和激活受体外，本身并无其他直接功能，它不能参加代谢产生有用产物，也不直接诱导任何细胞活性，更无酶的特点，它唯一的功能就是通过对受体的识别、结合和激活，向细胞传导在内外环境中存在的特殊信号或信息。
信号通路(细胞通讯)是指在多细胞生物的细胞间或细胞内通过高度精确和高效发送与接收信息的通讯机制，并通过放大引起快速的细胞生理生化反应，或启动基因活动，尔后发生一系列的细胞生理、生化活动来协调各组织活动，促使生命的统一整体对多变的内外界环境作出综合反应，这是生命机体的系统、组织、器官、细胞、亚细胞、分子、亚分子建造一个协调的生长、发育、防御和代谢的联结机制。
受体是指一类介导细胞信号转导的功能蛋白，能识别周围环境(细胞内外环境)中的某些微量物质，并与之识别、结合，被激活，通过信号放大系统触发后续的生理生化反应。受体是由细胞膜和细胞内的蛋白质、核酸、脂质、多糖等组成的生物大分子。受体在细胞生物学中是一个很泛的概念，意指任何能够同激素、神经递质、药物或细胞内外的信号分子结合并能引起细胞功能变化的生物大分子，此时的信号分子被称为配体。多细胞生物中有几百种不同的信号分子在细胞间和细胞内传递信息，这些信号分子中有蛋白质、氨基酸衍生物、核苷酸、胆固醇、脂肪酸衍生物以及可溶解的气体分子等。存在于细胞质膜上的受体称为膜受体，化学本质绝大部分是糖镶嵌蛋白；位于胞液和细胞核中的受体称为胞内受体，它们全部为DNA结合蛋白。
配体是一类信号物质，除了与受体识别、结合和激活受体外，本身并无其他直接功能，它不能参加代谢产生有用产物，也不直接诱导任何细胞活性，更无酶的特点，它唯一的功能就是通过对受体的识别、结合和激活，向细胞传导在内外环境中存在的特殊信号或信息。
配体与受体的结合是分子间识别激活过程，它靠离子配位键、氢键、π-π堆积作用、静电作用、疏水作用、范德华力等的作用，随着两种分子空间结构互补和互作程度增加，相互作用基团之间距离就会缩短，作用力就会大大增加，因此配体和受体分子空间结构的互作性和互补性是特异结合的主要因素，也即本发明所采用的“结构基团”或“表位”概念。同一配体可能对应两种或两种以上的不同受体，同一配体与不同类型受体结合会产生不同的细胞反应。配体与受体结合后，将引发有关系列生理活性，无论配体是 内源性的还是外源性的，与受体结合后，二者形成配体-受体结合面或复合物，从而传递信息，通过传导和转导，并通过放大引起快速的细胞生理、生化反应，或者启动基因活动，尔后发生一系列的级联反应来协调各组织、器官、细胞的活动，促成生命的统一整体对多变的内外界环境作出综合反应。
2008年，Leader等首次提出根据蛋白质药理学作用分类的思路，并将蛋白质药物分为如下四大类：①应用蛋白质的酶活性及调节活性进行治疗的蛋白质药物；②有特殊靶向活性的蛋白质药物；③重组蛋白质疫苗；④用于诊断的重组蛋白质药物。其中第一类和第二类主要用于基础蛋白质疗法，第三类和第四类重点强调蛋白质在疫苗及诊断用药中的应用。经过一个多世纪的摸索和曲折发展，蛋白质药物已经一步一步的成熟起来，在制药工业及临床应用中均占有举足轻重的地位。它们对肿瘤、感染、自身免疫性疾病、代谢性遗传病、各种老年病及退行性疾病等几乎所有疾病领域均具有重要影响，正在成为21世纪重要的治疗、预防和诊断用药。展望未来30年，以重组DNA技术为核心的生物技术的广泛应用必将赋予蛋白质药物更为广阔的发展空间：重组蛋白质药物将逐步取代非重组蛋白；重组改构、体内外修饰将成为常规；用哺乳动物细胞体系表达的产品将占主导地位；蛋白质药物非注射给药途径将受到越来越多的关注；生物仿制药和生物相似药将大有可为。(朱迅，蛋白质药物的功能分类及发展趋势，中国医药生物技术2010年2月第5卷第1期，China Med Biotechnol，February 2010，Vol.5，No.1)。
已有研究表明，配体与受体的识别结合，是由组成配体线性或和构象结构基团或表位的关键氨基酸残基决定的，比如，boFcγ2R的82-85位多肽FIGV线性配体结合表位的苯丙氨酸(Phe 82)、异亮氨酸(Ile83)和颉氨酸(Val 85)是识别结合牛IgG2受体的关键氨基酸残基，再比如，boFcγRⅠ的142-149位多肽TNLSHNGI线性配体结合表位的苏氨酸(Thr 142)、天门冬酰胺(Asn 143)、亮氨酸(Leu 144)、甘氨酸(Gly 148)和异亮氨酸(Ile 149)是识别结合牛IgG1受体的关键氨基酸残基；又比如，boFcγRⅢ的98-103位短肽AQRVVN线性配体结合表位的丙氨酸(Ala 98)、谷氨酸(Gln 99)、颉氨酸(Val 101)、颉氨酸(Val102)和天门冬酰胺(Asn 103)是识别结合牛IgG1受体的关键氨基酸残基。
Harpin是由革兰氏阴性细菌“过敏反应与致病性(hyper sensitive response and pathogenicity，hrp)”基因簇中的基因编码的性质和功能相似的一类蛋白质，富含甘氨酸、不含胱氨酸、对蛋白质酶敏感、热稳定，能在非寄主植物上引起过敏反应。过敏性反应(hypersensitive reaction,HR)表现为非寄主植物受侵染组织快速、局部的萎缩和坏死，从而限制了病原菌的扩散，进而诱导系统抗性，这是植物抵抗病原侵染的普遍表现形式和有效途径。经过近三十年来的研究，这些编码蛋白已获本领域生物学家、植物病理学家及应用研究者公认，属于诱发植物系统抗性的诱抗蛋白类的Harpin超敏蛋白，现已成为植物保护领域的能安全的能诱导植物产生抗病性、驱虫性、抗逆性并促进植物生长发育和提高产量的生物农药。
HrpZ型蛋白的整体简介：
HrpZpss蛋白是hrpZpss基因(Genbank ID:AAY36247.1)的表达产物，其由343个氨基酸残基组成，有一、二、三级结构而无四级结构的非酶蛋白质，不含胱氨酸和半胱氨酸，富含甘氨酸和丝氨酸，Mw＝34.73kDa。HrpZpss蛋白保守结构域由343个氨基酸组成，全序列均是保守结构域1-343；α-螺旋结构区37-52,61-72,80-93,109-128,140-155,157-159,168-173,180-199,248-259,263-265,290-309,317-336。
HrpZpst蛋白(GenBank accession number:AY999001)是hrpZpst基因(Pseudomonas syringae pv tomato Strain CSCS008)的表达产物，其由370个氨基酸残基组成，有一、二、三级结构而无四级结构的非酶蛋白质，不含胱氨酸和半胱氨酸，富含甘氨酸和丝氨酸，分子36.52kDa，HrpZpst蛋白保守结构域由370个氨基酸组成，全序列为保守结构区域，1-370，α-螺旋结构33-49，58-70，78-92，136-155，172-183，192-197，204-223，265-277，279-284，314-333，341-359，364-366的蛋白。
结构域是生物大分子中具有特异结构和独立功能的区域，特别是指蛋白质中由不同二级结构和超二级结构组合而成的独立的稳定结构区域，结构域也是蛋白质功能单元，在多结构域蛋白质中，不同的结构域常与不同的功能相联系；蛋白质的二级和超二级结构主要由氢键维持，包括α螺旋、β折叠、β转角、无规卷以及IDPs-结构(固有无序蛋白质，intrinsically disordered proteins，简称IDPs)等，α螺旋是一种重复性结构，螺旋中每个α-碳的Φ和Ψ分别为-57°和-47°附近。每圈螺旋占3.6个氨基酸残基，沿螺旋轴方向上升0.54nm，每个残基绕轴旋转100°，沿轴上升0.15nm，相邻螺圈之间形成氢键，氢键的取向几乎与螺旋轴平行；β折叠：β－折叠片由两条或多条伸展的多肽链(或一条多肽链的若干肽段)侧向聚集，通过相邻肽链主链上的N-H与C＝O之间有规则的氢键，形成锯齿状片层结构；IDPs-结构是固有无序蛋白质(intrinsically disordered proteins,简称IDPs)结构区域，具广泛的变构效应，作为柔性的连接区域，内存多种构象和运动状态，并以重复性高、带电性、易结合、以及空间优越性和高度协调性，广泛参与和调控转录、翻译、细胞分裂、蛋白质聚集和细胞信号转导，特别参与自组装调控过程。
HrpZ型蛋白是由“过敏反应与致病性(hyper sensitive response and pathogenicity，hrp)”基因簇中的基因编码的性质和功能相似的一类蛋白质，包括同源性较高，进化上亲缘关系相近的一类多结构域蛋白质，具有由多个关键氨基酸残基结合的线性和构象结构基团或表位，不同的结构域常与不同的功能相联系，从而决定了它们的在跨界识别激活动物(包括人类)细胞多类受体、膜蛋白以及信号通路和代谢通路并能引起多功能级联生物学效应的制药中的应用前景。但是，目前还未见这类蛋白跨界识别特别是在动物和人类上的相关报道及应用。
发明内容
本发明的目的在于：针对上述存在的问题，本发明提供HrpZ型蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的制药中的应用。HrpZ型蛋白作为一类富含多个线性和构象表位特殊结构的配体蛋白分子，能够跨界识别、激活、结合多种类型的动物的膜受体、膜蛋白、信息通路和代谢通路，HrpZ型蛋白是一类具有特殊多个表位结构、全新功能、全新作用机制和全新应用前景的配体蛋白，它们诱导的多方向、多层次和多方面的生物学效应和功能。根据HrpZ型蛋白的结构特点及其能够跨界识别、结合多种类型的动物的膜受体、膜蛋白，进而激活多个信息通路和代谢通路的功能特性，我们将其称之为HrpZ型多拟表位配体蛋白(multi epitopic-like ligand proteins)。
本发明采用的技术方案如下：
HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用。
HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、消毒品、化妆品、保健品或药物中的应用。
HrpZ型多拟表位配体蛋白含有一至多个疏水非极性氨基酸残基的结构基团或表位、含有一至多个极性不带电氨基酸残基的结构基团或表位、含有一至多个酰胺基极性不带电氨基酸残基的结构基团或表位、含有一至多个酸性带正电、碱性带负电氨基酸残基的结构基团或表位；疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸、蛋氨酸，极性不带电氨基酸残基：丝氨酸，酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺，酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、组氨酸、精氨酸；疏水非极性氨基酸残基，极性不带电氨基酸残基，酰胺基极性不带电氨基酸残基和酸性带正电、碱性带负电氨基酸残基在HrpZ型多拟表位配体蛋白分子的全序列中占比72.97％-70.65％，在保守结构域中占比72.97％-71.82％，在α-螺旋结构中占比85.98％-81.48％；疏水非极性氨基酸残基的结构基团或表位，极性不带电氨基酸残基的结构基团或表位，酰胺基极性不带电氨基酸残基的结构基团或表 位和酸性带正电、碱性带负电氨基酸残基的结构基团或表位通过氢键、离子键、疏水、非极性、极性、范德华力，实现配体和受体分子空间结构和电性的互补性、互作性以及特异识别、激活、结合，与多类型受体形成紧密结合面或复合物，能引起受体分子的构象、能量、电性和信息的变化，经信号传导和转导，放大表达系列生物学效应。
HrpZ型多拟表位配体蛋白包括HrpZPsa、HrpZPsm、HrpZPss、HrpZPst,HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat、HrpZPcory、HrpZPcp、HrpZPsav、HrpZPsavp、HrpZPvir、HrpZPspe、HrpZPam、HrpZPade、HrpZPsac、HrpZPsg、HrpZPsc。
依据生物信息学分析，这类分子同源性很高，从60％到99％；
HrpZ多拟表位配体蛋白同源性比较如下：
HrpZ同源性比较:
Figure PCTCN2021134715-appb-000001
Figure PCTCN2021134715-appb-000002
Figure PCTCN2021134715-appb-000003
Figure PCTCN2021134715-appb-000004
Figure PCTCN2021134715-appb-000005
HrpZPhylogenetic Tree(进化系统树):
Figure PCTCN2021134715-appb-000006
HrpZ型多拟表位配体蛋白富含多个线性和构象结构基团或表位，是指能与细胞膜受体、膜蛋白等识别结合的氨基酸残基组成的功能基团，这个功能基团是由以下氨基酸残基组成，包括能与受体识别、结合、激活的富含供质子型或接受质子型氨基酸残基；进一步的，含有一个至多个疏水非极性氨基酸残基，含有一个至多个酸性带正电、碱性带负电氨基酸残基，含有一个至多个酰胺基极性不带电氨基酸残基，含有一个至多个极性不带电氨基酸残基；进一步的，富含供质子型(蛋氨酸残基除外)或接受质子型(包括蛋氨酸残基)氨基酸残基：谷氨酸、天门冬酰酸、赖氨酸、组氨酸、蛋氨酸、丝氨酸、苏氨酸、酪氨酸、精氨酸，它们能与多类型受体蛋白对应氨基酸残基以氢键方式识别激活连接形成结合面或复合物；进一步的，疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸能以非极性疏水、范德华力与多类型受体形成紧密的结合面或复合物；酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、精氨酸能通过离子键与多类型受体形成紧密的结合面或复合物；酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺的酰胺基能与受体的半胱氨酸识别区Pam3 CSK4以较强氢键形成结合面或复合物；极性不带电氨基酸残基：丝氨酸通过极性以较强氢键与多类型受体形成紧密的结合面或复合物。
进一步的，HrpZpss多肽全序列有343个氨基酸残基，关键氨基酸残基235个，疏水非极性氨基酸残基105个，极性不带电氨基酸残基33个，酰胺基氨基酸残基40个，酸性、碱性带正电、负电氨基酸残基57个，分子量34.73kd、等电点PI4.6，关键氨基酸占比68.5％；保守结构区域的多肽序列有343个氨基酸残基，占全序列的100％，关键氨基酸残基235个，疏水非极性氨基酸残基105个，极性不带电氨基酸残基33个，酰胺基氨基酸残基40个，酸性带正电、碱性带负电氨基酸残基57个，关键氨基酸占比68.5％；α-螺旋结构区域有12个α-螺旋，有1个β-折叠以及8个do-结构区域，其中，α-螺旋区，有162个氨基酸残基，关键氨基酸残基127个，疏水非极性氨基酸残基66个，极性不带电氨基酸残基6个，酰胺基氨基酸残基19个，酸性带正电、碱性带负电氨基酸残基36个，关键氨基酸占比78.4％；进一步的，假单胞菌属中筛选、克隆、制备了HrpZPsa、HrpZPsm、HrpZPss、HrpZPst,HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat、HrpZPcory、HrpZPcp、HrpZPsav、HrpZPsavp、HrpZPvir、HrpZPspe、HrpZPam、HrpZPade、HrpZPsac、HrpZPsg、HrpZPsc等超敏蛋白，依据生物信息学分析这些分子结构表明，它们具有类似于上述多表位HrpZpss多拟表位配体蛋白的相似结构特征、结构进化趋势以及具有多个构象表位和线性表位结构：含有一至多个疏水非极性氨基酸残基、含有一至多个极性不带电氨基酸残基、含有一至多个酰胺基极性不带电氨基酸残基、含有一至多个酸性带正电、碱性带负电氨基酸残基；进一步的，疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸、蛋氨酸，极性不带电氨基酸残基：丝氨酸，酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺，酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、组氨酸、精氨酸；进一步的，以上所述关键氨基酸残基在这些蛋白分子的全序列中占比72.97％-70.65％，在保守结构域中占比72.97％-71.82％，在α-螺旋结构中占比85.98％-81.48％；进一步的，HrpZpss多拟表位配体蛋白的上述氨基酸残基(一般统称为关键氨基酸残基)，又不限于这些氨基酸残基，能通过氢键、离子键、疏水、非极性、极性、范德华力，实现配体和受体分子空间结构和电性的互补性、互作性以及特异识别、激活、结合，与多类型受体形成紧密结合面或复合物，能引起受体分子的构象、能量、电性和信息的变化，经信号传导和转导，放大表达系列生物学效应。
进一步的，HrpZpst多拟表位配体蛋白全序列有370个氨基酸残基，全序列为保守结构区域，有370个氨基酸残基，占全序列的100％，关键氨基酸残基261个，疏水非极性氨基酸残基114个，极性不带电 氨基酸残基43个，酰胺基氨基酸残基54个，酸性带正电、碱性带负电氨基酸残基50个，关键氨基酸残基占总氨基酸残基70.5％，分子量36.52kd、等电点PI 4.01；有12个α-螺旋，有2个β-折叠以及7个do-结构区域；α-螺旋区，有164个氨基酸残基，关键氨基酸残基136个，疏水非极性氨基酸残基66个，极性不带电氨基酸残基12个，酰胺基氨基酸残基29个，酸性带正电、碱性带负电氨基酸残基29个，关键氨基酸残基占比82.9％；进一步的，发明人从假单胞菌属中筛选、克隆、制备了HrpZPsa、HrpZPsm、HrpZPss、HrpZPst，HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat、HrpZPcory、HrpZPcp、HrpZPsav、HrpZPsavp、HrpZPvir、HrpZPspe、HrpZPam、HrpZPade、HrpZPsac、HrpZPsg、HrpZPsc等超敏蛋白，依据生物信息学分析这些分子结构表明，它们具有类似于上述多表位HrpZpst配体蛋白的相似结构特征、结构进化趋势以及具有多个构象表位和线性表位结构：含有一至多个疏水非极性氨基酸残基、含有一至多个极性不带电氨基酸残基、含有一至多个酰胺基极性不带电氨基酸残基、含有一至多个酸性带正电、碱性带负电氨基酸残基；进一步的，疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸、蛋氨酸，极性不带电氨基酸残基：丝氨酸，酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺，酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、组氨酸、精氨酸；进一步的，以上所述关键氨基酸残基在这些蛋白分子的全序列中占比72.97％-70.65％，在保守结构域中占比72.97％-71.82％，在α-螺旋结构中占比85.98％-81.48％；进一步的，HrpZpst多拟表位配体蛋白的上述氨基酸残基(一般统称为关键氨基酸残基)，又不限于这些氨基酸残基，能通过氢键、离子键、疏水、非极性、极性、范德华力，实现配体和受体分子空间结构和电性的 互补性、互作性以及特异识别、激活、结合，与多类型受体形成紧密结合面或复合物，能引起受体分子的构象、能量、电性和信息的变化，经信号传导和转导，放大表达系列生物学效应。
多功能级联生物学效应是指能诱导不同器官、组织的细胞组分、分子功能和生物学过程三个层次相关功能基因群显著表达差异，包括细胞组分(包括细胞、细胞结、细胞部分、细胞外基质、细胞外基质成分、细胞外区域、细胞外区域部分、大分子复合物、膜、膜部分、膜封闭腔、细胞器、细胞器的部分、超分子纤维、突触、突触部分、抗氧化活性等)，分子功能(包括绑定、催化活性、化学引诱物的活动、化学排斥物活动、电子载体活动、金属伴侣蛋白活动、分子功能监管机构、活动分子传感器、核酸结合转录因子的活性、信号传感器活动、结构分子活动、转录因子活性蛋白质结合、运输活动等)，生物过程(包括行为、生物粘附、生物调节、细胞聚集、细胞死亡、细胞成分组织或生物发生、细胞过程、解毒、发展的过程、增长、免疫系统的过程、本地化、运动、代谢过程、多生物过程、多细胞生物的过程、生物过程负调控、生物过程的正调控、突触前过程涉及突触传递、生物过程调节、繁殖、生殖过程、刺激反应、有节奏的过程、信号、单一生物过程等)的相关功能基因群表达差异发生显著性变化。
HrpZpss多拟表位配体蛋白的氨基酸序列如SEQ ID NO:1所示；HrpZpst多拟表位配体蛋白的氨基酸序列如SEQ ID NO:2所示。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的多类受体包括HLA-C主要组织相容性复合体、I,C类受体、游离脂肪酸受体4、酪氨酸蛋白激酶跨膜受体1、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体、胰岛素样生长因子2受体中的一种或多种。
优选的，HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的多类受体包括HLA-C主要组织相容性复合体，I，C类受体、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体、胰岛素样生长因子2受体、LDL受体相关蛋白1中的一种或多种。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的膜蛋白包括溶质载体家族5、成员6、溶质载体家族26,成员4、溶质载体家族38，成员2、DNM2动力蛋白2、CAP1腺苷 酸环化酶相关蛋白1、ICAM1细胞间粘附分子1LanC-类蛋白1、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白中的一种或多种。
优选的，HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的膜蛋白包括溶质载体家族38，成员2、DNM2动力蛋白2、SPTAN1非红细胞1α血影蛋白、β-互生蛋白1、CAP1腺苷酸环化酶相关蛋白1、ICAM1细胞间粘附分子1、LanC-类蛋白1、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白中的一种或多种。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的受体及膜蛋白参与的信号通路包括hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路中的一种或多种。
优选的，HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的受体及膜蛋白参与的信号通路包括hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路、hsa04668TNF信号通路中的一种或多种。
优选的，识别激活的受体及膜蛋白参与的信号通路包括代谢信号通路，代谢信号通路包括抗病毒、抗细菌、抗异物、抗炎性代谢通路；包括核酸、蛋白质、氨基酸、糖、脂肪代谢通路；包括细胞联结、神经连结、血管、内分泌、生殖系统代谢通路。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，所述识别激活的膜蛋白参与的抗病毒、抗细菌、抗异物、抗炎性代谢通路：hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、hsa04666Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa05130:致病性大肠杆菌感染、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa04916:杀菌作用、hsa04650自然杀伤细胞介导的细胞毒性、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa04670白细胞跨细胞迁移；所述识别激活的膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢通路：hsa03050:蛋白酶体、hsa04974蛋白消化吸收、hsa04120:泛素介导的蛋白水解作用；所述识别激活的膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统代谢通路：hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04261:心肌细胞的肾上腺素能信号、hsa04940I型糖尿病、hsa04924:肾素分泌、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04970:唾液分泌、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子(CAMs)、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
HrpZ型多拟表位配体蛋白为HrpZpst蛋白，所述识别激活的膜蛋白参与的抗病毒、抗细菌、抗异物、抗炎性代谢通路：hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、hsa04666Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05143非洲锥虫病、hsa04650自然杀伤细胞介导的细胞毒性、hsa05166人T细胞白血病病毒1感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05165人乳头瘤病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa05330同种异体移植 物排斥反应、hsa05332抗移植物、hsa04670白细胞跨细胞迁移；所述识别激活的膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢通路：hsa04974蛋白消化吸收；所述识别激活的膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统代谢通路：hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04940I型糖尿病、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，所述级联生物学效应包括细胞过程(Cellular Processes)、环境信息处理(Environmental Information Processing)、遗传信息处理(Genetic Information Processing)、新陈代谢(Metabolism)和生物体系统(Organismal Systems)等功能途径；进一步地，①细胞过程(Cellular Processes)：HrpZpss蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程；②环境信息处理(Environmental Information Processing):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了信号分子与相互作用，信号转导，膜运输等环境信息处理过程；③遗传信息处理(Genetic Information Processing):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了翻译，复制和修复，折叠、分类和降解等生物过程；④新陈代谢(Metabolism):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了生物降解和代谢，核苷酸代谢，其他氨基酸的代谢，代谢的辅助因子和维生素，脂质代谢，糖的生物合成和代谢，全局和概览地图，能量代谢，碳水化合物代谢及氨基酸代谢等代谢过程；⑤生物体系统(Organismal Systems):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了感觉系统，神经系统，免疫系统，排泄系统，环境适应，内分泌系统，消化系统，发育循环系统等生物过程。
HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，所述级联生物学效应包括细胞过程(Cellular Processes)、环境信息处理(Environmental Information Processing)、遗传信息处理(Genetic Information Processing)、新陈代谢(Metabolism)和生物体系统(Organismal Systems)等功能途径；进一步地，①细胞过程(Cellular Processes)：HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程；②环境信息处理(Environmental Information Processing):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了信号分子与相互作用，信号转导，膜运输等环境信息处理过程；③遗传信息处理(Genetic Information Processing):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了翻译，复制和修复，折叠、分类和降解等生物过程；④新陈代谢(Metabolism):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了生物降解和代谢，核苷酸代谢，其他氨基酸的代谢，代谢的辅助因子和维生素，脂质代谢，糖的生物合成和代谢，全局和概览地图，能量代谢，碳水化合物代谢及氨基酸代谢等代谢过程；⑤生物体系统(Organismal Systems):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了感觉系统，神经系统，免疫系统，排泄系统，环境适应，内分泌系统，消化系统，发育循环系统等生物过程。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，级联生物学效应还包括HrpZpss多拟表位配体蛋白诱导的基因功能群显著差异表达结果，其中包括：①生物过程相关差异表达基因：包括了繁殖，细胞死亡，免疫系统的过程，行为，代谢过程，细胞过程，生殖过程，生物粘附，信号，多细胞生物过程，发育过程，增长，运动，单个组织的过程，生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递；②细胞组分相关差异表达基因：涵盖了细胞及细胞外区域，类核， 膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维等；③分子功能相关差异表达基因：涵盖了转录因子活性，蛋白质结合，核酸结合转录因子活性，催化活性，信号传感器活动，结构分子活动，运输活动，绑定，电子载体活动，成形素活动，抗氧化活性，金属伴侣蛋白活性，蛋白质标记，化学引诱物的活动，转译调控，化学排斥物活性，活动分子传感器，分子功能调控等。
优选的，HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，级联生物学效应还包括HrpZpst多拟表位配体蛋白诱导的基因功能群显著差异表达结果，其中包括：①生物过程相关差异表达基因：包括了繁殖，细胞死亡，免疫系统的过程，行为，代谢过程，细胞过程，生殖过程，生物粘附，信号，多细胞生物过程，发育过程，增长，运动，单个组织的过程，生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递；②细胞组分相关差异表达基因：涵盖了细胞及细胞外区域，类核，膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维等；③分子功能相关差异表达基因：涵盖了转录因子活性，蛋白质结合，核酸结合转录因子活性，催化活性，信号传感器活动，结构分子活动，运输活动，绑定，电子载体活动，成形素活动，抗氧化活性，金属伴侣蛋白活性，蛋白质标记，化学引诱物的活动，转译调控，化学排斥物活性，活动分子传感器，分子功能调控等。
优选的，所述制药中的应用的制品或药物的剂型为液剂、粉剂、片剂或胶囊剂。
优选的，所述制药中的应用还包括为HrpZpss多拟表位配体蛋白依据药学治疗的活性化合物(HrpZpss多拟表位配体蛋白制剂和/或药物)和其衍生物通常以单位剂型或多次剂型的配制和施用，每个单位剂量含有预定量的治疗活性化合物，其与所需的药物载体、运载体或赋形剂结合足够产生希望的治疗效果。单位剂型的实例包括安瓿和注射器和单独包装的片剂或胶囊剂。可以以部分或其倍数施用单位剂型。多次剂型是在单个容器中包装的多个相同的单位剂型，其将以分开的单位剂型施用。多次剂型的实例包括小瓶、片剂或胶囊瓶或加仑瓶。所以，多次剂型是在包装中不分开的多个单位剂量。可以制备含有0.001％到100％的活性成分的剂型或组合物，剩余部分由无毒载体组成，对于口服施用，药物组合物可以采取例如片剂或胶嚢剂的形式，其通过常规方法用药学上可接受的赋形剂如黏合剂(包括，但不限于，预胶化的玉米淀粉、聚乙烯吡咯烷酮或者丙基甲基纤维素)；填充剂(包括，但不限于，乳糖、微晶纤维素)；润滑剂(包括，但不限于，硬脂酸镁、滑石粉或二氧化硅)；崩解剂(包括，但不限于，马铃薯淀粉或淀粉羟乙酸钠)；或湿润剂(包括，但不限于，十二烷基硫酸钠)制备。可以通过本领域公知的方法包衣片剂。药物组合物也可以为液体形式，包括，但不限于，溶液剂、糖浆剂或混悬剂，或者可以以药物产品给出，其在使用前用水或其他合适的运载体重构。此类液体制剂可以通过常规方法用药学上可接受的添加剂制备，所述添加剂为如悬浮剂(包括，但不限于，山梨醇糖浆、纤维素衍生物或食用脂肪)；乳化剂(包括，但不限于，卵磷脂或阿拉伯胶)；非水性运载体(包括，但不限于，杏仁油、油性酯，或者分级分离的植物油)；和防腐剂(包括，但不限于，对羟基苯甲酸甲酯或丙酯或山梨酸)。适于直肠施用的制剂可以作为单位剂量栓剂提供。这些可以通过将HrpZpss多拟表位配体蛋白活性化合物与一种或多种固体载体，如可可脂混合，然后将所得混合物成型来制备。适于局部应用于皮肤或眼睛的制剂包括，但不限于，软骨剂、霜剂、洗剂、糊剂、凝胶剂、喷雾剂、气雾剂和油。示例性载体包括，但不限于，凡士林、羊毛脂、聚乙二醇、醇类，和其两种或多种的组合。局部制剂也可以含有按重量计0.001％到15％、20％、25％的增稠剂，其 选自包括，但不限于，羟丙基甲基纤维素、甲基纤维素、聚乙烯吡咯烷酮、聚乙烯醇、聚乙二醇、聚/羟基烷基(甲基)丙烯酸酯或聚(甲基)丙烯酰胺类。通常通过滴注或作为软骨剂应用到结膜嚢中来应用局部制剂。它也可以用于冲洗或润滑眼、面部窦和外耳道。也可以将它注射到眼前房和其他地方。液体状态的局部制剂也可以以带或者隐形眼镜的形式存在于亲水的三维聚合物基质中，活性成分从所述基质释放。对于适于含服(舌下)施用的制剂包括，但不限于，在调味基质(通常蔗糖和阿拉伯胶或西黄蓍胶)中含有活性化合物的锭剂；和在惰性基质包括，但不限于，明胶和甘油或蔗糖和阿拉伯胶中含有化合物的软锭剂。可以配制配体同种型的药物组合物用于通过注射，包括，但不限于，通过快速浓注或连续灌注进行肠胃外施用。用于注射的制剂可以为单位剂型，例如，在安瓿或多剂量容器中，具有加入的添加剂。组合物可以为油性或水性载体中的混悬剂、溶液剂或乳剂，并且可以包括，但不限于，配制试剂，如悬浮剂、稳定剂，备选地，活性成分可以为粉末形式，在使用前用合适的载体如无菌无致热原的水或其他溶剂重构。适于经皮施用的制剂可以以离散的贴剂给出，适于在长时间内与接受者的表皮保持密切接触。此类贴剂合适地含有活性化合物作为活性化合物的任选緩冲的水溶液。适于经皮施用的制剂可以通过离子电渗疗法递送并采取活性化合物的任选緩沖的水溶液形式。
优选的，所述制药中的应用还包括为HrpZpst多拟表位配体蛋白质依据药学治疗的活性化合物(HrpZpst多拟表位配体蛋白制剂和/或药物)和其衍生物通常以单位剂型或多次剂型的配制和施用，每个单位剂量含有预定量的治疗活性化合物，其与所需的药物载体、运载体或赋形剂结合足够产生希望的治疗效果。单位剂型的实例包括安瓿和注射器和单独包装的片剂或胶囊剂。可以以部分或其倍数施用单位剂型。多次剂型是在单个容器中包装的多个相同的单位剂型，其将以分开的单位剂型施用。多次剂型的实例包括小瓶、片剂或胶囊瓶或加仑瓶。所以，多次剂型是在包装中不分开的多个单位剂量。可以制备含有0.001％到100％的活性成分的剂型或组合物，剩余部分由无毒载体组成，对于口服施用，药物组合物可以采取例如片剂或胶嚢剂的形式，其通过常规方法用药学上可接受的赋形剂如黏合剂(包括，但不限于，预胶化的玉米淀粉、聚乙烯吡咯烷酮或者丙基甲基纤维素)；填充剂(包括，但不限于，乳糖、微晶纤维素)；润滑剂(包括，但不限于，硬脂酸镁、滑石粉或二氧化硅)；崩解剂(包括，但不限于，马铃薯淀粉或淀粉羟乙酸钠)；或湿润剂(包括，但不限于，十二烷基硫酸钠)制备。可以通过本领域公知的方法包衣片剂。药物组合物也可以为液体形式，包括，但不限于，溶液剂、糖浆剂或混悬剂，或者可以以药物产品给出，其在使用前用水或其他合适的运载体重构。此类液体制剂可以通过常规方法用药学上可接受的添加剂制备，所述添加剂为如悬浮剂(包括，但不限于，山梨醇糖浆、纤维素衍生物或食用脂肪)；乳化剂(包括，但不限于，卵磷脂或阿拉伯胶)；非水性运载体(包括，但不限于，杏仁油、油性酯，或者分级分离的植物油)；和防腐剂(包括，但不限于，对羟基苯甲酸甲酯或丙酯或山梨酸)。适于直肠施用的制剂可以作为单位剂量栓剂提供。这些可以通过将HrpZpst多拟表位配体蛋白活性化合物与一种或多种固体载体，如可可脂混合，然后将所得混合物成型来制备。适于局部应用于皮肤或眼睛的制剂包括，但不限于，软骨剂、霜剂、洗剂、糊剂、凝胶剂、喷雾剂、气雾剂和油。示例性载体包括，但不限于，凡士林、羊毛脂、聚乙二醇、醇类，和其两种或多种的组合。局部制剂也可以含有按重量计0.001％到15％、20％、25％的增稠剂，其选自包括，但不限于，羟丙基甲基纤维素、甲基纤维素、聚乙烯吡咯烷酮、聚乙烯醇、聚乙二醇、聚/羟基烷基(甲基)丙烯酸酯或聚(甲基)丙烯酰胺类。通常通过滴注或作为软骨剂应用到结膜嚢中来应用局部制剂。它也可以用于冲洗或润滑眼、面部窦和外耳道。也可以将它注射到眼前房和其他地方。液体状态的局部制剂也可以以带或者隐形眼镜的形式存在于亲水的三维聚合物基质中，活性成分从所述基质释放。对于适于含服(舌下)施用的制剂包括，但不限于，在调味基质(通常蔗糖和阿拉伯胶或西黄蓍胶)中含有活性化合物的锭剂；和在惰性基质包括，但不限于，明胶和甘油或蔗糖和阿拉伯胶中含有化合物 的软锭剂。可以配制配体同种型的药物组合物用于通过注射，包括，但不限于，通过快速浓注或连续灌注进行肠胃外施用。用于注射的制剂可以为单位剂型，例如，在安瓿或多剂量容器中，具有加入的添加剂。组合物可以为油性或水性载体中的混悬剂、溶液剂或乳剂，并且可以包括，但不限于，配制试剂，如悬浮剂、稳定剂，备选地，活性成分可以为粉末形式，在使用前用合适的载体如无菌无致热原的水或其他溶剂重构。适于经皮施用的制剂可以以离散的贴剂给出，适于在长时间内与接受者的表皮保持密切接触。此类贴剂合适地含有活性化合物作为活性化合物的任选緩冲的水溶液。适于经皮施用的制剂可以通过离子电渗疗法递送并采取活性化合物的任选緩沖的水溶液形式。
优选的，HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，制品或药物主要由纯化的HrpZEcb多拟表位配体蛋白制备得到，质量含量为有0.001％-100％。
优选的，HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，制品或药物主要由纯化的HrpZEch多拟表位配体蛋白制备得到，质量含量为0.001％-100％。
HrpZ型多拟表位配体蛋白为纯化后的HrpZ型蛋白。
HrpZ型蛋白的纯化的方法，包括以下步骤：
步骤1：高压破碎机破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁,高压范围800-1000Mpa；
步骤2：用Ni-NTA琼脂糖凝胶柱纯化HrpZ多拟表位配体蛋白-His重组蛋白，得到纯化的HrpZ型多拟表位配体蛋白原药。
本发明采用的HrpZpss多拟表位配体蛋白的高效表达、纯化生产HrpZpss多拟表位配体蛋白的制备方法，包括以下步骤：
1.HrpZpss多拟表位配体蛋白的工程菌发酵制备：将带有编码HrpZpss多拟表位配体蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)质粒的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpss多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条34.73kd条带，它就是基因hrpZpss的表达产物HrpZpss多拟表位配体蛋白。
2.高压破碎机破碎工程菌，连续用800-1000Mpa压力，破碎工程菌。
3.离心收集HrpZpss多拟表位配体蛋白分子，离心力范围1000-8000g，优选地离心力1000-2000g；优选地离心力2000-3500g；优选地离心力8000-6000g；优选地离心力6000-4500g；最优选地离心力3500-4500g。HrpZpss多拟表位配体蛋白存在于上清液中。
4.用Ni-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按Ni-NTA琼脂糖凝胶柱厂家建议方法实施，得到纯化的HrpZ型多拟表位配体蛋白原药。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpss蛋白制剂的使用途径，可通过本领域技术人员已知的任一途径施用，所述途径包括内用、外用、口服、注射、肌内、静脉内、皮内、腹膜内、皮下、鼻、口、直肠、局部、含服和经皮施用或任何途径；可以通过任何方便的途径施用HrpZpss多拟表位配体蛋白，例如通过灌注或快速灌注，通过上皮或皮肤粘膜内层(例如，口粘膜、鼻腔黏膜、胃黏膜、直肠和肠粘膜等等)吸收，并且可以与其它生物活性剂顺序、间歇地或在相同组合物中施用；依据治疗部位，施用可以是局部的、表面的或者全身的。局部施用于需要 治疗的区域可以，但不限于，局部灌注、表面应用，通过浸泡，通过注射，通过导管，通过栓剂；施用还可以包括控释系统，包括控释制剂和装置控释，如通过泵；在任一给定情况下最合适的途径将取决于被治疗的疾病或状况的性质和严重性和使用的具体组合物的性质。多种递送系统是已知的并且可以用于施用多拟表位配体蛋白，可以在脂质体、微粒、微嚢中包裹。可以制备多拟表位配体蛋白的药物组合物，通常，将按照管理机构的批准制备或者根据公认的药典制备药学上可接受的组合物用于患者。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效的HrpZpss多拟表位配体蛋白白引起的多功能级联生物学效应和多样性功能广泛涉及多系统、组织、器官、细胞相关疾病和状况的诊断、或和预防、或和治疗、或和康复以及广泛涉及有关疾病和状况的食字号、消字号、妆字号、械字号和健字号制品或药物的制药中的应用。
本发明所述制药中应用的涉及识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpss多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复神经系统、消化系统、运动系统、循环系统、呼吸系统、内分泌系统、免疫系统、泌尿系统、生殖系统疾病和状况中的应用：
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复神经连结疾病、痴呆、帕金森病、中枢神经系统疾病、神经肌肉病、癫痫、头痛和神经痛、周围神经病、注意缺陷多动障碍和抽动障碍、失眠症、抑郁症、焦虑障碍、双相情感障碍、精神病性障碍、神经性皮炎相关的神经系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复胃酸分泌不调、胃肠神经官能症、胃肠动力、胃肠黏膜炎、肝脏疾病、微生态障碍相关的消化系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复关节炎、肌肉痉挛、疼痛、肌营养不良、肌肉神经损伤、脱水相关的运动系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复心力衰竭、心律失常、高血压、心肌损伤、缺血、心绞痛、高脂血症、钙通道阻滞、血管痉挛、血凝、血象异常、心肌梗死相关的循环系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复哮喘、慢性阻塞性肺疾病、支气管扩张、过敏原免疫、变态反应、肺炎、急性或慢性支气管炎、支气管哮喘、胃食管反流、鼻炎相关的呼吸系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复糖尿病、甲状腺疾病、垂体疾病、高催乳素血症、尿崩症、肾上腺疾病、甲状旁腺疾病、骨质疏松症相关的内分泌系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复免疫低下、类风湿关节炎、红斑狼疮相关的免疫系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复肾病综合征、间质性肾炎、肾衰竭、泌尿、生殖系统感染、肾盂肾炎、膀胱炎、前列腺炎、尿道炎、附睾炎或睾丸炎、前列腺增生、膀胱过度活动症、性功能障碍相关、以及各类男科、妇科感染性炎症和功能性疾病等的泌尿生殖系统疾病和状况中的应用。
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复全身肌肤细胞营养、激活、再生、修复、清除、细腻光洁、紫外黑色素沉积、湿疹、粗糙、裂纹、暗纹、干枯、硬皮、红斑、过敏、神经性皮炎、损伤、青春痘、暗疮、疤痕、暗沉、螨虫、油性皮肤、炎症性皮肤病、自身 免疫性皮肤病、色素性皮肤病、皮肤萎缩、变薄、干燥、色素沉着、皱纹增生、表皮角化不良、干皮症、接触性皮炎、抗皮肤衰老、改善皮肤功能、美白祛斑、防治皮肤疾病的相关的皮肤系统疾病和状况中的应用。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpNEcb多拟表位配体蛋白的制备，包括以下方法：
1、所述HrpZpss多拟表位配体蛋白的制备，采用含hrpZpss基因(GenBank:AAY36247.1)(克隆到高效表达载体PET28a(+))的工程菌，通过发酵，纯化制备HrpZpss多拟表位配体蛋白：
1)HrpZpss蛋白的工程菌发酵制备：将编码HrpZpss蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropylβ-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpss多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条34.73kd条带，它就是基因hrpZpss的表达产物HrpZpss多拟表位配体蛋白；
其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH范围是1-14；优选地pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-7；最优选地pH 6.5-5.5；
发酵温度范围0-60℃。优选地温度为0-20℃；优选地温度为20-35℃；优选地温度为60-50℃；优选地温度为50-45℃；最优选地温度为37-38℃；
发酵增殖液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地0.00％-0.01％；优选地1.00％-0.3％；最优选地0.01％-0.05％；最优选地0.1％-0.05％；
发酵诱导液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地1.00％-0.3％；优选地0.3％-0.1％；优选地0.1％-0.05％；最优选地0.05％-0.00％；
发酵诱导液体培养基乳糖浓度范围10.00％-0.00％；优选地10.00％-1.00％；优选地0.00％-0.1％；优选地1.00％-0.6％；优选地0.1％-0.3％；最优选地0.5％-0.4％；
发酵诱导液体培养时间范围0-24h；优选地时间0-2h；优选地时间为24-15h；优选地时间为2-6h；优选地时间为15-10h；最优选地时间为7-9h。
2)工程菌HrpZpss多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液(pH范围是1-14，葡萄糖浓度范围是0-2500mmol，缓冲系统pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-6；最优选地pH 5-5.5。葡萄糖浓度为0-100mmol；优选地浓度为100-200mmol；优选地浓度为2500-1000mmol；优选地浓度为1000-300mmol；最优选地浓度为200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁，HrpZpss多拟表位配体蛋白存在于上清液中。
3)HrpZpss多拟表位配体蛋白分子的纯化
纯化HrpZpss多拟表位配体蛋白：用NI-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成HrpZpss多拟表位配体蛋白的纯化制备。
3、所述HrpZpss多拟表位配体蛋白的制备，进一步，HrpZpss多拟表位配体蛋白也可以通过“人工合成基因”的表达蛋白进行制备，通过发酵，纯化制备HrpZpss多拟表位配体蛋白，具体包括以下步骤：
编码HrpZpss蛋白的hrpZpss基因的人工合成及其表达蛋白制备
1)按照GenBank公布的编码HrpZpss蛋白(GenBank:AAY36247.1)的hrpZpss基因核苷酸序列,人工合成hrpZpss基因，其DNA序列为：
Figure PCTCN2021134715-appb-000007
2)根据以上DNA序列，人工合成蛋白基因时，在基因的5′和3′分别加上BamHI和HindIII酶切位点，方便蛋白基因克隆；
人工基因合成委托Thermo Fisher Scientific公司的GeneArt基因合成与服务部门完成。人工合成蛋白基因的优点主要是：a)合成周期短，可以保证序列的100％正确无误；b)可以对密码子进行优化，以提高基因的表达效率；由于每个物种偏爱的编码子不同，当异源蛋白在大肠杆菌里表达时，有些蛋白很难得到高表达。如果将异源蛋白的密码子改为大肠杆菌偏爱的密码子，就可以实现蛋白的基因的高效表达，提高该基因的表达水平，适于大规模工业生产；c)可根据需要进行基因的定点突变以改造基因，提高蛋白的作用效率；d)研究人员可根据自己的意愿设计得到自然界中很难获得甚至不存在的基因。
3)将合成的编码HrpZpss蛋白基因的DNA片段，克隆到高效蛋白表达载体PET28a(+)(含His-Tag标签)BamHI-HindIII位点，经DNA测序确保克隆的准确性；
4)HrpZpss多拟表位配体蛋白的工程菌发酵制备：将1)至3)编码HrpZpss蛋白的基因克隆转入大肠杆菌工程菌(E.coli)中，相关蛋白的生产系(E.coli)是K-12原菌经特殊改造后的衍生菌JY-01(DE3)；在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体，用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析编码HrpZpss蛋白，在电泳胶板的样品泳道上，会呈现一条34.73kda条带，它就是基因hrpZpss的表达产物HrpZpss多拟表位配体蛋白。
其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH范围是1-14；优选地pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-7；最优选地pH 6.5-5.5；
发酵温度范围0-60℃。优选地温度为0-20℃；优选地温度为20-35℃；优选地温度为60-50℃；优选地温度为50-45℃；最优选地温度为37-38℃；
发酵增殖液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地0.00％-0.01％；优选地1.00％-0.3％；最优选地0.01％-0.05％；最优选地0.1％-0.05％；
发酵诱导液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地1.00％-0.3％；优 选地0.3％-0.1％；优选地0.1％-0.05％；最优选地0.05％-0.00％；
发酵诱导液体培养基乳糖浓度范围10.00％-0.00％；优选地10.00％-1.00％；优选地0.00％-0.1％；优选地1.00％-0.6％；优选地0.1％-0.3％；最优选地0.5％-0.4％；
发酵诱导液体培养时间范围0-24h；优选地时间0-2h；优选地时间为24-15h；优选地时间为2-6h；优选地时间为15-10h；最优选地时间为7-9h。
5)工程菌生产HrpZpss多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液(pH范围是1-14，葡萄糖浓度范围是0-2500mmol，缓冲系统pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-6；最优选地pH 5-5.5。葡萄糖浓度为0-100mmol；优选地浓度为100-200mmol；优选地浓度为2500-1000mmol；优选地浓度为1000-300mmol；最优选地浓度为200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁，HrpZpss多拟表位配体蛋白存在于上清液中。
6)HrpZpss多拟表位配体蛋白分子的纯化
纯化HrpZpss多拟表位配体蛋白：用NI-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成HrpZpss多拟表位配体蛋白的纯化制备。
本发明采用的HrpZpst蛋白的高效表达、纯化生产HrpZpst蛋白的制备方法，包括以下步骤：
1.HrpZpst蛋白的工程菌发酵制备：将带有编码HrpZpst多拟表位配体蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)质粒的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpst蛋白，在电泳胶板的样品泳道上，会呈现一条36.52kda条带，它就是基因hrpZpst的表达产物HrpZpst多拟表位配体蛋白。
2.高压破碎机破碎工程菌，连续用800-1000Mpa压力，破碎工程菌。
3.离心收集HrpZpst多拟表位配体蛋白分子，离心力范围1000-8000g，优选地离心力1000-2000g；优选地离心力2000-3500g；优选地离心力8000-6000g；优选地离心力6000-4500g；最优选地离心力3500-4500g。HrpZpst多拟表位配体蛋白存在于上清液中。
4.用Ni-NTA琼脂糖凝胶柱纯化HrpZpst多拟表位配体蛋白-His重组蛋白，蛋白纯化按Ni-NTA琼脂糖凝胶柱厂家建议方法实施，得到纯化的HrpZ型多拟表位配体蛋白原药。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpst蛋白制剂的使用途径，可通过本领域技术人员已知的任一途径施用，所述途径包括内用、外用、口服、注射、肌内、静脉内、皮内、腹膜内、皮下、鼻、口、直肠、局部、含服和经皮施用或任何途径；可以通过任何方便的途径施用HrpZpst多拟表位配体蛋白，例如通过灌注或快速灌注，通过上皮或皮肤粘膜内层(例如，口粘膜、鼻腔黏膜、胃黏膜、直肠和肠粘膜等等)吸收，并且可以与其它生物活性剂顺序、间歇地或在相同组合物中施用；依据治疗部位，施用可以是局部的、表面的或者全身的。局部施用于需要治疗的区域可以，但不限于，局部灌注、表面应用，通过浸泡，通过注射，通过导管，通过栓剂；施用还可以包括控释系统，包括控释制剂和装置控释，如通过泵；在任一给定情况下最合适的途径将取决于被治疗的疾病或状况的性质和严重性和使用的具体组合物的性质。多种递送系统是已知的并且可以用于施 用多拟表位配体蛋白，可以在脂质体、微粒、微嚢中包裹。可以制备多拟表位配体蛋白的药物组合物，通常，将按照管理机构的批准制备或者根据公认的药典制备药学上可接受的组合物用于患者。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效的HrpZpst多拟表位配体蛋白引起的多功能级联生物学效应和多样性功能广泛涉及多系统、组织、器官、细胞相关疾病和状况的诊断、或和预防、或和治疗、或和康复以及广泛涉及有关疾病和状况的食字号、消字号、妆字号、械字号和健字号制品或药物的制药中的应用。
本发明所述制药中应用的涉及识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpst多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复神经系统、消化系统、运动系统、循环系统、呼吸系统、内分泌系统、免疫系统、泌尿系统、生殖系统疾病和状况中的应用：
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复神经连结疾病、痴呆、帕金森病、中枢神经系统疾病、神经肌肉病、癫痫、头痛和神经痛、周围神经病、注意缺陷多动障碍和抽动障碍、失眠症、抑郁症、焦虑障碍、双相情感障碍、精神病性障碍、神经性皮炎相关的神经系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复胃酸分泌不调、胃肠神经官能症、胃肠动力、胃肠黏膜炎、肝脏疾病、微生态障碍相关的消化系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复关节炎、肌肉痉挛、疼痛、肌营养不良、肌肉神经损伤、脱水相关的运动系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复心力衰竭、心律失常、高血压、心肌损伤、缺血、心绞痛、高脂血症、钙通道阻滞、血管痉挛、血凝、血象异常、心肌梗死相关的循环系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复哮喘、慢性阻塞性肺疾病、支气管扩张、过敏原免疫、变态反应、肺炎、急性或慢性支气管炎、支气管哮喘、胃食管反流、鼻炎相关的呼吸系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复糖尿病、甲状腺疾病、垂体疾病、高催乳素血症、尿崩症、肾上腺疾病、甲状旁腺疾病、骨质疏松症相关的内分泌系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复免疫低下、类风湿关节炎、红斑狼疮相关的免疫系统疾病和状况中的应用；
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复肾病综合征、间质性肾炎、肾衰竭、泌尿、生殖系统感染、肾盂肾炎、膀胱炎、前列腺炎、尿道炎、附睾炎或睾丸炎、前列腺增生、膀胱过度活动症、性功能障碍相关、以及各类男科、妇科感染性炎症和功能性疾病等的泌尿生殖系统疾病和状况中的应用。
本发明所述多拟表位配体蛋白的制品或药物在诊断、或和预防、或和治疗、或和康复全身肌肤细胞营养、激活、再生、修复、清除、细腻光洁、紫外黑色素沉积、湿疹、粗糙、裂纹、暗纹、干枯、硬皮、红斑、过敏、神经性皮炎、损伤、青春痘、暗疮、疤痕、暗沉、螨虫、油性皮肤、炎症性皮肤病、自身免疫性皮肤病、色素性皮肤病、皮肤萎缩、变薄、干燥、色素沉着、皱纹增生、表皮角化不良、干皮症、接触性皮炎、抗皮肤衰老、改善皮肤功能、美白祛斑、防治皮肤疾病的相关的皮肤系统疾病和状况中的应用。
本发明所述识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpst多拟表位配体蛋白的制备，包括以下方法：
1、所述HrpZpst多拟表位配体蛋白的制备，采用含hrpZpst基因(GenBank:AY999001)(克隆到高效表达载体PET28a(+))的工程菌，通过发酵，纯化制备HrpZpst多拟表位配体蛋白：
1)HrpZpst蛋白的工程菌发酵制备：将带有编码HrpZpst蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)质粒的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropylβ-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpst多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条36.52kda条带，它就是基因hrpZpst的表达产物HrpZpst多拟表位配体蛋白；
其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH范围是1-14；优选地pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-7；最优选地pH 6.5-5.5；
发酵温度范围0-60℃。优选地温度为0-20℃；优选地温度为20-35℃；优选地温度为60-50℃；优选地温度为50-45℃；最优选地温度为37-38℃；
发酵增殖液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地0.00％-0.01％；优选地1.00％-0.3％；最优选地0.01％-0.05％；最优选地0.1％-0.05％；发酵诱导液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地1.00％-0.3％；优选地0.3％-0.1％；优选地0.1％-0.05％；最优选地0.05％-0.00％；发酵诱导液体培养基乳糖浓度范围10.00％-0.00％；优选地10.00％-1.00％；优选地0.00％-0.1％；优选地1.00％-0.6％；优选地0.1％-0.3％；最优选地0.5％-0.4％；
发酵诱导液体培养时间范围0-24h；优选地时间0-2h；优选地时间为24-15h；优选地时间为2-6h；优选地时间为15-10h；最优选地时间为7-9h。
2)工程菌生产HrpZpst多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液(pH范围是1-14，葡萄糖浓度范围是0-2500mmol，缓冲系统pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-6；最优选地pH 5-5.5。葡萄糖浓度为0-100mmol；优选地浓度为100-200mmol；优选地浓度为2500-1000mmol；优选地浓度为1000-300mmol；最优选地浓度为200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁，HrpZpst多拟表位配体蛋白存在于上清液中。
3)HrpZpst多拟表位配体蛋白分子的纯化
纯化HrpZpst多拟表位配体蛋白：用NI-NTA琼脂糖凝胶柱纯化HrpZpst多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成HrpZpst多拟表位配体蛋白的纯化制备。
3、所述HrpZpst多拟表位配体蛋白的制备，进一步，HrpZpst蛋白也可以通过“人工合成基因”的表达蛋白进行制备，通过发酵，纯化制备HrpZpst多拟表位配体蛋白，具体包括以下步骤：
编码HrpZpst蛋白的hrpZpst基因的人工合成及其表达蛋白制备
1)按照GenBank公布的编码HrpZpst蛋白的hrpZpst基因(GenBank:AY999001)核苷酸序列,人工合成hrpZpst基因，其DNA序列为：
Figure PCTCN2021134715-appb-000008
Figure PCTCN2021134715-appb-000009
2)根据以上DNA序列，人工合成蛋白基因时，在基因的5′和3′分别加上BamHI和HindIII酶切位点，方便蛋白基因克隆；
人工基因合成委托Thermo Fisher Scientific公司的GeneArt基因合成与服务部门完成。人工合成蛋白基因的优点主要是：a)合成周期短，可以保证序列的100％正确无误；b)可以对密码子进行优化，以提高基因的表达效率；由于每个物种偏爱的编码子不同，当异源蛋白在大肠杆菌里表达时，有些蛋白很难得到高表达。如果将异源蛋白的密码子改为大肠杆菌偏爱的密码子，就可以实现蛋白的基因的高效表达，提高该基因的表达水平，适于大规模工业生产；c)可根据需要进行基因的定点突变以改造基因，提高蛋白的作用效率；d)研究人员可根据自己的意愿设计得到自然界中很难获得甚至不存在的基因。
3)将合成的编码HrpZpst蛋白基因的DNA片段，克隆到高效蛋白表达载体PET28a(+)(含His-Tag标签)BamHI-HindIII位点，经DNA测序确保克隆的准确性；
4)HrpZpst多拟表位配体蛋白的工程菌发酵制备：将1)至3)编码HrpZpst蛋白的基因克隆转入大肠杆菌工程菌(E.coli)中，相关蛋白的生产系(E.coli)是K-12原菌经特殊改造后的衍生菌JY-01(DE3)；在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体，用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析编码HrpZpst蛋白，在电泳胶板的样品泳道上，会呈现一条36.52kda条带，它就是基因hrpZpst的表达产物HrpZpst多拟表位配体蛋白。
其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH范围是1-14；优选地pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-7；最优选地pH 6.5-5.5；
发酵温度范围0-60℃。优选地温度为0-20℃；优选地温度为20-35℃；优选地温度为60-50℃；优选地温度为50-45℃；最优选地温度为37-38℃；
发酵增殖液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地0.00％-0.01％；优选地1.00％-0.3％；最优选地0.01％-0.05％；最优选地0.1％-0.05％；
发酵诱导液体培养基葡萄糖浓度范围3.00％-0.00％；优选地3.00％-1.00％；优选地1.00％-0.3％；优选地0.3％-0.1％；优选地0.1％-0.05％；最优选地0.05％-0.00％；
发酵诱导液体培养基乳糖浓度范围10.00％-0.00％；优选地10.00％-1.00％；优选地0.00％-0.1％；优选地1.00％-0.6％；优选地0.1％-0.3％；最优选地0.5％-0.4％；
发酵诱导液体培养时间范围0-24h；优选地时间0-2h；优选地时间为24-15h；优选地时间为2-6h； 优选地时间为15-10h；最优选地时间为7-9h。
5)工程菌生产HrpZpst多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液(pH范围是1-14，葡萄糖浓度范围是0-2500mmol，缓冲系统pH 1-3；优选地pH 14-10；优选地pH 4-5；优选地pH 9-6；最优选地pH 5-5.5。葡萄糖浓度为0-100mmol；优选地浓度为100-200mmol；优选地浓度为2500-1000mmol；优选地浓度为1000-300mmol；最优选地浓度为200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁，HrpZpst多拟表位配体蛋白存在于上清液中。
6)HrpZpst多拟表位配体蛋白分子的纯化
纯化HrpZpst多拟表位配体蛋白：用NI-NTA琼脂糖凝胶柱纯化HrpZpst多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成HrpZpst多拟表位配体蛋白的纯化制备。
与现有的技术相比本发明的有益效果是：
HrpZ型多拟表位配体蛋白作为一类富含多个线性和构象表位特殊结构的配体蛋白分子，能够跨界识别、激活、结合多种类型的动物的膜受体、膜蛋白、信息通路和代谢通路，HrpZ型多拟表位配体蛋白是一类具有特殊多个表位结构、全新功能、全新作用机制和全新应用前景的配体蛋白，它们诱导的多方向、多层次和多方面的生物学效应和功能，广泛涉及多系统、多组织、多器官、多细胞相关疾病和状况的诊断、或和预防、或和治疗、或和康复以及广泛涉及有关疾病和状况的食字号、消字号、妆字号、械字号和健字号制品或药物的制药中的应用。
上述已写完
附图说明
图1为HrpZpst多拟表位配体蛋白纯化前后的电泳检测：左边为分子量标识带，其中1：高效表达HrpZpst多拟表位配体蛋白条带(纯化前)；2：纯化后多拟表位配体蛋白HrpZpst条带；
图2为HrpZpst多拟表位配体蛋白液注射诱导烟草叶片过敏反应图:其中所见焦斑处是经过HrpZpst蛋白液处理24hr左右所形成，两侧：H 2O注射；1、2：HrpZpst蛋白液(300μg/ml)注射，即HrpZpst蛋白在烟草叶片上的超敏反应，两侧为对照，1、2为处理；
图3为本发明的HrpZpst多拟表位配体蛋白通过口服和涂抹实验鼠诱导肝脏表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h；
图4为本发明的HrpZpst多拟表位配体蛋白通过口服和涂抹实验鼠诱导丘脑表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h；
图5为本发明的HrpZpst多拟表位配体蛋白通过口服和涂抹实验鼠诱导心脏表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图6为本发明的HrpZpst多拟表位配体蛋白通过口服和涂抹实验鼠诱导大脑皮层表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图7为本发明的HrpZpst多拟表位配体蛋白口服和涂抹实验鼠诱导大脑海马表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图8为本发明的HrpZpst多拟表位配体蛋白口服和涂抹实验鼠诱导肝脏表达差异基因集聚类热图，自左至右依次为口服6h、口服24h；涂抹6h；(处理组左3道，对照组右4道)；
图9为本发明的HrpZpst多拟表位配体蛋白口服和涂抹实验鼠诱导丘脑表达差异基因集聚类热图，自 左至右依次为口服6h、口服24h；涂抹6h；(处理组左3道，对照组右4道)；
图10为本发明的HrpZpst多拟表位配体蛋白口服和涂抹实验鼠诱导海马表达差异基因集聚类热图，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；(对照组左3道，处理组右3道)；
图11为本发明的HrpZpst多拟表位配体蛋白口服和涂抹实验鼠诱导大脑皮层表达差异基因集聚类热图，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；(对照组左3道，处理组右3道)；
图12为本发明的HrpZpst多拟表位配体蛋白处理实验鼠肝脏与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图13为本发明的HrpZpst多拟表位配体蛋白处理实验鼠肝脏与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图14为本发明的HrpZpst多拟表位配体蛋白处理实验鼠肝脏与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；
图15为本发明的HrpZpst多拟表位配体蛋白处理实验鼠心脏与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图16为本发明的HrpZpst多拟表位配体蛋白处理实验鼠心脏与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图17为本发明的HrpZpst多拟表位配体蛋白处理实验鼠心脏与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图18为本发明的HrpZpst多拟表位配体蛋白处理实验鼠海马与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图19为本发明的HrpZpst多拟表位配体蛋白处理实验鼠海马与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图20为本发明的HrpZpst多拟表位配体蛋白处理实验鼠海马与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图21为本发明的HrpZpst多拟表位配体蛋白处理实验鼠大脑皮层与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图22为本发明的HrpZpst多拟表位配体蛋白处理实验鼠大脑皮层与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图23为本发明的HrpZpst多拟表位配体蛋白处理实验鼠大脑皮层与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h、涂抹12h；
图24为本发明的HrpZpst多拟表位配体蛋白处理大实验鼠脑丘脑与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图25为本发明的HrpZpst多拟表位配体蛋白处理实验鼠大脑丘脑与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图26为本发明的HrpZpst多拟表位配体蛋白处理实验鼠大脑丘脑与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图27为本发明的mRNA(RNA-Seq)测序实验流程图；
图28为本发明的mRNA测序数据分析流程图；
图29为HrpZpss蛋白纯化前后的电泳检测：左边为分子量标识带，1：纯化前HrpZpss多拟表位配体蛋白条带；2：纯化后HrpZpss多拟表位配体蛋白条带；
图30为HrpZpss多拟表位配体蛋白液注射诱导烟草叶片过敏反应图:其中所见焦斑处是经过HrpZpss多拟表位配体蛋白液处理24hr左右所形成，两侧：H 2O注射；3、4：HrpZpss多拟表位配体蛋白液(300μg/ml)注射，即HrpZpss多拟表位配体蛋白在烟草叶片上的超敏反应，两侧为对照，3、4为处理；
图31为本发明的HrpHrpZpss多拟表位配体蛋白通过口服和涂抹实验鼠诱导肾脏表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h；
图32为本发明的HrpHrpZpss多拟表位配体蛋白通过口服和涂抹实验鼠诱导睾丸表达差异基因火山图，自左至右依次为口服6h、口服24h；涂抹6h；
图33为本发明的HrpHrpZpss多拟表位配体蛋白口服和涂抹实验鼠诱导肾脏表达差异基因集聚类热图，自左至右依次为口服6h、口服24h；涂抹6h；
图34为本发明的HrpHrpZpss多拟表位配体蛋白口服和涂抹实验鼠诱导睾丸表达差异基因集聚类热图，自左至右依次为口服6h、口服24h；涂抹6h；
图35为本发明的HrpZpss多拟表位配体蛋白处理实验鼠肾脏与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图36为本发明的HrpZpss多拟表位配体蛋白处理实验鼠肾脏与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图37为本发明的HrpZpss多拟表位配体蛋白处理实验鼠肾脏与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图38为本发明的HrpZpss多拟表位配体蛋白处理实验鼠睾丸与对照比较KEGG Pathway(总基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图39为本发明的HrpZpss多拟表位配体蛋白处理实验鼠睾丸与对照比较KEGG Pathway(上调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图40为本发明的HrpZpss多拟表位配体蛋白处理实验鼠睾丸与对照比较KEGG Pathway(下调基因)，自左至右依次为口服6h、口服24h；涂抹6h；
图41为本发明的mRNA(RNA-Seq)测序实验流程图；
图42为本发明的mRNA测序数据分析流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合附图及实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅用以解释本发明，并不用于限定本发明。
下述实施例中所使用的试验方法如无特殊，均为常规方法。
下述实施例中所用的材料、试剂等，如无特殊的说明，均可从商业途径得到。
实施例1
HrpZ同源性比较如说明书所述，此处不再重复。
实施例2
HrpZpst多拟表位配体蛋白采用带有已注册的(Pseudomonas syringae pv tomato Strain CSCS008)hrpZpst基因(GenBank:AY999001)(克隆到高效表达载体PET28a(+))质粒的工程菌发酵，纯化制备和收集HrpZpst多拟表位配体蛋白，具体包括以下步骤：
1)HrpZpst多拟表位配体蛋白的工程菌发酵制备：将编码HrpZpst多拟表位配体蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每 升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpst多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条36.52kda条带，它就是基因hrpZpst的表达产物HrpZpst多拟表位配体蛋白。其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统pH 6.5-5.5；发酵温度为37-38℃；发酵增殖液体培养基葡萄糖浓度0.01％-0.05％；发酵诱导液体培养基葡萄糖浓度0.05％-0.00％；发酵诱导液体培养基乳糖浓度0.5％-0.4％；发酵诱导液体培养时间为7-9h。
2)工程菌生产系在多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液，pH 5-5.5，葡萄糖浓度200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌。
3)离心收集HrpZpst多拟表位配体蛋白分子，离心力范围1000-8000g，优选地离心力1000-2000g；优选地离心力2000-3500g；优选地离心力8000-6000g；优选地离心力6000-4500g；最优选地离心力3500-4500g。HrpZpst多拟表位配体蛋白存在于上清液中。
4)用Ni-NTA琼脂糖凝胶柱纯化HrpZpst多拟表位配体蛋白-His重组蛋白，蛋白纯化按Ni-NTA琼脂糖凝胶柱厂家建议方法实施，得到纯化的HrpNEcb多拟表位配体蛋白原药。
实施例3
HrpNEcb蛋白通过“人工合成基因”的表达蛋白进行制备，具体包括以下步骤：
第一步：编码HrpZpst蛋白的hrpZpst基因的人工合成；
1)按照GenBank公布的编码HrpZpst蛋白的hrpZpst基因(GenBank:AY999001)核苷酸序列，人工合成hrpZpst基因，其DNA序列如下：
Figure PCTCN2021134715-appb-000010
第二步：2)根据以上DNA序列，人工合成蛋白基因时，在基因的5′和3′分别加上BamHI和HindIII酶切位点，方便蛋白基因克隆；
第三步：人工基因合成委托Thermo Fisher Scientific公司的GeneArt基因合成与服务部门完成。3)将合成的编码HrpZpst蛋白基因的DNA片段，逐一克隆到高效蛋白表达载体PET28a(+)(含His-Tag标签) 的BamHI-HindIII位点，经DNA测序确保克隆的准确性；
第四步：将1)至3)编码HrpZpst蛋白的基因克隆转入大肠杆菌工程菌(E.coli)中，相关蛋白的生产系(E.coli)是K-12原菌经特殊改造后的衍生菌JY-01(DE3)；在LB液体培养基(每升含卡那霉素50微克)中，37℃条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体，用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpst多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条36.52kda条带，它就是基因hrpZpst的表达产物HrpZpst多拟表位配体蛋白，详见图1；
其中发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH6.5-5.5；发酵增殖液体培养基葡萄糖浓度为0.01％-0.05％；发酵诱导液体培养基乳糖浓度0.5％-0.4％；
第五步：将收集菌体悬浮到Na 2HPO 4-KH 2PO 4缓冲液中，在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃，在蝶式连续流离心机里清洗工程菌体五至八次，导入高压破碎机，连续用800-1000Mpa压力下，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁，收集HrpZpst多拟表位配体蛋白分子，HrpZpst多拟表位配体蛋白存在于上清液中；
第六步：HrpZpst多拟表位配体蛋白分子的纯化
用NI-NTA琼脂糖凝胶柱纯化多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成HrpZpst多拟表位配体蛋白的纯化制备。
10％SDS聚丙酰胺凝胶电泳检测高效表达的纯化蛋白-His重组条带，详见图1。
如图1所示，左面为分子量标识带；泳道1为纯化前的电泳谱带，对应分子量区聚集了较多的条带，也包括36.52kda条带；泳道2为纯化后的HrpZpst蛋白条带，分子量36.52kda，在蛋白对应分子量区，表明已经得到相应的纯化的HrpZpst多拟表位配体蛋白。
如图2所示，纯化的多拟表位配体蛋白的过敏实验检测：HrpZpst多拟表位配体蛋白制剂以及无菌水处理后24hr的烟草叶片反应结果见图2，其中，A、C点为注射300μg·mL -1的HrpZpst多拟表位配体蛋白液100μL；B、D点为注射无菌水100μL为对照处理。300μg·mL -1的HrpEcb多拟表位配体蛋白液处理12hr左右引起烟草叶片萎缩、塌陷，24hr该处枯死；水对照处理烟草叶片无过敏反应。
纯化的多拟表位配体蛋白能普遍引发多种植物叶片发生超敏反应，供试植物种类可以是：烟草、辣椒、茄子、西红柿、土豆、草莓、黄瓜、空心菜、鸡冠花、玻璃海棠、九月菊、三色堇、胭脂花、矮牵牛、葡萄、月季、槐树、豌豆、桃树、一串红、丝瓜、四季豆、花椰菜、菠菜、油菜、薯蓣、豇豆、蚕豆、玉米、水稻、大豆、仙客来、桑树、南瓜、枇杷、椿树等36个种类的不同植物。
实施例4
动物实验mRNA(mRNA-Seq)测序
mRNA测序的研究对象为特定细胞在某一功能状态下所能转录出来的所有带ploy-A尾的RNA，主要为mRNA。通过逆转录过程将细胞产生的mRNA转化为DNA(cDNA，互补，并对获得的cDNA进行文库构建)。然后对得到的DNA进行测序，并从观察到的特定DNA丰度中，从中推断细胞中mRNA的原始量，从而找到在实验条件下转录水平发生变化的基因或转录本，即差异表达。通过找到这些差异表达的基因和转录本，能够全面快速地获得某一物种特定组织或器官在某一状态下的几乎所有mRNA表达丰度，已广泛应用于基础研究和药物研发等多个领域。我们采用mRNA-seq技术，证明了HrpZpst多拟表位配体蛋白诱导小鼠多个器官中多基因的差异表达。
1.实验动物样品处理
本实验委托上海华盈生物医药科技有限公司蛋白质谱技术平台实施。
实验样品处理：实验选用8周龄的balb/C的实验小鼠，分为HrpZpst多拟表位配体蛋白处理组，包括口服6小时、24小时和涂抹6小时、12小时共4种处理，每种处理3只实验鼠，共计12只；空白对照组4只实验鼠；无HrpZpst多拟表位配体蛋白的缓冲液对照假手术组，包括口服6小时、24小时和涂抹6小时、12小时共4种处理，每种处理4只实验鼠，共计16只实验鼠，三次重复；对实验处理组鼠用600mg·L-1浓度的HrpZpst多拟表位配体蛋白缓冲液饲喂和涂抹处理，缓冲液对照假手术组小鼠用缓冲液饲喂和涂抹处理，空白对照组小鼠不做任何处理。在相同饲养条件下，按不同时间，分别分组取小鼠肝脏、丘脑、心脏、大脑皮层、大脑海马等组织，进行RNA-Seq的测序及分析。
2.mRNA(RNA-Seq)测序
通过新一代测序，能够全面快速地获得某一物种特定组织或器官在某一状态下的几乎所有mRNA表达丰度，见图27mRNA(RNA-Seq)测序实验流程图。
I.RNA抽提与质检
采用miRNeasy Micro Kit(Cat#1071023 Qiagen)并且根据生产厂商提供的标准操作流程进行样品的总RNA抽提。总RNA经NanoDrop ND-2000分光光度计及Agilent Bioanalyzer 4200(Agilent technologies，Santa Clara，CA，US)进行质检，质检合格的RNA用于后续的测序实验。
II.文库构建与质检
由于真核生物大部分mRNA都带有polyA尾，利用Oligo(dT)可以富集带有polyA尾的mRNA。接下来对富集mRNA进行片段化、双链cDNA合成、末端修复、3’末端加A、连接接头、扩增。
构建的文库使用
Figure PCTCN2021134715-appb-000011
2.0 Fluorometer检测浓度，Agilent2100检测大小。
III.上机测序
对文库进行Illumina测序，测序仪通过捕获荧光信号，并通过计算机软件将光信号转化为测序峰，从而获得待测片段的序列信息。
IV.mRNA测序数据分析按图28数据分析流程进行。
3.结果分析
1)HrpZpst多拟表位配体蛋白诱导的差异表达基因筛选
首先对fragment counts进行归一化，再根据假设检验模型计算p-value，最后对p-value多重假设检验校正，得到FDR值。FP KM值计算差异表达倍数(Fold-change)，使用edgeR软件。差异基因筛选条件如下：p-value<0.05且|Fold-change|>＝2。
2)HrpZpst多拟表位配体蛋白诱导的差异基因火山图
采用差异基因火山图显示HrpZpst多拟表位配体蛋白诱导的表达差异显著性基因的整体分布情况。横坐标：基因在不同样本中的表达倍数变化(log2 Fold-Chan ge)；纵坐标：基因表达差异的显著性水平(-log10 p-value)；右侧点表达显著上调基因；左侧点表达显著下调基因；下部点表达变化不显著基因。图3-7分别为小鼠的肝脏、丘脑、心脏、大脑皮层及大脑海马HrpZpst多拟表位配体蛋白通过口服和涂抹诱导的差异基因火山图,图中HrpZpst缩写为Z1。
3)HrpZpst蛋白诱导的差异基因聚类图
差异基因集进行聚类分析，将表达模式相近的基因聚在一起，显示基因具有共同功能或参与到共同信号通路。将log10(FPKM+1)值进行归一化转换(scale number)并进行聚类。图8-11分别为肝脏、丘脑、大脑皮层、海马表达差异基因集聚类热图，图中HrpZpst缩写为Z1。
4)HrpZpst蛋白诱导的差异基因GO富集分析
基因本体(Gene Ontology，GO)是一个在生物信息学领域中广泛使用的本体。基因本体论是对基因在不同维度和不同层次上的描述，涵盖了生物学的生物过程(biological_process)，细胞组分(cellular_component)及分子功能(molecular_function)。生物过程是在说明该基因参与了哪些生物学过程；细胞组分解释的是基因存在在哪里，包括该基因在细胞质还是在细胞核？如果存在细胞质那在哪个细胞器上？如果是在线粒体中那是存在线粒体膜上还是在线粒体的基质当中等等，这些信息都属于细胞组；分子功能解释的是该基因在分子层面的功能是什么？描述其在个体分子生物学上的活性，如催化活性或结合活性。基因本体数据库(Gene Ontology)是GO组织(Gene Ontology Consortium)在2000年构建的一个结构化的标准生物模型，旨在建立基因及其产物知识的标准词汇体系，涵盖了基因的生物学过程(biological process)，细胞组分(cellular component)、分子功能(molecular function)。Term是GO里面的基本描述单元。GO Terms用于描述基因产物的功能。通过将差异基因做GO富集分析，可以把基因按照不同的功能进行归类，达到对基因进行注释和分类的目的。我们对HrpZpst多拟表位配体蛋白诱导的差异表达基因进行了GO term富集分析，其结果证明、证实了HrpZpst多拟表位配体蛋白作为一类具有多个表位特殊结构，全新功能，全新作用机制和全新应用前景的配体蛋白，诱导了受试小鼠多个器官(肝脏、丘脑、心脏、大脑皮层及大脑海马等)多基因的差异表达，这些差异表达基因涵盖了生物过程、细胞组分及分子功能。差异表达基因利用Fisher精确检验进行GO分析。Fisher精确检验计算得到p-value，并进行多重假设检验校正得到q-value。筛选p-value小于0.05的GO条目作为显著富集的GO条目。
HrpZpst蛋白诱导的差异基因GO富集分析结果进一步表述如下：①生物过程(biological_process)相关差异表达基因包括了繁殖，细胞死亡，免疫系统的过程，行为，代谢过程，细胞过程，生殖过程，生物粘附，信号，多细胞生物过程，发育过程，增长，运动，单个组织的过程，生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递。生物过程GO富集分析结果详见表1至表6。②细胞组分(cellular_component)相关差异表达基因涵盖了细胞及细胞外区域，类核，膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维等。细胞组分GO富集分析结果详见表1至表6。③分子功能(molecular function)相关差异表达基因涵盖了转录因子活性，蛋白质结合，核酸结合转录因子活性，催化活性，信号传感器活动，结构分子活动，运输活动，绑定，电子载体活动，成形素活动，抗氧化活性，金属伴侣蛋白活性，蛋白质标记，化学引诱物的活动，转译调控，化学排斥物活性，活动分子传感器，分子功能调控等。分子功能GO富集分析结果详见表1至表6。
其中，表1-6中HrpZpst缩写为HrpZ1，所有表格中，空格表示没有收集到对应的未达到p-value小于0.05标准的相关数据，以下及其所有表格空白含义与此相同。
表1 HrpZpst多拟表位配体蛋白诱导肝脏、心脏的生物学过程、细胞组分和分子功能相关功能群显著上调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000012
Figure PCTCN2021134715-appb-000013
Figure PCTCN2021134715-appb-000014
Figure PCTCN2021134715-appb-000015
表2 HrpZpst多拟表位配体蛋白诱导大脑皮层的生物学过程、细胞组分和分子功能相关功能群显著上调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000016
Figure PCTCN2021134715-appb-000017
Figure PCTCN2021134715-appb-000018
Figure PCTCN2021134715-appb-000019
表3 HrpZpst多拟表位配体蛋白诱导丘脑、海马的生物学过程、细胞组分和分子功能相关功能群显著上调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000020
Figure PCTCN2021134715-appb-000021
Figure PCTCN2021134715-appb-000022
Figure PCTCN2021134715-appb-000023
Figure PCTCN2021134715-appb-000024
表4 HrpZpst多拟表位配体蛋白诱导肝脏、心脏的生物学过程、细胞组分和分子功能相关功能群显著下调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000025
Figure PCTCN2021134715-appb-000026
Figure PCTCN2021134715-appb-000027
Figure PCTCN2021134715-appb-000028
Figure PCTCN2021134715-appb-000029
表5 HrpZpst多拟表位配体蛋白诱导大脑皮层的生物学过程、细胞组分和分子功能相关功能群显著下调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000030
Figure PCTCN2021134715-appb-000031
Figure PCTCN2021134715-appb-000032
Figure PCTCN2021134715-appb-000033
表6 HrpZpst多拟表位配体蛋白诱导丘脑、海马的生物学过程、细胞组分和分子功能相关功能群显著下调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时、涂抹12小时)
Figure PCTCN2021134715-appb-000034
Figure PCTCN2021134715-appb-000035
Figure PCTCN2021134715-appb-000036
Figure PCTCN2021134715-appb-000037
Figure PCTCN2021134715-appb-000038
5.差异表达基因的KEGG pathway富集分析
京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes，KEGG)，是系统分析基因功能与基因组信息的数据库，它整合了基因组学、生物化学和系统功能组学的信息，有助于研究者把基因及表达信息的过程作为一个网络进行整体研究。
KEGG主要的特点是将基因与各种生化反应联系在了一起，提供整合的代谢途径。KEGG目前共包含了19个子数据库，它们被分类为系统信息、基因组信息和化学信息三个类别。在生物体内，不同的基因产物相互协调来行使生物学功能，对差异表达基因的通路(Pathway)注释分析有助于进一步解读基因的功能。对HrpZpst蛋白诱导的差异表达基因进行了KEGG pathway富集分析，获得这些差异表达基因在信号通路中的角色(上下游关系)和生物学功能，深入理解基因与功能的关系。差异表达基因利用Fisher精确检验进行Pathway分析。Fisher精确检验计算得到p-value，并进行多重假设检验校正得到q-value。筛选p-value小于0.05的Pathway作为显著富集的Pathway。
研究结果证明、证实了HrpZpst多拟表位配体蛋白作为一类具有多表位特殊结构，全新功能，全新作用机制和全新应用前景的配体蛋白，诱导了小鼠多个器官(肝脏、丘脑、心脏、大脑皮层及大脑海马等)多基因的差异表达，这些差异表达基因参与了归属于细胞过程(Cellular Processes)、环境信息处理(Environmental Information Processing)、遗传信息处理(Genetic Information Processing)、新陈代谢(Metabolism)和生物体系统(Organismal Systems)等功能途径。HrpZpst多拟表位配体蛋白诱导的差异基因GO富集分析结果进一步表述如下：①细胞过程(Cellular Processes)：HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程(详见图12至图26)。②环境信息处理(Environmental Information Processing):HrZpst蛋白诱导的多个差异表达基因参与了信号分子与相互作用，信号转导，膜运输等环境信息处理过程(详见图12至图26)。③遗传信息处理(Genetic Information Processing):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了翻译，复制和修复，折叠、分类和降解等生物过程(详见图12至图26)。④新陈代谢(Metabolism):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了生物降解和代谢，核苷酸代谢，其他氨基酸的代谢，代谢的辅助因子和维生素，脂质代谢，糖的生物合成和代谢，全局和概览地图，能量代谢，碳水化合物代谢及氨基酸代谢等代谢过程(详见图12至图26)。⑤生物体系统(Organismal Systems):HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了感觉系统，神经系统，免疫系统，排泄系统，环境适应，内分泌系统，消化系统，发育循环系统等细胞过程(详见图12至图26)。
与GO分类统计类似，对KEGG各个生物学途径(pathway)上的差异表达基因数目进行统计并以图形展示如图12至图26所示。
说明：图形右边示图，细胞过程、信息过程、遗传信息过程、代谢过程、组织系统发育过程；横坐标：涉及表达差异的各功能基因群的基因数目；纵坐标：涉及表达差异的细胞过程、信息过程、遗传信息过程、代谢过程、组织系统发育过程的功能基因群。
实施例5
HrpZpst蛋白识别结合特异蛋白的pull-down实验
1.样品准备和处理
1)HrpZpst多拟表位配体蛋白纯化
用NI-NTA琼脂糖凝胶柱纯化HrpZpst多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，制备的HrpZpst多拟表位配体蛋白备用(以下称为捕获蛋白或目的蛋白)。
2)实验用培养肝细胞总蛋白(以下称为钓饵蛋白)抽提
I.培养肝细胞总蛋白的抽提：①用移液枪吸取裂解液(IP专用裂解液，加入1×cocktail蛋白酶抑制剂)加入到细胞。超声，冰上静置2h以上；②使用超声细胞破碎仪，冰上超声2s，停5s，共1min，冰上裂解总时长2h以上(间隔30min振荡器震荡混匀)；③将细胞裂解产物4℃下13000rpm离心15min，吸取上清转移至新的1.5mLEP管，冰上放置待用；④将蛋白抽提液再次于4℃下13000rpm离心5min，小心地吸取中间层的溶液，转移至新的1.5mL EP管中，4℃冰箱放置待用，并取部分稀释后测浓度(稀释10倍)，采用BCA蛋白浓度测定法测定浓度。
II.蛋白浓度测定：参照BCA试剂盒的方法，对提取的蛋白溶液进行浓度测定。
表7 BCA法测定蛋白浓度
NO. 样本名称 实验编号 浓度(μg/μL) 体积(μL) 总量(μg)
1 HEPG2 HEPG2 8.34 2500 20861.30
2.pull-down实验流程
1)平衡固定链霉亲和素凝胶:①准备Pierce TM Spin Column管；②上下颠倒重悬凝胶液，吸取50μl悬液于标记好的Spin Column管，塞好底塞并放置于收集管中；③再向Spin Column管中加入250μl TBS，拧紧顶盖，轻轻上下颠倒4次混匀液体；④去掉顶盖和底塞，1250×g离心50s，弃掉收集管中的清洗液，把SpinColumn管重新插入收集管中；⑤重复步骤3和步骤4两次。再在Spin Column管底部塞上管底塞。
2)生物素标记生物素标记钓饵蛋白和生物素的固定:①向Spin Column管中分别加入生物素和生物素标记钓饵蛋白，拧紧顶盖和底塞；②在旋转平台rotating platform上温和地摇动，4℃孵育60min；③孵育结束后，移去Spin Column管顶盖和底塞，放入收集管中；④1250×g，60s离心后，将Spin Column管重新放入收集管中。
3)生物素的封闭:①向Spin Column管中加入250μl生物素封闭溶液。拧紧顶盖和底塞，轻轻上下颠倒4次使之混匀；②室温下孵育5min。移去顶盖，将Spin Column管放于收集管中，1250×g离心50s；③重复步骤1和步骤2一次；④再向Spin Column管中加入TBS 250μl。拧紧顶盖，轻轻上下颠倒4次使之混匀；⑤移去顶盖，放于收集管中，1250×g离心50s；⑥重复步骤3和步骤4两次，Spin Column管重新放入收集管。
4)生物素标记生物素标记蛋白的捕获:①向Spin Column管中加入300μL(1mg蛋白)的捕获蛋白(目的蛋白)样品溶液，拧紧顶盖；②在旋转平台rotating platform上温和地摇动，4℃孵育过夜；③孵育结束后，移去顶盖和底塞。将Spin Column管放入准备好的收集管中；④将收集管，1250×g，60s，离心，收集管标记“prey flow-through(B)”；⑤移去收集管中Spin Column管，盖好收集管的盖子，冰上放置以便后续分析；⑥将Spin Column管放入新的收集管，准备洗脱。
5)Spin Column管的诱饵蛋白和靶蛋白复合物的洗脱:①在每个Spin Column管中加入250μl Wash Buffer。拧紧顶盖和底塞，轻轻颠倒6次使之混匀；②将Spin Column管在室温下孵育1分钟。将顶盖底塞去掉，将Spin Column管置于收集管上，1250×g离心50s。另外重复步骤1-2，3次；③在冲洗 的过程中，在收集管上写上标签“Wash1，……，Wash3”；④最后一次冲洗时，加入200μl Wash Buffer后，将管内液体连同珠子一起转移至1.5mL；⑤新的离心管中，离心后弃170μl上清，该步骤重复3次。
6)检测：①吸干Sepharose上面的液体后，加入20μl 1×蛋白电泳上样缓冲液，沸水浴5min，放入-20℃冰箱备用；②通过SDS-PAGE和Western blot进行检测。
3.结果分析
1)HrpZpst多拟表位配体蛋白识别结合的细胞膜受体：识别结合5个膜受体，包括HLA-C主要组织相容性复合体，I，C类受体、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体(APMAP)、胰岛素样生长因子2受体(IGF2R)、LDL受体相关蛋白1(LRPAP1)。
2)HrpZpst多拟表位配体蛋白识别结合的细胞膜蛋白：识别结合10个膜蛋白，包括溶质载体家族38，成员2(SLC38A2)、DNM2动力蛋白2、SPTAN1非红细胞1α血影蛋白、β-互生蛋白1(SNTB1)、CAP1腺苷酸环化酶相关蛋白1、ICAM1细胞间粘附分子1、LanC-类蛋白1(羊毛硫氨酸合成酶C)(LANCL1)、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白。
3)HrpZpst多拟表位配体蛋白识别结合的膜蛋白参与的信号通路：识别结合4条，包括hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路、hsa04668TNF信号通路。
4)HrpZpst多拟表位配体蛋白识别结合的膜蛋白参与的与抗病毒、抗细菌、抗异物、抗炎性相关代谢通路：识别结合27条，hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、hsa04666Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05143非洲锥虫病、hsa04650自然杀伤细胞介导的细胞毒性、hsa05166人T细胞白血病病毒1感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05165人乳头瘤病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa05330同种异体移植物排斥反应、hsa05332抗移植物、hsa04670白细胞跨细胞迁移。
5)HrpZpst多拟表位配体蛋白识别结合的膜蛋白参与的重要神经疾病代谢通道：未检出。
6)HrpZpst多拟表位配体蛋白识别结合的膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢相关通路：识别结合1条，包括hsa04974蛋白消化吸收。
7)HrpZpst多拟表位配体蛋白识别结合的膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统等代谢通路：识别结合12条，hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04940I型糖尿病、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子(CAMs)、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
HrpZpst多拟表位配体蛋白，作为一类富含特殊多个线性和构象表位结构的配体蛋白分子，能够跨界识别、结合多种类型的膜受体、膜蛋白、信息通路和代谢通路，进一步分析这些膜受体、膜蛋白、信息通路和代谢通路的位置、结构、特性、作用机制和功能，它们广泛涉及和影响机体的生长、发育、代谢、防御和细胞程序性死亡的生命基本属性，并广泛涉及诊断、预防、治疗、康复神经系统、消化系统、运动系统、循环系统、呼吸系统、内分泌系统、免疫系统、泌尿系统、生殖系统、皮肤系统疾病和状况。HrpZpst多拟表位配体蛋白是一类具有全新功能，全新作用机制和全新应用前景的特殊多拟表位配体蛋 白。
实施例6
所述HrpZpss多拟表位配体蛋白采用已注册的基因的工程菌发酵，高效表达，纯化制备，具体包括以下步骤：
1)HrpZpss多拟表位配体蛋白的工程菌发酵制备：将带有编码HrpZpss多拟表位配体蛋白的基因(包括，但不限于生物样品天然基因、化学合成基因、转基因遗传重组体基因以及相似基因及其基因修饰)质粒的工程菌(E.coli)，相关蛋白的生产系是K-12原菌经特殊改造后的衍生菌JY-01(DE3)，在LB液体培养基(每升含卡那霉素50微克)中，在一定的温度下条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体。用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpss多拟表位配体蛋白，在电泳胶板的样品泳道上，会呈现一条34.73kd条带，它就是基因hrpZpss的表达产物多拟表位配体HrpZpss蛋白。其中，发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统pH 6.5-5.5；发酵温度为37-38℃；发酵增殖液体培养基葡萄糖浓度0.01％-0.05％；发酵诱导液体培养基葡萄糖浓度0.05％-0.00％；发酵诱导液体培养基乳糖浓度0.5％-0.4％；发酵诱导液体培养时间为7-9h。
2)工程菌生产系在HrpZpss多拟表位配体蛋白生产发酵结束后的后处理：①灭菌：发酵液在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃以下；②清洗：用葡萄糖Na 2HPO 4-KH 2PO 4缓冲液，pH 5-5.5，葡萄糖浓度200-300mmol，在蝶式连续流离心机里清洗工程菌体五至八次；③破碎工程菌并清除细胞壁，再用pH 5-5.5、葡萄糖浓度200-300mmol的Na 2HPO 4-KH 2PO 4缓冲液稀释菌体，调节菌体鲜重为稀释液的20％-30％，导入高压破碎机，连续用800-1000Mpa压力，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁。
3)HrpZpss多拟表位配体蛋白分子的纯化：用NI-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成纯化HrpZpss多拟表位配体蛋白制备。
实施例7
HrpZpss多拟表位配体蛋白通过“人工合成基因”的表达蛋白进行制备，具体包括以下步骤：
第一步：编码HrpZpss蛋白的hrpZpss基因的人工合成；
1)按照GenBank公布的编码HrpZpss蛋白(GenBank:AAY36247.1)的hrpZpss基因核苷酸序列,人工合成hrpZpss基因，其DNA序列为：
Figure PCTCN2021134715-appb-000039
Figure PCTCN2021134715-appb-000040
第二步：2)根据以上DNA序列，人工合成蛋白基因时，在基因的5′和3′分别加上BamHI和HindIII酶切位点，方便蛋白基因克隆；
第三步：人工基因合成委托Thermo Fisher Scientific公司的GeneArt基因合成与服务部门完成。3)将合成的编码HrpNEcb蛋白基因的DNA片段，克隆到高效蛋白表达载体PET28a(+)(含His-Tag标签)的BamHI-HindIII位点，经DNA测序确保克隆的准确性；
第四步：将1)至3)编码HrpNEcb蛋白的基因克隆转入大肠杆菌工程菌(E.coli)中，相关蛋白的生产系(E.coli)是K-12原菌经特殊改造后的衍生菌JY-01(DE3)；在LB液体培养基(每升含卡那霉素50微克)中，37℃条件下，培养至OD600＝0.7时，加入IPTG(异丙基硫代半乳糖苷，Isopropyl β-D-Thiogalactosid)(终浓度1mMol)，继续培养后离心收集菌体，用10％SDS－PAGE聚丙烯酰胺凝胶电泳分析表达产物HrpZpss蛋白，在电泳胶板的样品泳道上，会呈现一条36.64kda条带，它就是基因hrpZpss的表达产物HrpZpss多拟表位配体蛋白，详见图29；
其中发酵用培养基Na 2HPO 4-KH 2PO 4缓冲系统，缓冲系统的pH6.5-5.5；发酵增殖液体培养基葡萄糖浓度为0.01％-0.05％；发酵诱导液体培养基乳糖浓度0.5％-0.4％；
第五步：将收集菌体悬浮到Na 2HPO 4-KH 2PO 4缓冲液中，在80℃温度下，30分钟完成灭菌处理，迅速降温至30℃，在蝶式连续流离心机里清洗工程菌体五至八次，导入高压破碎机，连续用800-1000Mpa压力下，破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁；
第六步：用NI-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，完成纯化HrpZpss多拟表位配体蛋白的制备。
10％SDS聚丙酰胺凝胶电泳检测高效表达的纯化蛋白-His重组条带，详见图29。
如图29所示，左面为分子量标识带；泳道1为纯化前的电泳谱带，对应分子量区聚集了较多的条带，也包括34.73kd条带；泳道2为纯化HrpZpss多拟表位配体蛋白条带，分子量34.73kd，在蛋白对应分子量区，表明已经得到相应的HrpZpss纯化蛋白。
如图30所示，HrpZpss多拟表位配体蛋白的过敏实验检测：HrpZpss多拟表位配体蛋白制剂以及无菌水处理后24hr的烟草叶片反应结果见图31，其中，A、C点为注射300μg·mL -1的HrpZpss多拟表位配体蛋白液100μL；B、D点为注射无菌水100μL为对照处理。300μg·mL -1的HrpZpss多拟表位配体蛋白液处理12hr左右引起烟草叶片萎缩、塌陷,24hr该处枯死；水对照处理烟草叶片无过敏反应。
纯化的HrpZpss多拟表位配体蛋白能普遍引发多种植物叶片发生超敏反应，供试植物种类可以是：烟草、辣椒、茄子、西红柿、土豆、草莓、黄瓜、空心菜、鸡冠花、玻璃海棠、九月菊、三色堇、胭脂花、矮牵牛、葡萄、月季、槐树、豌豆、桃树、一串红、丝瓜、四季豆、花椰菜、菠菜、油菜、薯蓣、豇豆、蚕豆、玉米、水稻、大豆、仙客来、桑树、南瓜、枇杷、椿树等36个种类的不同植物。
实施例8
动物实验mRNA(RNA-Seq)测序
mRNA测序的研究对象为特定细胞在某一功能状态下所能转录出来的所有带ploy-A尾的RNA，主要为mRNA。通过逆转录过程将细胞产生的mRNA转化为DNA(cDNA，互补，并对获得的cDNA进行文库构建)。然后对得到的DNA进行测序，并从观察到的特定DNA丰度中，从中推断细胞中mRNA的原始量，从而找到在实验条件下转录水平发生变化的基因或转录本，即差异表达。通过找到这些差异表 达的基因和转录本，能够全面快速地获得某一物种特定组织或器官在某一状态下的几乎所有mRNA表达丰度，已广泛应用于基础研究和药物研发等多个领域。我们采用mRNA-seq技术，证明了HrpZpss多拟表位配体蛋白诱导小鼠多个器官中多基因的差异表达。
1.实验动物样品处理
本实验委托上海华盈生物医药科技有限公司蛋白质谱技术平台实施。
实验样品处理：实验选用8周龄的balb/C的实验小鼠，分为HrpZpss多拟表位配体蛋白处理组，包括口服6小时、24小时和涂抹6小时、12小时共4种处理，每种处理3只实验鼠，共计12只；空白对照组4只实验鼠；不含HrpZpss多拟表位配体蛋白的缓冲液对照假手术组，包括口服6小时、24小时和涂抹6小时、12小时共4种处理，每种处理4只实验鼠，共计16只实验鼠，三次重复；对实验处理组鼠用含600mg·L-1HrpZpss多拟表位配体蛋白的缓冲液饲喂和涂抹处理，缓冲液对照假手术组小鼠用缓冲液饲喂和涂抹处理，空白对照组小鼠不做任何处理。在相同饲养条件下，按不同时间，分别分组取小鼠肾脏、睾丸等组织，进行RNA-Seq的测序及分析。
2.mRNA(RNA-Seq)测序
通过新一代测序，能够全面快速地获得某一物种特定组织或器官在某一状态下的几乎所有mRNA表达丰度，见图41mRNA(RNA-Seq)测序实验流程图。
I.RNA抽提与质检
采用miRNeasy Micro Kit(Cat#1071023 Qiagen)并且根据生产厂商提供的标准操作流程进行样品的总RNA抽提。总RNA经NanoDrop ND-2000分光光度计及Agilent Bioanalyzer 4200(Agilent technologies,Santa Clara,CA,US)进行质检，质检合格的RNA用于后续的测序实验。
II.文库构建与质检
由于真核生物大部分mRNA都带有polyA尾，利用Oligo(dT)可以富集带有polyA尾的mRNA。接下来对富集mRNA进行片段化、双链cDNA合成、末端修复、3’末端加A、连接接头、扩增。
构建的文库使用
Figure PCTCN2021134715-appb-000041
2.0 Fluorometer检测浓度，Agilent2100检测大小。
III.上机测序
对质检合格的文库进行Illumina测序，测序仪通过捕获荧光信号，并通过计算机软件将光信号转化为测序峰，从而获得待测片段的序列信息。
IV.mRNA测序数据分析按图42数据分析流程进行。
3.结果分析
1)HrpZpss多拟表位配体蛋白诱导的差异基因筛选
首先对fragment counts进行归一化，再根据假设检验模型计算p-value，最后对p-value多重假设检验校正，得到FDR值。FP KM值计算差异表达倍数(Fold-change)，使用edgeR软件。差异基因筛选条件如下：p-value<0.05且|Fold-change|>＝2。
2)HrpZpss多拟表位配体蛋白诱导的差异基因火山图
采用差异基因火山图显示HrpNEcb蛋白诱导的表达差异显著性基因的整体分布情况。横坐标：基因在不同样本中的表达倍数变化(log2Fold-Chan ge)；纵坐标：基因表达差异的显著性水平(-log10p-value)；右侧点表达显著上调基因；左侧点表达显著下调基因；下部点表达变化不显著基因。图31-32分别为小鼠的肾脏、睾丸HrpZpss蛋白通过口服和涂抹诱导的差异基因火山图，图中HrpZpss缩写为Z2。
3)HrpZpss多拟表位配体蛋白诱导的差异基因聚类图
差异基因集进行聚类分析，将表达模式相近的基因聚在一起，显示基因具有共同功能或参与到共同信号通路。将log10(FPKM+1)值进行归一化转换(sca le number)并进行聚类。图33-34分别为肾脏、睾丸表达差异基因集聚类热图，图中HrpZpss缩写为Z2。
4)HrpZpss多拟表位配体蛋白诱导的差异基因GO富集分析
基因本体(Gene Ontology，GO)是一个在生物信息学领域中广泛使用的本体。基因本体论是对基因在不同维度和不同层次上的描述，涵盖了生物学的生物过程(biological_process)，细胞组分(cellular_component)及分子功能(molecular_function)。生物过程是在说明该基因参与了哪些生物学过程；细胞组分解释的是基因存在在哪里，包括该基因在细胞质还是在细胞核？如果存在细胞质那在哪个细胞器上？如果是在线粒体中那是存在线粒体膜上还是在线粒体的基质当中等等，这些信息都属于细胞组；分子功能解释的是该基因在分子层面的功能是什么？描述其在个体分子生物学上的活性，如催化活性或结合活性。基因本体数据库(Gene Ontology)是GO组织(Gene Ontology Consortium)在2000年构建的一个结构化的标准生物模型，旨在建立基因及其产物知识的标准词汇体系，涵盖了基因的生物学过程(biological process)，细胞组分(cellular component)、分子功能(molecular function)。Term是GO里面的基本描述单元。GO Terms用于描述基因产物的功能。通过将差异基因做GO富集分析，可以把基因按照不同的功能进行归类，达到对基因进行注释和分类的目的。我们对HrpNEcb多拟表位配体蛋白诱导的差异表达基因进行了GO term富集分析,其结果证明、证实了HrpNEcb多拟表位配体蛋白作为一类具有多个表位特殊结构，全新功能，全新作用机制和全新应用前景的配体蛋白，诱导了受试小鼠多个器官(肾脏、睾丸)多基因的差异表达，这些差异表达基因涵盖了生物过程、细胞组分及分子功能。差异表达基因利用Fisher精确检验进行GO分析。Fisher精确检验计算得到p-value，并进行多重假设检验校正得到q-value。筛选p-value小于0.05的GO条目作为显著富集的GO条目。HrpNEcb多拟表位配体蛋白诱导的差异基因GO富集分析结果进一步表述如下：①生物过程(biological_process)相关差异表达基因包括了繁殖,细胞死亡,免疫系统的过程,行为,代谢过程,细胞过程,生殖过程,生物粘附,信号,多细胞生物过程,发育过程，增长，运动，单个组织的过程，生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递。生物过程GO富集分析结果详见表8至表9。②细胞组分(cellular_component)相关差异表达基因涵盖了细胞及细胞外区域，类核，膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维等。细胞组分GO富集分析结果详见表8至表9。③分子功能(molecular function)相关差异表达基因涵盖了转录因子活性，蛋白质结合,核酸结合转录因子活性,催化活性,信号传感器活动,结构分子活动,运输活动,绑定,电子载体活动,成形素活动,抗氧化活性,金属伴侣蛋白活性,蛋白质标记,化学引诱物的活动,转译调控，化学排斥物活性，活动分子传感器，分子功能调控等。分子功能GO富集分析结果详见表8至表9。
其中，表8-9中HrpZpss缩写为HrpZ2，所有表格中，空格表示没有收集到对应的未达到p-value小于0.05标准的相关数据，以下及其所有表格空白含义与此相同。
表8 HrpZpss多拟表位配体蛋白诱导睾丸、肾脏的生物学过程、细胞组分和分子功能相关功能群显著上调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时)
Figure PCTCN2021134715-appb-000042
Figure PCTCN2021134715-appb-000043
Figure PCTCN2021134715-appb-000044
Figure PCTCN2021134715-appb-000045
Figure PCTCN2021134715-appb-000046
Figure PCTCN2021134715-appb-000047
表9 HrpZpss多拟表位配体蛋白诱导睾丸、肾脏的生物学过程、细胞组分和分子功能相关功能群显著下调表达GO terms分类基因数统计表(口服6、24小时和涂抹6小时)
Figure PCTCN2021134715-appb-000048
Figure PCTCN2021134715-appb-000049
Figure PCTCN2021134715-appb-000050
Figure PCTCN2021134715-appb-000051
Figure PCTCN2021134715-appb-000052
5.差异表达基因的KEGG pathway富集分析
京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)，是系统分析基因功能与基因组信息的数据库，它整合了基因组学、生物化学和系统功能组学的信息，有助于研究者把基因及表达信息的过程作为一个网络进行整体研究。
KEGG主要的特点是将基因与各种生化反应联系在了一起，提供整合的代谢途径。KEGG目前共包含了19个子数据库，它们被分类为系统信息、基因组信息和化学信息三个类别。在生物体内，不同的基因产物相互协调来行使生物学功能，对差异表达基因的通路(Pathway)注释分析有助于进一步解读基因的功能。对HrpZpss多拟表位配体蛋白诱导的差异表达基因进行了KEGG pathway富集分析，获得这些差异表达基因在信号通路中的角色(上下游关系)和生物学功能，深入理解基因与功能的关系。研究结果证明、证实了HrpZpss多拟表位配体蛋白作为一类具有多表位特殊结构，全新功能，全新作用机制和全新应用前景的配体蛋白，诱导了小鼠多个器官(肾脏、睾丸等)多基因的差异表达，这些差异表达基因参与了归属于细胞过程(Cellular Processes)、环境信息处理(Environmental Information Processing)、遗传信息处理(Genetic Information Processing)、新陈代谢(Metabolism)和生物体系统(Organismal Systems)等功能途径。HrpZpss多拟表位配体蛋白诱导的差异基因GO富集分析结果进一步表述如下：①细胞过程(Cellular Processes)：HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程(详见图35至图40)。②环境信息处理(Environmental Information Processing):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了信号分子与相互作用,信号转导,膜运输等环境信息处理过程(详见图35至图40)。③遗传信息处理(Genetic Information Processing):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了翻译,复制和修复,折叠、分类和降解等生物过程(详见图35至图40)。④新陈代谢(Metabolism):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了生物降解和代谢,核苷酸代谢,其他氨基酸的代谢,代谢的辅助因子和维生素,脂质代谢,糖的生物合成和代谢,全局和概览地图,能量代谢,碳水化合物代谢及氨基酸代谢等代谢过程(详见图35至图40)。⑤生物体系统(Organismal Systems):HrpZpss多拟表位配体蛋白诱导的多个差异表达基因参与了感觉系统,神经系统,免疫系统,排泄系统,环境适应,内分泌系统,消化系统,发育循环系统等细胞过程(详见图35至图40)。
与GO分类统计类似，对KEGG各个生物学途径(pathway)上的差异表达基因数目进行统计并以图形展示如图35至图40所示。
说明：图形右边示图：细胞过程、信息过程、遗传信息过程、代谢过程、组织系统发育过程；横坐标：涉及表达差异的各功能基因群的基因数目；纵坐标：涉及表达差异的细胞过程、信息过程、遗传信 息过程、代谢过程、组织系统发育过程的功能基因群。
实施例9
HrpZpss多拟表位配体蛋白识别结合特异蛋白的pull-down实验
1.样品准备和处理
1)HrpZpss蛋白纯化
用NI-NTA琼脂糖凝胶柱纯化HrpZpss多拟表位配体蛋白-His重组蛋白，蛋白纯化按NI-NTA琼脂糖凝胶柱厂家建议方法实施，纯化制备的HrpZpss多拟表位配体蛋白备用(以下称为捕获蛋白或目的蛋白)。
2)实验用培养肝细胞总蛋白(以下称为钓饵蛋白)抽提
I.培养肝细胞总蛋白的抽提：①用移液枪吸取裂解液(IP专用裂解液，加入1×cocktail蛋白酶抑制剂)加入到细胞。超声，冰上静置2h以上；②使用超声细胞破碎仪，冰上超声2s，停5s，共1min，冰上裂解总时长2h以上(间隔30min振荡器震荡混匀)；③将细胞裂解产物4℃下13000rpm离心15min，吸取上清转移至新的1.5mLEP管，冰上放置待用；④将蛋白抽提液再次于4℃下13000rpm离心5min，小心地吸取中间层的溶液，转移至新的1.5mL EP管中，4℃冰箱放置待用，并取部分稀释后测浓度(稀释10倍)，采用BCA法测定浓度。
II.蛋白浓度测定：参照BCA试剂盒的方法，对提取的蛋白溶液进行浓度测定。
表10 BCA法测定蛋白浓度
NO. 样本名称 实验编号 浓度(μg/μL) 体积(μL) 总量(μg)
1 HEPG2 HEPG2 8.34 2500 20861.30
2.pull-down实验流程
1)平衡固定链霉亲和素凝胶:①准备Pierce TM Spin Column管；②上下颠倒重悬凝胶液，吸取50μl悬液于标记好的Spin Column管，塞好底塞并放置于收集管中；③再向Spin Column管中加入250μl TBS，拧紧顶盖，轻轻上下颠倒4次混匀液体；④去掉顶盖和底塞，1250×g离心50s，弃掉收集管中的清洗液，把SpinColumn管重新插入收集管中；⑤重复步骤3和步骤4两次。再在Spin Column管底部塞上管底塞。
2)生物素标记生物素标记钓饵蛋白和生物素的固定:①向Spin Column管中分别加入生物素和生物素标记钓饵蛋白，拧紧顶盖和底塞；②在旋转平台rotating platform上温和地摇动，4℃孵育60min；③孵育结束后，移去Spin Column管顶盖和底塞，放入收集管中；④1250×g，60s离心后，将Spin Column管重新放入收集管中。
3)生物素的封闭:①向Spin Column管中加入250μl生物素封闭溶液。拧紧顶盖和底塞，轻轻上下颠倒4次使之混匀；②室温下孵育5min。移去顶盖，将Spin Column管放于收集管中，1250×g离心50s；③重复步骤1和步骤2一次；④再向Spin Column管中加入TBS 250μl。拧紧顶盖，轻轻上下颠倒4次使之混匀；⑤移去顶盖，放于收集管中，1250×g离心50s；⑥重复步骤3和步骤4两次，Spin Column管重新放入收集管。
4)生物素标记生物素标记蛋白的捕获:①向Spin Column管中加入300μL(1mg蛋白)的捕获蛋白(目的蛋白)样品溶液，拧紧顶盖；②在旋转平台rotating platform上温和地摇动，4℃孵育过夜；③孵育结束后，移去顶盖和底塞。将Spin Column管放入准备好的收集管中；④将收集管，1250×g，60s，离心，收集管标记“prey flow-through(B)”；⑤移去收集管中Spin Column管，盖好收集管的盖子，冰上放置以便后续分析；⑥将Spin Column管放入新的收集管，准备洗脱。
5)Spin Column管的诱饵蛋白和靶蛋白复合物的洗脱:①在每个Spin Column管中加入250μl Wash Buffer。拧紧顶盖和底塞，轻轻颠倒6次使之混匀；②将Spin Column管在室温下孵育1分钟。将顶盖底塞去掉，将Spin Column管置于收集管上，1250×g离心50s。另外重复步骤1-2，3次；③在冲洗的过程中，在收集管上写上标签“Wash1，……，Wash3”；④最后一次冲洗时，加入200μl Wash Buffer后，将管内液体连同珠子一起转移至1.5mL；⑤新的离心管中，离心后弃170μl上清，该步骤重复3次。
6)检测：①吸干Sepharose上面的液体后，加入20μl 1×蛋白电泳上样缓冲液，沸水浴5min，放入-20℃冰箱备用；②通过SDS-PAGE和Western blot进行检测。
3.结果分析
1)HrpZpss多拟表位配体蛋白识别结合的细胞膜受体：HLA-C主要组织相容性复合体，I,C类受体、游离脂肪酸受体4、酪氨酸蛋白激酶跨膜受体1、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体(APMAP)、胰岛素样生长因子2受体(IGF2R)。
2)HrpZpss多拟表位配体蛋白识别结合的细胞膜蛋白：溶质载体家族5(钠依赖维生素转运蛋白),成员6、溶质载体家族26,成员4、溶质载体家族38，成员2(SLC38A2)、DNM2动力蛋白2、CAP1腺苷酸环化酶相关蛋白1、ICAM1细胞间粘附分子1LanC-类蛋白1(羊毛硫氨酸合成酶C)(LANCL1)、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白。
3)HrpZpss多拟表位配体蛋白识别结合的信号通路：hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路。
4)HrpZpss多拟表位配体蛋白识别结合膜蛋白参与的与抗病毒、抗细菌、抗异物、抗炎性相关代谢通路：hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、hsa04666Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa05130:致病性大肠杆菌感染、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa04916:杀菌作用、hsa04650自然杀伤细胞介导的细胞毒性、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa04670白细胞跨细胞迁移。
5)HrpZpss多拟表位配体蛋白识别结合膜蛋白参与的重要神经疾病代谢通道：未检出。
6)HrpZpss多拟表位配体蛋白识别结合膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢相关通路：hsa03050:蛋白酶体、hsa04974蛋白消化吸收、hsa04120:泛素介导的蛋白水解作用。
7)HrpZpss多拟表位配体蛋白识别结合膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统等代谢通路：hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04261:心肌细胞的肾上腺素能信号、hsa04940 I型糖尿病、hsa04924:肾素分泌、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04970:唾液分泌、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子(CAMs)、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
HrpZpss多拟表位配体蛋白，作为一类富含特殊多个线性和构象表位结构的配体蛋白分子，能够跨界识别、结合多种类型的膜受体、膜蛋白、信息通路和代谢通路，进一步分析这些膜受体、膜蛋白、信息通路和代谢通路的位置、结构、特性、作用机制和功能，它们广泛影响机体的生长、发育、代谢、防御和细胞程序性死亡的生命基本属性，并广泛涉及诊断、预防、治疗、康复神经系统、消化系统、运动系 统、循环系统、呼吸系统、内分泌系统、免疫系统、泌尿系统、生殖系统、皮肤系统疾病和状况。HrpZpss多拟表位配体蛋白是一类具有全新功能，全新作用机制和全新应用前景的特殊多拟表位配体蛋白。
本发明所述HrpZ型多拟表位配体蛋白在食品、化妆品、保健品和药物中的应用还涉及识别激活动物的多类受体、膜蛋白及其信号通路并诱发多功能级联生物学效应的HrpZpst、HrpZpss等多拟表位配体蛋白的制品在食品、化妆品、保健品中的应用；进一步的，HrpZpst、HrpZpss等多拟表位配体蛋白识别结合特异蛋白的pull-down实验表明，它们识别结合的动物的多类受体、膜蛋白及其信号通路蛋白，从机体内到机体外，广泛涉及机体的生长功能，发育功能，防御、免疫、除菌消炎功能，内分泌、多类型分子代谢功能以及细胞程序性死亡功能的表达和调节控制，广泛参与机体的不同系统、器官、组织、细胞、亚细胞、分子、亚分子的从结构到功能的再生、修复和清除；进一步的，HrpZpst、HrpZpss等多拟表位配体蛋白的动物实验mRNA(RNA-Seq)测序表明，HrpZpst、HrpZpss等多拟表位配体蛋白诱导的多功能级联生物学效应是指能诱导不同器官、组织的细胞组分、分子功能和生物学过程三个层次的相关功能基因群显著差异表达的GO Term富集分析，以及HrpZpst、HrpZpss等多拟表位配体蛋白诱导的多功能级联生物学效应是指能诱导不同器官、组织的细胞过程、环境信息过程、遗传信息过程、新陈代谢和生物体系统过程等五个生物过程的相关功能基因群显著差异表达的KEGG Pathway富集分析,采用对实验动物进行的口服和涂抹处理，所诱导的级联生物学效应相关功能基因群显著差异表达，同样从机体内到机体外，广泛涉及机体的生长、发育、防御、代谢以及细胞程序性死亡功能的表达和调节控制，广泛参与机体的不同系统、器官、组织、细胞、亚细胞、分子、亚分子的从结构到功能的再生、修复和清除；进一步的，HrpZpst、HrpZpss等多拟表位配体蛋白，采用口服或和涂抹处理的方式，HrpZ型多拟表位配体蛋白的制品可以在食品、化妆品、保健品中广泛应用，HrpZ型多拟表位配体蛋白的辅助调理功能主要包括1、增强免疫力功能；2、辅助降血脂功能；3、辅助降血糖功能；4、抗氧化功能；5、辅助改善记忆功能；6、缓解视疲劳功能；7、促进排铅功能；8、清咽功能；9、辅助降血压功能；10、改善睡眠功能；11、促进泌乳功能；12、缓解体力疲劳功能；13、提高缺氧耐受力功能；14、对辐射危害有辅助保护功能；15、减肥功能；16、改善生长发育功能；17、增加骨密度功能；18、改善营养性贫血功能；19、对化学肝损伤有辅助保护功能；20、祛痤疮功能；21、去黄褐斑功能；22、改善皮肤水份功能；23、改善皮肤油份功能；24、调节肠道菌群功能；25、促进消化功能；26、通便功能；27、对胃黏膜损伤有辅助保护功能。进一步的：
本发明所述HrpZ型多拟表位配体蛋白的制品可以在辅助调理机体的生长、发育、防御、代谢以及细胞程序性死亡功能的表达和调节控制的食品中的应用，包括各种供人食用或者饮用的成品和原料；
本发明所述HrpZ型多拟表位配体蛋白的制品可以在辅助调理机体的生长、发育、防御、代谢以及细胞程序性死亡功能的表达和调节控制的化妆品中的应用，包括以涂擦、喷洒或者其他类似的方法，散布于人体表面任何部位，包括皮肤、毛发、指甲、口唇等，以达到清洁、消除不良气味、护肤、美容和修饰目的的生物技术产品，或包括普通化妆品和特殊用途化妆品；
本发明所述HrpZ型多拟表位配体蛋白的制品可以在辅助调理机体的生长、发育、防御、代谢以及细胞程序性死亡功能的表达和调节控制的保健品中的应用，包括保健功能食品，是食品的一个种类，具有一般食品的共性，能调节人体的机能，适用于特定人群食用，但不以治疗疾病为目的。
以上所述实施例仅表达了本申请的具体实施方式，其描述较为具体和详细，但并不能因此而理解为对本申请保护范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本申请技术方案构思的前提下，还可以做出若干变形和改进，这些都属于本申请的保护范围。
Figure PCTCN2021134715-appb-000053
Figure PCTCN2021134715-appb-000054
Figure PCTCN2021134715-appb-000055
Figure PCTCN2021134715-appb-000056

Claims (26)

  1. HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用。
  2. 根据权利要求1所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白含有一至多个疏水非极性氨基酸残基的结构基团或表位、含有一至多个极性不带电氨基酸残基的结构基团或表位、含有一至多个酰胺基极性不带电氨基酸残基的结构基团或表位、含有一至多个酸性带正电、碱性带负电氨基酸残基的结构基团或表位；疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸、蛋氨酸，极性不带电氨基酸残基：丝氨酸，酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺，酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、组氨酸、精氨酸；疏水非极性氨基酸残基，极性不带电氨基酸残基，酰胺基极性不带电氨基酸残基和酸性带正电、碱性带负电氨基酸残基在HrpZ型多拟表位配体蛋白分子的全序列中占比72.97％-70.65％，在保守结构域中占比72.97％-71.82％，在α-螺旋结构中占比85.98％-81.48％；疏水非极性氨基酸残基的结构基团或表位，极性不带电氨基酸残基的结构基团或表位，酰胺基极性不带电氨基酸残基的结构基团或表位和酸性带正电、碱性带负电氨基酸残基的结构基团或表位通过氢键、离子键、疏水、非极性、极性、范德华力，实现配体和受体分子空间结构和电性的互补性、互作性以及特异识别、激活、结合，与多类型受体形成紧密结合面或复合物，能引起受体分子的构象、能量、电性和信息的变化，经信号传导和转导，放大表达系列生物学效应。
  3. 根据权利要求1所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白包括HrpZPsa、HrpZPsm、HrpZPss、HrpZPst,HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat、HrpZPcory、 HrpZPcp、HrpZPsav、HrpZPsavp、HrpZPvir、HrpZPspe、HrpZPam、HrpZPade、HrpZPsac、HrpZPsg、HrpZPsc。
  4. 根据权利要求3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZpss多拟表位配体蛋白的氨基酸序列如SEQ ID NO:1所示。
  5. 根据权利要求3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZpst多拟表位配体蛋白的氨基酸序列如SEQ ID NO:2所示。
  6. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的多类受体包括HLA-C主要组织相容性复合体、I,C类受体、游离脂肪酸受体4、酪氨酸蛋白激酶跨膜受体1、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体、胰岛素样生长因子2受体中的一种或多种。
  7. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的多类受体包括HLA-C主要组织相容性复合体，I，C类受体、ASGPR1去唾液酸糖蛋白受体1、脂肪细胞质膜相关蛋白受体、胰岛素样生长因子2受体、LDL受体相关蛋白1中的一种或多种。
  8. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的膜蛋白包括溶质载体家族5、成员6、溶质载体家族26,成员4、溶质载体家族38，成员2、DNM2 动力蛋白2、CAP1腺苷酸环化酶相关蛋白1、ICAM1细胞间粘附分子1LanC-类蛋白1、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白中的一种或多种。
  9. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的膜蛋白包括溶质载体家族38，成员2、DNM2动力蛋白2、SPTAN1非红细胞1α血影蛋白、β-互生蛋白1、CAP1腺苷酸环化酶相关蛋白1、ICAM1细胞间粘附分子1、LanC-类蛋白1、MLEC应激蛋白-雄激素样受体激酶、TJP2紧密连接蛋白2、ZYX斑联蛋白中的一种或多种。
  10. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，识别结合的信号通路包括hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路中的一种或多种。
  11. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，识别结合的信号通路包括hsa04933年龄-愤怒信号通路在糖尿病并发症中的作用、hsa04064 NF-kappa B信号通路、hsa04072磷脂酶D信号通路、hsa04668 TNF信号通路中的一种或多种。
  12. 根据权利要求1或3所述的HrpZ型蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：识别激活的信号通路包括代谢信号通路，代谢信号通路包括抗病毒、抗细菌、抗异物、抗炎性代谢通路；包括核酸、蛋白质、氨基酸、糖、脂肪代谢通路；包括细胞联结、神经连结、血管、内分泌、生殖系统代谢通路。
  13. 根据权利要求12所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，所述识别激活的膜蛋白参与的抗病毒、抗细菌、抗异物、抗炎性代谢通路：hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、hsa04666 Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa05130:致病性大肠杆菌感染、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa04916:杀菌作用、hsa04650自然杀伤细胞介导的细胞毒性、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa04670白细胞跨细胞迁移；所述识别激活的膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢通路：hsa03050:蛋白酶体、hsa04974蛋白消化吸收、hsa04120:泛素介导的蛋白水解作用；所述识别激活的膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统代谢通路：hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04261:心肌细胞的肾上腺素能信号、hsa04940 I型糖尿病、hsa04924:肾素分泌、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04970:唾液分泌、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子(CAMs)、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
  14. 根据权利要求12所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst蛋白，所述识别激活的膜蛋白参与的抗病毒、抗细菌、抗异物、抗炎性代谢通路：hsa04144内吞作用、hsa04145吞噬体、hsa04142溶酶体、 hsa04666 Fc伽玛r介导的吞噬作用、hsa04210细胞凋亡、hsa04218细胞衰老、hsa04612抗原处理及呈递、hsa05100细菌入侵上皮细胞、hsa05168单纯疱疹病毒1感染、hsa05203病毒致癌作用、hsa05164甲型流感、hsa05150金黄色葡萄球菌感染、hsa05143非洲锥虫病、hsa04650自然杀伤细胞介导的细胞毒性、hsa05166人T细胞白血病病毒1感染、hsa05167卡波济肉瘤伴疱疹病毒感染、hsa05169爱泼斯坦巴尔病毒感染、hsa05416病毒性心肌炎、hsa05110霍乱弧菌感染、hsa05144疟疾、hsa05163人巨细胞病毒感染、hsa05165人乳头瘤病毒感染、hsa05170人类免疫缺陷病毒1型感染、hsa05323类风湿性关节炎、hsa05330同种异体移植物排斥反应、hsa05332抗移植物、hsa04670白细胞跨细胞迁移；所述识别激活的膜蛋白参与的核酸、蛋白质、氨基酸、糖、脂肪代谢通路：hsa04974蛋白消化吸收；所述识别激活的膜蛋白参与的细胞联结、神经连结、血管、内分泌、生殖系统代谢通路：hsa04510粘着斑、hsa04724谷氨酸能的突触、hsa04530紧密连接、hsa04940 I型糖尿病、hsa04721突触囊泡周期、hsa04961内分泌等因素调节钙的再吸收、hsa04979胆固醇代谢、hsa04918甲状腺激素合成、hsa04514细胞粘附分子、hsa04727神经元突触、hsa05320自身免疫性甲状腺疾病、hsa05418流体剪切应力与动脉粥样硬化。
  15. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，级联生物学效应包括细胞过程、环境信息处理、遗传信息处理、新陈代谢和生物体系统功能途径；其中，细胞过程包括HrpZpss蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程；环境信息处理包括HrpZpss蛋白诱导的多个差异表达基因参与了信号分子与相互作用，信号转导，膜运输环境信息处理过程；遗传信息处理包括HrpZpss蛋白诱导的多个差异表达基因参与了翻译，复制和修复，折叠、分类和降解生物过程；新陈代谢包括HrpZpss蛋白诱导的多个差异表达基因参与了生物降解和代谢，核苷酸代谢，氨基 酸的代谢，代谢的辅助因子和维生素，脂质代谢，糖的生物合成和代谢，全局和概览地图，能量代谢，碳水化合物代谢及氨基酸代谢过程；生物体系统包括HrpZpss蛋白诱导的多个差异表达基因参与了感觉系统，神经系统，免疫系统，排泄系统，环境适应，内分泌系统，消化系统，发育循环系统生物过程。
  16. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，级联生物学效应包括细胞过程、环境信息处理、遗传信息处理、新陈代谢和生物体系统功能途径；其中，细胞过程包括HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了运输和分解代谢，细胞群体，细胞活性，细胞生长与死亡等细胞过程；环境信息处理包括HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了信号分子与相互作用，信号转导，膜运输环境信息处理过程；遗传信息处理包括HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了翻译，复制和修复，折叠、分类和降解生物过程；新陈代谢包括HrpZpst多拟表位配体蛋白诱导的多个差异表达基因参与了生物降解和代谢，核苷酸代谢，氨基酸的代谢，代谢的辅助因子和维生素，脂质代谢，糖的生物合成和代谢，全局和概览地图，能量代谢，碳水化合物代谢及氨基酸代谢代谢过程；生物体系统包括HrpZpst蛋白诱导的多个差异表达基因参与了感觉系统，神经系统，免疫系统，排泄系统，环境适应，内分泌系统，消化系统，发育循环系统生物过程。
  17. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，级联生物学效应还包括HrpZpss多拟表位配体蛋白诱导的基因功能群显著差异表达结果，其中包括：生物过程相关差异表达基因：包括了繁殖，细胞死亡，免疫系统的过程，行为，代谢过程，细胞过程，生殖过程，生物粘附，信号，多细胞生物过程，发育过程，增长，运动，单个组织的过程， 生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递；细胞组分相关差异表达基因：涵盖了细胞及细胞外区域，类核，膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维；分子功能相关差异表达基因：涵盖了转录因子活性，蛋白质结合，核酸结合转录因子活性，催化活性，信号传感器活动，结构分子活动，运输活动，绑定，电子载体活动，成形素活动，抗氧化活性，金属伴侣蛋白活性，蛋白质标记，化学引诱物的活动，转译调控，化学排斥物活性，活动分子传感器，分子功能调控。
  18. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，级联生物学效应还包括HrpZpst多拟表位配体蛋白诱导的基因功能群显著差异表达结果，其中包括：生物过程相关差异表达基因：包括了繁殖，细胞死亡，免疫系统的过程，行为，代谢过程，细胞过程，生殖过程，生物粘附，信号，多细胞生物过程，发育过程，增长，运动，单个组织的过程，生物相，有节奏的过程，生物过程的正调控，生物过程负调控，生物过程调节，刺激反应，定位，生物调节，细胞成分组织或生物发生，细胞聚集，解毒以及突触前过程涉及突触传递；细胞组分相关差异表达基因：涵盖了细胞及细胞外区域，类核，膜，病毒粒子，细胞结，细胞外基质，细胞膜封闭腔，复杂大分子，细胞器，细胞外基质成分，细胞外区域部分，细胞器部件，病毒粒子部件，膜部件，突触部分，细胞部件，突触，以及细胞超分子纤维；分子功能相关差异表达基因：涵盖了转录因子活性，蛋白质结合，核酸结合转录因子活性，催化活性，信号传感器活动，结构分子活动，运输活动，绑定，电子载体活动，成形素活动，抗氧化活性，金属伴侣蛋白活性，蛋白质标记，化学引诱物的活动，转译调控，化学排斥物活 性，活动分子传感器，分子功能调控。
  19. 根据权利要求1或3所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：所述制药中的应用的制品或药物的剂型为液剂、粉剂、片剂或胶囊剂。
  20. 根据权利要求19所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpss多拟表位配体蛋白，制品或药物主要由纯化的HrpZpss多拟表位配体蛋白制备得到，质量含量为有0.001％-100％。
  21. 根据权利要求19所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为HrpZpst多拟表位配体蛋白，制品或药物主要由纯化的HrpZpst多拟表位配体蛋白制备得到，质量含量为0.001％-100％。
  22. 根据权利要求1-21任一项所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其参与的信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白为纯化后的HrpZ型多拟表位配体蛋白。
  23. 根据权利要求22所述的HrpZ型多拟表位配体蛋白在识别激活多类受体和/或膜蛋白及其信号通路并引起级联生物学效应的食品、化妆品、保健品或制药中的应用，其特征在于：HrpZ型多拟表位配体蛋白纯化的方法，包括以下步骤：
    步骤1：高压破碎机破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁,高压范围800-1000Mpa。
    步骤2：用Ni-NTA琼脂糖凝胶柱纯化HrpZ多拟表位配体蛋白-His重组蛋白，得到纯化的HrpZ型多拟表位配体蛋白原药。
  24. HrpZ型蛋白纯化的方法，其特征在于，包括以下步骤：
    步骤1：高压破碎机破碎工程菌，将破碎菌液通入蝶式连续流离心机，清除细胞壁,高压 范围800-1000Mpa。
    步骤2：用Ni-NTA琼脂糖凝胶柱纯化HrpZ多拟表位配体蛋白-His重组蛋白，得到纯化的HrpZ型多拟表位配体蛋白原药。
  25. 根据权利要求24所述的HrpZ型多拟表位配体蛋白的纯化的方法，其特征在于，HrpZ型多拟表位配体蛋白含有一至多个疏水非极性氨基酸残基的结构基团或表位、含有一至多个极性不带电氨基酸残基的结构基团或表位、含有一至多个酰胺基极性不带电氨基酸残基的结构基团或表位、含有一至多个酸性带正电、碱性带负电氨基酸残基的结构基团或表位；疏水非极性氨基酸残基：缬氨酸、亮氨酸、异亮氨酸、丙氨酸、苯丙氨酸、蛋氨酸，极性不带电氨基酸残基：丝氨酸，酰胺基极性不带电氨基酸残基：天冬酰胺、谷氨酰胺，酸性带正电、碱性带负电氨基酸残基：天冬酰酸、谷氨酸、赖氨酸、组氨酸、精氨酸；疏水非极性氨基酸残基，极性不带电氨基酸残基，酰胺基极性不带电氨基酸残基和酸性带正电、碱性带负电氨基酸残基在HrpZ型多拟表位配体蛋白分子的全序列中占比72.97％-70.65％，在保守结构域中占比72.97％-71.82％，在α-螺旋结构中占比85.98％-81.48％；疏水非极性氨基酸残基的结构基团或表位，极性不带电氨基酸残基的结构基团或表位，酰胺基极性不带电氨基酸残基的结构基团或表位和酸性带正电、碱性带负电氨基酸残基的结构基团或表位通过氢键、离子键、疏水、非极性、极性、范德华力，实现配体和受体分子空间结构和电性的互补性、互作性以及特异识别、激活、结合，与多类型受体形成紧密结合面或复合物，能引起受体分子的构象、能量、电性和信息的变化，经信号传导和转导，放大表达系列生物学效应。
  26. 根据权利要求24所述的HrpZ型多拟表位配体蛋白的纯化的方法，其特征在于，HrpZ型多拟表位配体蛋白包括HrpZPsa、HrpZPsm、HrpZPss、HrpZPst,HrpZPsap、HrpZPsr、HrpZPsth、HrpZPave、HrpZPam、HrpZPcar、HrpZPcor、HrpZPcst、HrpZPcat、HrpZPcory、HrpZPcp、HrpZPsav、HrpZPsavp、HrpZPvir、HrpZPspe、HrpZPam、HrpZPade、HrpZPsac、HrpZPsg、HrpZPsc。
PCT/CN2021/134715 2020-12-31 2021-12-01 HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用 WO2022142977A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021411563A AU2021411563A1 (en) 2020-12-31 2021-12-01 Use of hrpz-type multi-mimotope epitope ligand protein in foods, cosmetics, health care products or pharmaceuticals

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011631000.3A CN114762723A (zh) 2020-12-31 2020-12-31 HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN202011644674.7A CN114681591A (zh) 2020-12-31 2020-12-31 HrpZpss蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN202011631000.3 2020-12-31
CN202011644674.7 2020-12-31

Publications (1)

Publication Number Publication Date
WO2022142977A1 true WO2022142977A1 (zh) 2022-07-07

Family

ID=82259025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/134715 WO2022142977A1 (zh) 2020-12-31 2021-12-01 HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用

Country Status (2)

Country Link
AU (1) AU2021411563A1 (zh)
WO (1) WO2022142977A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411896A1 (en) * 2000-06-16 2001-12-27 Eden Bioscience Corporation Hypersensitive response eliciting domains of bacterial harpins and use thereof
CN101386859A (zh) * 2008-10-31 2009-03-18 吉林农业大学 烟草野火病病原菌hrpZ基因及其表达产物与应用
CN101812475A (zh) * 2009-11-19 2010-08-25 无锡亚克生物科技有限公司 表达Harpin蛋白的重组载体pGAprEHS及其工程菌
CN104926929A (zh) * 2015-06-30 2015-09-23 成都稷安生物工程有限公司 HHrpEcc蛋白及其编码基因和应用
CN105567682A (zh) * 2016-01-12 2016-05-11 吉林省农业科学院 转基因大豆事件b4j8049外源插入片段旁侧序列及其应用
CN107304231A (zh) * 2016-04-18 2017-10-31 华中农业大学 一种结核分枝杆菌融合蛋白及应用
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN112773884A (zh) * 2020-12-31 2021-05-11 吴伯骥 HrpWpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411896A1 (en) * 2000-06-16 2001-12-27 Eden Bioscience Corporation Hypersensitive response eliciting domains of bacterial harpins and use thereof
CN101386859A (zh) * 2008-10-31 2009-03-18 吉林农业大学 烟草野火病病原菌hrpZ基因及其表达产物与应用
CN101812475A (zh) * 2009-11-19 2010-08-25 无锡亚克生物科技有限公司 表达Harpin蛋白的重组载体pGAprEHS及其工程菌
CN104926929A (zh) * 2015-06-30 2015-09-23 成都稷安生物工程有限公司 HHrpEcc蛋白及其编码基因和应用
CN105567682A (zh) * 2016-01-12 2016-05-11 吉林省农业科学院 转基因大豆事件b4j8049外源插入片段旁侧序列及其应用
CN107304231A (zh) * 2016-04-18 2017-10-31 华中农业大学 一种结核分枝杆菌融合蛋白及应用
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN112773884A (zh) * 2020-12-31 2021-05-11 吴伯骥 HrpWpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein NCBI; 15 February 2006 (2006-02-15), ANONYMOUS : "harpin [Pectobacterium betavasculorum]", XP055948805, Database accession no. ABD22989 *
DATABASE Protein NCBI; 27 July 2020 (2020-07-27), ANONYMOUS : "MULTISPECIES: harpin HrpZ family protein [Pseudomonas]", XP055948804, Database accession no. WP_011266879 *

Also Published As

Publication number Publication date
AU2021411563A1 (en) 2023-08-17
AU2021411563A9 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CN112773884A (zh) HrpWpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114599670B (zh) 一种角蛋白bd-13、制法和其药物组合物与用途
CN114599671B (zh) 一种角蛋白bd-10、制法和其药物组合物与用途
CN116102640A (zh) 重组乳铁蛋白衍生肽及其在提高免疫力方面的应用
CN112675293A (zh) HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114599667B (zh) 一种角蛋白bd-1、制法和其药物组合物与用途
WO2022142977A1 (zh) HrpZ型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用
WO2022142978A1 (zh) HrpW型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用
WO2022142976A1 (zh) HrpN型多拟表位配体蛋白在食品、化妆品、保健品或制药中的应用
CN104945490B (zh) 分离的植物防御素多肽及其制备方法和在治疗肺癌中的用途
CN111269292A (zh) 具有促进组织修复的家蝇多肽及其制备方法与应用
CN112794894A (zh) 一种角蛋白bd-17、制法和其药物组合物与用途
CN114599673B (zh) 一种角蛋白bd-6、制法和其药物组合物与用途
CN114599672B (zh) 一种角蛋白bd-11、制法和其药物组合物与用途
CN114762723A (zh) HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114681591A (zh) HrpZpss蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
WO2020259109A1 (zh) 植物生产的epo与转铁蛋白的融合蛋白及其应用
CN114762724A (zh) HrpWEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114685681A (zh) HrpNEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114599669B (zh) 一种角蛋白bd-4、制法和其药物组合物与用途
CN112724228B (zh) 一种角蛋白bd-14、制法和其药物组合物与用途
CN112724234B (zh) 一种角蛋白bd-5、制法和其药物组合物与用途
WO2024074107A1 (zh) 一种角蛋白yk93-2、制法和其药物组合物与用途
CN112724232B (zh) 一种角蛋白bd-2、制法和其药物组合物与用途
RU2815384C1 (ru) Кератин bd-3, способ его получения и его фармацевтическая композиция и применение

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21913718

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021411563

Country of ref document: AU

Date of ref document: 20211201

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 21913718

Country of ref document: EP

Kind code of ref document: A1